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Clonal expansion of antigen-specific CD8 and CD4 T cells in vivo has been shown to differ 
between the two T cells subsets. It has been previously reported by Foulds et. al. that CD8 T 
cells undergo extensive proliferation compared to CD4 T cells. We wanted to investigate why 
CD8 T cells proliferated more than CD4 T cells and used an in vitro system with naïve CD8+ 
and CD4+ T cells sorted from naïve C57/BL6 mice according to their expression of 
CD44low-int CD62L+ CD25- to carry out our study. 
 
Cells were stained with carboxyfluorescein succinimidyl ester (CFSE) and their proliferation 
tracked for up to 48hrs after activation with either anti-CD3ε antibodies alone or anti-CD3ε 
together with positively selected CD11c+ dendritic cells (DCs). We report the following 
observations: 1) An average of 30% of sorted CD8 T cells remained undivided after 
activation with anti-CD3ε while an average of 60% of sorted CD4 T cells activated with anti-
CD3ε alone remained undivided. 2) CD8 T cells initiated their first cell division earlier than 
CD4 T cells, regardless of whether they were stimulated with anti-CD3ε alone or together 
with CD11c+ DCs.  
 
Western blot analysis of levels of p27, a cell cycle inhibitor, in naïve CD8 and CD4 T cells 
indicated that naïve CD4 T cells had higher levels of p27, possibly setting a higher activation 
threshold for CD4 T cells. We went on to further investigate the effect of p27, a cell cycle 
inhibitor, on the proliferation of naïve CD8 and CD4 T cells using p27 KO mice. We 
observed that CD4 proliferation is enhanced greatly in p27KO mice, comparable to that of 
WT CD8 T cells while proliferation of p27 KO CD8 showed slight enhancement. 
Interestingly, we also observed that loss of p27 significantly increased CD4 effector 
population (TEM – CD44hi CD62Llow population). 
 ix 
 
Our results indicate that in CD4 T cells, p27 might be a potential target that can be used to 
manipulate their proliferation kinetics. However, in depth studies to dissect and compare the 
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 Chapter 1 - Introduction 
 
1.1 Overview of Immunology 
Immunology is the study of the immune system, which defends an organism against 
foreign intrusion by pathogens. The immune system can be divided into two main 
components: the innate and the adaptive immune system. The innate immune system 
provides the host with a rapid non-specific response when pathogens breach through 
the physical barriers of the host (e.g. the skin, gastrointestinal tract, respiratory 
airways, namely the epithelium).  
 
The adaptive immune system, is slower and has a lag time between pathogen 
exposure and maximal response that normally peaks between 5 and 10 days in a 
primary response (Whitmire, Murali-Krishna et al. 2000; Lee, Topham et al. 2009; 
Miao, Hollenbaugh et al. 2010) and is for a specific pathogen or antigen. The adaptive 
immune system generates immunological memory which confers long-lasting 
protection to the host. The adaptive immune system is thought of as an evolutionary 
development of the innate immune system and is only found in jawed vertebrates such 
as mammals and birds. Interestingly, a group of researchers from Max Planck recently 
shown that lampreys, which are jawless vertebrates, have a thymus-like structure 
(Bajoghli, Guo et al. 2011) and other recent studies have shown that lampreys have 
lymphocytes that express somatically diversified antigen receptors termed variable 
lymphocyte receptors (VLRs) (Pancer, Amemiya et al. 2004; Pancer, Saha et al. 2005). 
 
Both the innate and adaptive immune system and be further classified into two 




include macrophages, dendritic cells, mast cells, neutrophils, basophils, eosinophils, 
NK cells and γδ T cells The innate immune and adaptive immune cells are not 
mutually exclusive. There are substantial overlaps and interactions between the cells 
from the two classified groups. γδ T cells are considered somewhere belonging ‘in-
between” both the innate and adaptive immune systems. Dendritic cells (DCs) from 
the innate immune system present antigens to T cells from the adaptive immune 
system which results in their activation and expansion. Antibodies produced by 
plasma cells from the adaptive immune system help in the opsonisation and 
phagocytosis of foreign antigens by macrophages from the innate immune system or 
activate complement, the humoral component of the innate immune system, which 
kills foreign pathogens by punching holes in their membranes.  
 
The individual cellular and humoral components of the innate and adaptive immune 
system will be briefly described but more focus will be given to CD8 and CD4 T cells; 
the immune cells that are the focus of this thesis. 
 
1.2 Cellular components of the innate immune system 
Natural killer (NK) cells directly kill infected cells primarily through perforin and 
granzymes. NK cells can be activated by cytokines such as IL-12 (Parihar, 
Dierksheide et al. 2002) and IL-15 (Allavena, Giardina et al. 1997) and recognise 
infected cells through the downregulation of MHC I. They are also able to recognise 







Figure 1.1 Simplified overview of the immune system 
The immune system is divided into two main branches: innate and adaptive immune system. Innate immune system serves as the first line of 
defence against foreign pathogens and response to the pathogen is generic and it does not confer long-lasting immunity. It is thought of to be a 
more “primitive” form of immunity. The adaptive immune system, on the other hand, reacts quite specifically to a particular pathogen and 
confers long-lasting immunity to the host. It is plays a larger role in the reinfection than first-time infection of a pathogen. Each branch of the 
immune system can be further divided into its cellular and humoral components. It is important to note that the two branches of the immune 
system are not mutually exclusive; instead there is quite an overlap and interaction between the cells of the two branches. This overview serves 




γδ T cells are a small subset of T cells and comprises only about 2-6% of CD3+ T 
cells in the blood. They are different from CD8 and CD4 T cells in that they express 
one γ- and one δ-chain as their T cell receptor (TCR) which associate with CD3 
instead of  α- and β- chains (Bank, DePinho et al. 1986). γδ T cells are unique that 
they are able to recognise microbial [(E)-1-hydroxy-2-methyl-but-2-enyl 4-
diphosphate, HMB-PP] and eukaryotic pyrophosphates (isopentenyl pyrophosphate, 
IPP) which αβ T cells are unable to recognise (Wrobel, Shojaei et al. 2007). 
 
Mast cells (MCs) are granulated, tissue-resident leukocytes often associated with 
pathogenic inflammatory sequelae such as allergy (Secor, Secor et al. 2000; Lee, 
Friend et al. 2002). However, they also play an important role in healing of wounds 
and pathogen defence (Prussin and Metcalfe 2003). MCs contain pre-stored granules 
such as histamine and serotonin (Riley 1953; Kapeller-Adler 1965).  
 
Basophils and Eosinophils are granulocytes, together with MCs are commonly 
responsible for allergic reactions and play a role in asthma. Eosinophils make up 
about 1-4% of all white blood cells while basophils make up about 0.5-1% of all 
white blood cells. Characteristics of these cells are that they contain numerous 
granules in their cytoplasm that are released when triggered, similar to MCs. As part 
of the innate immune system, they are involved in the combat against parasites and 
contribute to the inflammatory response during the innate immune response. 





Phagocytes are cells that are able to engulf and ingest particles or other cells such as 
bacteria to be degraded when the phagosome (which contains the foreign particle or 
pathogen) fuses with the lysosome (containing enzymes) 
 
Macrophages are large cells that have differentiated from monocytes and play an 
important role in the removal of cellular debris within the body, particularly at the 
lung-surface interface. They also get rid of engulf foreign pathogens and are able to 
process and present the antigens to T cells of the adaptive immune system. One of the 
ways macrophages engulf foreign pathogens is through their Fc receptors. Fc receptor 
expressed on macrophages will bind to the Fc regions of antibodies that have coated 
the microbial pathogen, facilitating phagocytosis. 
 
Neutrophils comprise approximately 50-70% of all white blood cells, making them 
the most common type of white blood cell. The average life span of a non-activated 
neutrophil in circulation is about 5.4 days (Pillay, den Braber et al. 2010).  
Neutrophils are highly mobile and normally the first immune cells to arrive at a site of 
infection through chemotaxis. When activated by activated endothelial cells at sites of 
infection and/or inflammation, they contribute to the inflammatory response by 
producing IL-8, MIP-1a (CCL3) GRO-b (CXCL2), VEGF and IL-1b (Theilgaard-
Mönch, Knudsen et al. 2004).  
 
Dendritic cells (DCs) play a central role in the immune system. They are the primary 
antigen presenting cells to the adaptive immune system (Banchereau and Steinman 
1998; Banchereau, Briere et al. 2000). Immature DCs are strategically located in 




They are also efficient at macropinocytosis and endocytosis (Sallusto, Cella et al. 
1995; Guermonprez, Valladeau et al. 2002). 
 
Upon pathogen encounter, immature DCs become activated and take up antigen and 
transport it to draining lymph nodes (Steinman and Swanson 1995). Mature DCs have 
numerous “dendritic” extensions which greatly increase their surface area, allowing 
them to form close contacts with many T cells simultaneously. They also increase the 
expression of costimulatory molecules such as CD80/86 which are important proper 
activation of T cells in the adaptive immune system. Mature DCs also secrete 
numerous cytokines which can influence the outcome of the adaptive immune 
response (Banchereau and Steinman 1998). 
 
1.3 Humoral components of the innate immune system 
Complement is a family of molecules that can be activated via three different 
pathways: the classical pathway (CP), the alternative pathway (AP) and the lectin 
pathway (LP). The CP is activated when its ligands such as immune-complexes (IC) 
interact with C1q. The result of activating any of these three pathways generates C3-
convertases which in turn activates the common terminal pathway to genereate 
several effector processes, such as chemotaxis by C3a and C5a, opsonization by C3b, 
and lysis by the membrane attack complex (Ricklin, Hajishengallis et al. 2010). 
 
Antibodies, also known as immunoglobulins are Y-shaped proteins produced by 
plasma cells (also known as effector B cells). Antibodies have two regions: Fab and 
Fc region. The Fab region of the antibody is responsible for binding to its specific 




surface of other immune cells such as macrophages and proteins of the complement 
system. They are used by the adaptive immune system to identify and neutralize 
foreign antigens by marking the microbe for phagocytosis by a process called 
opsonisation and to activate the complement system for form the membrane attack 
complex on the surface of the microbe which results in lysis of the microbe. 
 
There are five classes of antibody or isotypes: IgA, IgD, IgE, IgG and IgM. IgG is the 
most abundant antibody isotype in the body, comprising of up to 75% of antibodies in 
the blood. IgG is a monomer mainly functions to protect against the reinfection of 
microorganisms and is generally produced later in the immune response. IgA exists as 
a dimer while IgE exists as a monomer. These two antibodies have similar functions 
to IgG, however, they are located in different parts of the body. IgA is highly 
concentrated in mucosal linings such as the respiratory tract, gut, vagina, and anus. In 
addition, it is the only antibody isotype that is secreted in breast milk. IgE is involved 
in triggering the immune system to attack helminths but is also involved in triggering 
allergic reactions. 
 
IgM is one of the earliest antibody isotype that is produced in the initial immune 
response to an infection by B cells when they first become activated. IgM exists as a 
pentamer and is capable of triggering the complement cascade. However, its affinity 
for antigen is not as strong as IgG. IgD is known to be involved in the early life cycle 
of B cells by functioning as an antigen receptor (Geisberger, Lamers et al. 2006). It 





1.4 Cellular components of the adaptive immune system 
B cells produce antibodies. B cells differentiate from hemapoietic stem cells (HSCs) 
in the bone marrow (Nagasawa 2006) and mature into effector/memory B cells in 
secondary lymphoid tissue such as the lymph nodes (LNs) and mucosa-associated 
lymphoid tissues (MALTs), the bone marrow and the spleen (McHeyzer-Williams 
and McHeyzer-Williams 2005; Allen, Okada et al. 2007) 
 
Activation of naïve B cells occur when they receive stimulatory signals from the 
antigen-triggered B-cell receptor (BCR) and CD40, which is triggered by CD40L 
upregulated on T-helper cells when their TCR form an immunological synapse with 
the antigen-MHCII complex on the B cell. (Parker 1993; Banchereau, Bazan et al. 
1994; Mills and Cambier 2003; Manz, Hauser et al. 2005).  
 
T cells and T cell development 
The thymus is an organ that supports the differentiation and selection of T cells 
(Takahama 2006). T cells begin their development in the thymus from haematopoietic 
stem cells in the thymus. Immature T cells express a productive, functional β chain on 
the double negative (DN) thymocytes. The β chain associates with CD3 and pre- T 
cell receptor (pre-TCR)α  chain to form pre-TCR (von Boehmer and Fehling 1997). 
Successful expression of pre-TCR chain on DN thymocytes turns off the 
recombination activating gene (RAG) while the genes for CD4 and CD8 are turned on. 
After the expression of CD4 and CD8 co-receptors on the surface, the pre-TCRα 
chain is replaced with a rearranged TCRα to form a complete αβ TCR. This is how 





Immature T cells whose TCR does not bind MHC I or II die. Further selection 
removes these T cells that bind strongly to self-peptide-MHC. Depending on whether 
they recognise MHC I or MHC II, CD4 or CD8 is down-regulated to become single 
positive cells that are exported out of the thymus. 
 
CD8 T cells are cytotoxic and recognize antigenic peptides presented by MHC class I. 
Although all nucleated cells express MHC class I, only infected cells, tumour cells, or 
some soluble antigens that are presented on MHC class I targets them for destruction 
by antigen-specific CD8 T cells. CD8 T cells kill these cells using their cytotoxic 
granules. The cytotoxic granules contain components perforin and enzymes such as 
granzyme A and B. They also have a natural tendency to produce high levels of Th1 
associated cytokines, like IFN-γ and are known as the Tc1 subset. Though CD8 T 
cells are typically Tc1, in vitro they are able to differentiate into Tc2 CD8 T cells that 
secrete IL-4 (Le Gros and Erard 1994; Noble and Kemeny 1995; Noble, Macary et al. 
1995; Sad, Marcotte et al. 1995) 
 
CD4 T cells also known as T helper cells (Th) because modulate the immune system 
to execute a variety of immune functions. Activation of CD4 T cells occurs through 
the recognition of antigenic peptides presented on MHC class II and depending on the 
nature of cytokines produced by the innate immune system, they are able to 
differentiate into several effector subsets such as Th1, Th2, Th17, regulatory T cells 
(Treg) and follicular helper T cells (Tfh cells) (Mosmann, Sad et al. 1995; Nishimura, 
Sakihama et al. 2004; Langrish, Chen et al. 2005; Shevach 2009; Tran, Andersson et 




Subsets of CD4 effector subsets, CD4 T cells are responsible for providing help to B 
cells for antibody secretion, enhance and maintain CD8 T cell responses during an 
infection (Shedlock and Shen 2003; Shedlock, Whitmire et al. 2003), regulate 
macrophage function (Munder, Eichmann et al. 1998), direct immune responses 
against a wide variety of pathogenic microorganisms, and regulate immune responses 
to control autoimmunity(Teshigawara, Wang et al. 1987; Takeshita, Ohtani et al. 1992; 
Sakaguchi, Ono et al. 2006; Long and Buckner 2011) and antitumor responses 
(Setoguchi, Hori et al. 2005; Malek 2008). Therefore, CD4 T cells can also be seen as 
the coordinators of the adaptive immunity.  
 
Th1/Th2 paradigm 
In 1986, Coffman and Mosmann showed that CD4 T cells could be divided into Th1 
and Th2 according to the cytokines they need (Coffman and Carty 1986; Mosmann, 
Cherwinski et al. 1986). Th1 cells make IFN-γ while Th2 cells make IL-4, IL-5 and 
IL-13 as their signature cytokines. Th1 cells are differentiated in vitro from naive 
CD4 T cells with the addition of IL-12 and neutralization of IL-4 in cultures (Hsieh, 
Macatonia et al. 1993). For Th2 cells, the presence of IL-4 and blocking of IL-12 is 
required during the differentiation process (Swain, Weinberg et al. 1990; Hsieh, 
Heimberger et al. 1992; Seder, Paul et al. 1992; Maloy, Salaun et al. 2003). Th1 cells 
are effective against intracellular bacteria, viruses and tumours while Th2 cells are 
mainly involved in the humoral immunity against parasites. 
 
Transcription factors in Th1/Th2 differentiation 
The transcription factor involved in Th1 cell development is T bet (Szabo, Kim et al. 




of T-bet is through the action of IL-12 and IFN-γ which triggers STAT1 and STAT4 
(Tripp, Lahti et al. 1995; Morokata, Ishikawa et al. 1999; Lighvani, Frucht et al. 2001). 
Transcription factor GATA-3 is involved in Th2 differentiation which regulates the 
transcription of Th2 cytokines such as IL-4, IL-5, IL-6, IL-10 and IL-13 (Lindstein, 
June et al. 1989; Zheng and Flavell 1997; Geginat, Lanzavecchia et al. 2003).  
 
Th17 cells 
A third major effector population of CD4 T cell that could be derived from naive CD4 
T cells was reported in 2003 (Graus, van Breda Vriesman et al. 1993; Liu, 
Matsuguchi et al. 2002; Li, Wan et al. 2007) and designated as Th17 cells (Ullrich, 
Bowles et al. 1996; Nishimura, Sakihama et al. 2004; Tran, Andersson et al. 2009). 
They were characterized by the production of IL-17A, IL-17F, and IL-22 as signature 
cytokines and are also good producers of IL-21 (Medina 1974; Korn, Bettelli et al. 
2007; Nurieva, Yang et al. 2007). Cytokines IL-6 and IL-21 function synergistically 
with TGF-β, and sequentially with IL-23 to induce the Th17 lineage through the 
transcription factor RORγt (Ivanov, McKenzie et al. 2006; Annunziato, Cosmi et al. 
2007). Th17 cells arise as a part of mucosal host defence to provide protection against 
extracellular bacterial infections (Ye, Rodriguez et al. 2001; Happel, Dubin et al. 2005; 
Strauss, Bergmann et al. 2007), though under certain circumstances they are involved 
in the pathogenesis of chronic inflammatory disorders and some models of 
autoimmune diseases such as myasthenia gravis and experimental autoimmune 
encephalomyelitis (EAE) (Graus, van Breda Vriesman et al. 1993; Constantinescu, 
Wysocka et al. 1998; Oppmann, Lesley et al. 2000; Livolsi, Busuttil et al. 2001; Gran, 





Natural and inducible regulatory T cells 
T regulatory cells were first characterised as a subset of CD4+ T cells that expressed 
CD25 and had potent suppressor activity (Ricci, Del Boccio et al. 1991). Subsequent 
studies to search for the transcription factor that controls differentiation of CD4 T 
cells into regulatory T cells lead to transcription factor Foxp3 (Bellelli, Agro et al. 
1991; Bidart, Troalen et al. 1991; Wada, Rindress et al. 1991). It had been 
demonstrated that in scurfy mice and patients with immunodeficiency, 
polyendocrinopathy, and enteropathy, X-linked syndrome (IPEX) lack naturally-
occurring Tregs (nTregs) and is attributed to Foxp3 mutation (Burns and Bell 1991; 
Icely, Gros et al. 1991; Janssen, Morales et al. 1991). Naive CD4 T cells could also be 
induced in vitro to differentiate into cells with characteristics of regulatory T cells 
(Lee and Bell 1991; Asaoka, Nakamura et al. 1992; Nishizuka 1992; Nishizuka 1995). 
They were designated induced Tregs (iTregs) to distinguish them from nTregs. iTregs 
have been shown to have similar functions to that of nTregs in vitro and in vivo 
functions in the murine model(Nishizuka 1986) but in human, these iTregs have not 
shown to demonstrate activity in an in vitro Treg functional assay (Shevach 2009).  
 
Type1 T- regulatory cells (Tr1) are designated as one type of nTregs. These cells are 
defined by their ability to produce large amounts of IL-10 and TGF-β. They have low 
proliferative capacity and suppress naïve and memory Th1 and Th2 responses via IL-
10 and TGF-β. (Groux 2003). Immature DCs that produce IL-10 have been shown to 
differentiate peripheral naïve CD4 T cells into Tr1 cells and did not require the 
presence of CD4+CD25+ Treg cells (Akbari, DeKruyff et al. 2001; McGuirk, 
McCann et al. 2002; Levings, Gregori et al. 2005). Studies have shown the 
importance of Tr1 cells in the prevention of colitis (Morrissey, Charrier et al. 1993; 




10 produced in these Tr1 cells (Asseman, Mauze et al. 1999; Annacker, Pimenta-
Araujo et al. 2001; Liu, Hu et al. 2003) 
 
Follicular T helper cells (Tfh) 
CD4 T cells activate B cells to produce antibodies and control of immunoglobulin 
class switching. A subset of CD4+ cells that carry out this function have been 
observed to express CXCR5, a chemokine receptor responsible for positioning B and 
T cells in the follicular areas of lymphoid tissues (Bell and Jones 1991; Ansel, 
McHeyzer-Williams et al. 1999; Breitfeld, Ohl et al. 2000; Schaerli, Willimann et al. 
2000) and its ligand is CXCL13, which is expressed on follicular stromal cells and 
follicular dendritic cells (FDCs)(Bellas, Bendori et al. 1991; Jones and Bellion 1991). 
Therefore, these CD4+ CXCR5+ T cells have been termed as follicular T helper cells 
(Tfh) due to their predominant localization at B cell follicles in the germinal centres 
(Hjelmstad and Bell 1991; Hjelmstad and Bell 1991; Schaerli, Willimann et al. 2000). 
Bcl-6, a transcriptional repressor, has been shown to be critical in Tfh cell 
differentiation (Ghosh and Baltimore 1990; Turcotte, Meyer et al. 1991; Johnston, 
Poholek et al. 2009). Tfh cells are T cells that are CXCR5+ PD-1+ Bcl-6+, express 
IL-21 and found in the follicle (Deenick and Ma 2011). 
 
1.5 Why study T cell clonal expansion? 
T cells have a diverse repertoire (maximum theoretical diversity of up to 106 - 107) 
which allows the adaptive immune system to respond to most pathogens present in the 
environment. A typical T cell response comprises of three phases: clonal expansion, 
contraction and maintenance. A T cells response is initiated when there is a cognate 




dendritic cells (DCs) carrying antigen migrate into the lymphoid tissues and induce 
naïve T cells that recognise the antigen presented on major histocompatability (MHC) 
complex, they form an immunological synapse and this signalling activates the T cells 
to clonally expand and differentiate into their effector cells – either into cytotoxic T 
lymphocytes (CTLs) for CD8+ T cells or T helper (TH) cells for CD4+ T cells. The 
contraction phase of the T cell response begins after the acute infection is resolved 
(usually 4-5 weeks) where more than 90%-95% of the effector T cells die (Williams 
and Bevan 2007). The final phase of the T cell response is maintenance, where the 
remaining 5-10% of pathogen-specific T cells numbers stabilize, become memory 
cells and are maintained for long periods of time. CD8+ memory T cells can be 
maintained for up to 75 years post-vaccination in humans, presumably conferring 
lifelong protection (Hammarlund, Lewis et al. 2003).  
 
Ideally, the immune response should be able to eliminate a pathogen before it has an 
opportunity to become established (Davenport, Price et al. 2007).  In reality, this is 
often not achievable firstly because the flipside of having a diverse naïve T cell 
repertoire that is able to respond to most pathogens is that the precursor frequency of 
naïve epitope-specific T cells is low in the entire T-cell population (in the range of 
tens to hundreds of cells per mouse) (Casrouge, Beaudoing et al. 2000; Blattman, 
Antia et al. 2002; Pewe, Netland et al. 2004; Kedzierska, Day et al. 2006; Moon, Chu 
et al. 2007). 
 
To initiate a CD8+ T cell response to an invading pathogen requires antigen-bearing 




CD8 T cells in an uninfected mouse that is able to recognise that specific antigen 
(Blattman, Antia et al. 2002). Second, when the antigen-bearing DCs do find the rare 
epitope-specific naïve T cells, the T cells have to undergo substantial proliferative 
expansion in order to generate the numbers required to effectively combat the 
infection. This delay gives the pathogen ample time to establish itself in the host. 
Hence, it would be more realistic to try to modulate the infection phase and its 
concomitant pathology, which in either case, would require rapid kinetics to mobilize 
epitope-specific T cells as well as rapid acquisition of competent effector functions 
soon after infection.  
 
Thus, the understanding of the regulation of T cell clonal expansion is of particular 
importance: 
(1) To generate T cells of a particular effector function. The acquisition of effector 
function (cytokine secretion) is not correlated with time after activation but the 
number of cell divisions. For example, IL-2 production is highest in CD4 T cells 
in the first 4 cell divisions and starts to decline while effector cytokines such as 
IFN-γ or IL-4 start to increase in levels starting from 6th cell division onwards 
(Bird, Brown et al. 1998; Gett and Hodgkin 1998; Oehen and Brduscha-Riem 
1998; Gudmundsdottir, Wells et al. 1999; Wells, Walsh et al. 2000). It has been 
mainly attributed to epigenetic modifications which occur to the cell as it 
undergoes cell division, becoming more differentiated after each round of cell 
division. Therefore, it is plausible that the shorter the time required for an 
activated T cell to complete one cycle of cell division and its subsequent cycles, 




the generation of effector CD8+ T cells and CD4+ T cells by vaccination to control 
pathogens that are capable of causing rapid disease and morbidity such as 
biological agents Bacillus anthracis and Yersinia pestis (Pulendran and Ahmed 
2006). Such knowledge could be especially useful in the case of a sudden, new 
pandemic, where newly developed vaccines not only activate epitope-specific T 
cells but also speed up the rate at which these epitope-specific T cells are 
generated to confer protection as early as possible. This acquisition of effector 
function tied to cell cycle progression does not only apply to naïve T cells but to 
memory T cells as well (Meng, Harlin et al. 2006). 
 
(2) As described earlier, the contraction phase of a T cell response normally leaves 
behind about 5-10% of the epitope-specific T cells that become memory T cells. 
More recently, a study demonstrated that a single naïve CD8+ T cell precursor has 
the capacity to develop into a diverse range of effector and memory subsets after 
its gets activated and clonally expands in vivo (Stemberger, Huster et al. 2007). 
Since the number of memory T cells formed is primarily determined by the initial 
burst size when the naïve T cell is activated, it would be safe to assume that 
increasing the initial burst size would in turn increase the numbers of memory T 
cells formed, resulting in enhanced protection against a pathogen (Figure 1. 2 ). 
This has certain implications in the design of vaccines and the strategies employed. 
 
(3) Though T cells are important in combating infections, they also precipitate 
autoimmune diseases as well as organ transplant rejection. It is estimated that as 




alloimmune response in vivo (Suchin, Langmuir et al. 2001). Understanding how 
T cell clonal expansion is regulated will allow for better development and use of 
drugs to reduce transplant rejections or treat autoimmune diseases. 
 
(4) In reviews by Rosenberg et. al., they discussed the possibility of using adoptive 
cell transfer as a clinical path to effective immunotherapy against cancer. This 
process involves the generation of anti-tumour T cells generated ex vivo before 
they are reinfused post-lymphodepletion (Rosenberg, Restifo et al. 2008). Wieder 
et. al also provided evidence that adoptive transfer of tumour antigen-specific T 
helper (Th) cells has potential of being used as an anti-tumour therapy. This relied 
on the inhibition of tumour angiogenesis, inhibition of tumour cell proliferation 
and induction of tumour dormancy (Wieder, Braumuller et al. 2008). Another 
recent review by Cubillos-Ruiz et. al. suggested eliminating and/or modulating the 
phenotype of microenvironmental leukocytes such as Tregs in vivo or in situ as a 
novel intervention to complement standard ovarian cancer treatments (Cubillos-
Ruiz, Rutkowski et al. 2010). Wu et al. also discussed the potential of adoptive T-
cell therapy for metastatic melanoma (Wu, Forget et al. 2012) 
 
(5) Understanding the mechanisms that underlie T cell clonal expansion may help to 
accelerate the generation of sufficient numbers of tumour antigen-specific T cells, 
both CD8 and CD4. For certain vaccines that require cell mediated immune 
responses such as those against tuberculosis and malaria to confer protection, 






Figure 1. 2 Concept of immunological protection and phases of a T cell response.  
The graph represents a typical T cell response which consists of the expansion (consists of 
the peak of the response), contraction and maintenance phase. The dashed line represents a 
minimum number of antigen-specific T cells needed to have immunological protection. The 
red line represents a scenario where insufficient numbers of antigen-specific T cells were 
generated during the immune response, therefore, ineffective immunological protection. The 
green line represents an effective immunological protection acquired due to sufficient 
antigen-specific T cell numbers generated. All phases of the immune response can potentially 
be manipulated to generate immunological protection. (1) Expansion phase: Improve 
proliferation of T cells to generate greater cell number to make up for loss of cells during the 
contraction phase. (2) Contraction phase: Improve viability of cells, enhance survival/prevent 
apoptosis to decrease the number of cells that are lost during the contraction phase. 
(3)Maintenance: Improve the survivability of remaining antigen-specific T cells. Modified 
from Pulendran, B. and R. Ahmed (2006). "Translating innate immunity into immunological 




1.6 T cell expansion rate and burst size 
Apart from preventing primary infections from further progression if the innate 
immune system fails to eliminate the invading pathogen, T cells are also involved in 
protecting the body against future re-infections. In order to fulfil their roles in the 
immune system, one unique aspect of T cells is their ability to proliferate much more 
rapidly than other cell types. However, this ability to proliferate rapidly is lost as we 
age (Plunkett, Franzese et al. 2007; Henson and Akbar 2010; van de Berg, Griffiths et 
al. 2010). 
 
After commitment to expansion by antigen stimulation, it has been observed that 
CD8+ T cells proliferate at a faster rate both in vitro and in vivo as compared to CD4+ 
T cells. In addition, CD4+ T cells have limited proliferative capacity, exhibiting 
proliferative arrest in early divisions, compared to CD8+ T cells. This is demonstrated 
in viral and bacterial infections in mice where the increase in number of antigen-
specific CD8+ T cells is considerably greater than CD4+ T cells and CD8+ T cell 
response peaked earlier than CD4+ T cells (Whitmire and Ahmed 2000).  
 
How does having faster proliferative kinetics in CD8 T cells as a feature of the 
adaptive immune response benefit/ harm an organism in contrast to CD4 T cells 
having that proliferative capability? CD8 T cells produce large amounts of IFN-γ, a 
cytokine which plays an important immunomodulatory function that boosts DC 
antigen processing and presentation, up-regulates MHC molecules, activates 
macrophages as well as polarize CD4+ T cells towards a Th1 response (Bradley, 




addition, IFN-γ has a direct effect on limiting viral replication in infected cells 
(Boehm, Klamp et al. 1997). 
 
Apart from playing a role in late immunity, some studies have also indicated CD8 T 
cell involvement in the early stages of immunity (Katz, Benoist et al. 1993; Wang, 
Gonzalez et al. 1996; Gurunathan, Stobie et al. 2000; Verma, Hutchings et al. 2000; 
Mailliard, Egawa et al. 2002; Schuler and Blankenstein 2002). For example, naïve 
CD8 T cells produce IFN-γ very early on after activation (Mailliard, Egawa et al. 
2002), driving the development of Th1 CD4 T cells by inducing DC maturation 
(Ruedl, Kopf et al. 1999; Schuler and Blankenstein 2002).  
 
The downside of CD8 T cells proliferating faster and their ability to produce IFN-γ 
readily is that CD8 T cells have also been shown to participate in the early event of 
autoimmunity such as diabetes mellitus in non-obese diabetic (NOD) mice. When a 
mutation in β-2 microglobulin is generated in these NOD mice , they lack MHC-I 
molecules and therefore mature CD8 T cells, do not develop insulitis (Katz, Benoist et 
al. 1993). It was observed that the CD4 T cells normally though to be responsible for 
the initiation of type-1 diabetes mellitus, were more Th2 in the absence of the CD8 T 
cells in those NOD mice. 
 
Understanding regulation of T cell proliferation kinetics, CD8 T cells in particular, 
would allow scientists to modulate the immune response towards their desired 




1.7 CD8+ and CD4+ T cells are intrinsically different  
In CD8+ T cell anti-viral responses, it has been shown that for some viral infections, 
CD4+ T cell presence in important in assisting CD8+  T cells in combating the 
infection (Whitmire and Ahmed 2000). Also, in the area of generating effective CD8+ 
memory T cells, studies have shown that CD8+ T cells generated in the CD4+ T cell 
deficient mice responds normally during primary infection, but are defective in their 
ability to proliferate and respond to secondary infection (Shedlock and Shen 2003; 
Sun and Bevan 2003). The lag in the peak of CD4+ T cell response during a viral 
infection may be a contributing factor in the effective generation of CD8+ memory T 
cells.  
 
Foulds et. al. demonstrated both in vitro and in vivo that CD4+ T cells responding to 
infections only divide a limited number of times (on average, seven rounds of 
division), with progeny exhibiting proliferative arrest in early divisions (Foulds, 
Zenewicz et al. 2002). CD8 T cells in contrast, were able to undergo extensive 
proliferation (on average, 15 rounds of division). They were able to demonstrate that 
the differences in proliferative patterns of CD8+ and CD4+ T cells hold between mice 
from different backgrounds, at varying doses of antigen stimulation, by using 
different strains of Listeria moncytogenes (LM) to infect the mice as well as by using 
anti-CD3 monoclonal antibody together with IL-2 to stimulate the T cells. Their 
findings have important implications in the study of T cell clonal expansion. It 
demonstrates that intrinsic control mechanisms that regulate T cell expansion are 
distinct between the two T cell subsets. The intrinsic capacity to divide may also 




and after an infection are always greater than CD4 T cells (Whitmire, Murali-Krishna 
et al. 2000). 
 
The intrinsic differences between CD8+ and CD4+ T cells have implications in trying 
to manipulate T cell clonal expansion during viral infections, or the design of 
effective vaccination strategies because as seen in this literature review, targeting the 
same molecule in CD8+ T cells and CD4+ T cells may not elicit the same type of 
response. CD8 T cell expansion had been described as being on “autopilot” mode by 
Bevan M.J. and Fink P.M (Bevan and Fink 2001). Three independent groups: van 
Stipdonk et al, Kaech SM and Ahmed R and Mercado R et al observed that naïve 
CD8 T cells are programmed to go through multiple rounds of proliferation just with a 
brief encounter with antigen (as short as 2hrs), which results in the acquisition 
effector function and the eventual generation of CD8 T cell memory (Mercado, Vijh 
et al. 2000; Kaech and Ahmed 2001; van Stipdonk, Lemmens et al. 2001). 
 
CD4 T cells, on the other hand, require persistence of antigen to drive their 
proliferation (Obst, van Santen et al. 2005). Rabenstein H and Obst R suggested that 
an inducible mechanism is triggered in CD4 T cells which may explain the need for 
antigen persistence for continual expansion of CD4 T cells but not in CD8 T cells 
(Rabenstein and Obst 2009). Since p27kip1 is important in the regulation of cell cycle 
entry and exit (Hathcock, Laszlo et al. 1994; Sherr 1994; Singh, Jatzek et al. 2010), it 
is possible that the regulation of p27kip1 may be involved as part of the inducible 




This concept of intrinsic capability is supported by Turner et. al. through their study 
of B cells. They suggested that B cell proliferation capacity is intrinsically limited 
even in maximal stimulation conditions (Turner, Hawkins et al. 2008). In addition, 
they demonstrated that Bcl-2 over-expressing B cells compared to wild-type B cells 
underwent the same maximal number of divisions even when survival was enforced in 
the transgenic B cells. This suggests that cell division progression and cell death are 
regulated independently, and cell death has no effect on the rate of division of cells. 
They also demonstrated B cells that divided earlier did not necessarily have a higher 
total cell number compared to cells that divided later and cell death is an age-
dependent stochastic event. 
 
1.8 Mammalian Cell cycle 
Since the mechanisms that control CD8+ and CD4+ T cell expansion are intrinsic, it 
may be useful to turn our attention to cell cycle and cell cycle machinery. The basic 
function of the cell cycle is to accurately duplicate the huge amount of DNA in the 
chromosomes and to segregate the copies into two genetically identical daughter cells.  
 
The cell cycle is divided into four sequential phases: G1 is the first gap phase in which 
cells grow in size and prepare for DNA replication; S phase is the period of DNA 
synthesis where the entire set of chromosomes are replicated; G2 is the second gap 
phase in which cells prepare for mitosis; and finally, M phase is the period of cell 
division where two genetically identical daughter cells are generated (Figure 1. 3). G1, 
S and G2 are collectively known as the interphase. The progression of cell cycle is 




kinase inhibitors (CKIs) and each of these phases follow one another in strict order 
and are regulated by “checkpoints” which provide cues to the cell to progress from 
one phase to the next. 
 
At the end of cell division, cells can exit the cell cycle to settle into a quiescent state 
(G0 phase) in response to the nutrient deprivation and insufficient growth factor 
stimulation. In the G0 phase, basic cellular metabolism is depressed which includes 
transcription and translation. Differentiation and programmed cell death (apoptosis) 
(Williams and Smith 1993; Holman, Walsh et al. 2005) are other scenarios that can 




Figure 1. 3 The four phases of the cell cycle.  
Cells exit G0 (quiescence) and enter into G1 phase due to mitogenic signals from the 
external environment. During G1 phase, the cell grows in size from protein production, 
including the components required for DNA replication, and replication of cellular 
organelles. Once a sufficient cell size is achieved, the cell moves into the S phase 
where all the cellular DNA is replicated. After the completion of DNA replication, the 
cell enters G2 phase where the cell continues to grow in size with protein synthesis 
and prepares for the M phase. M phase is the phase where nuclear division occurs 
followed by cytokinesis, resulting in the generation of two genetically identical 
daughter cells. The percentage in the brackets of each phase indicates how much each 









1.9 Cyclins and Cyclin-dependent kinases (CDKs) 
Cyclins are a family of proteins that control the progression of cells through the cell 
cycle by binding to cyclin-dependent kinases (Cdks) to form complexes that are 
involved in different cell cycle transitions (Freitas and Rocha 1993). Cyclins are 
synthesized and destroyed at specific times during the cell cycle, thus regulating 
kinase activity in a timely manner where their levels vary in a cyclical fashion. Hence, 
they were named cyclins. There are ten cyclins belonging to four different classes that 
are involved in cell cycle. They are A1, A2 (A-type cylins), B1, B2 (B-type cyclins), 
D1, D2, D3 (D-type cyclins) and E1, E2 (E-type cyclins). 
 
Cyclin-dependent kinases (CDKs) are a family of serine/theorine kinases (Morgan 
1997). Although there are many CDKs, not all are involved in the cell cycle. The 
CDKs that are involved in driving the cell cycle are the interphase CDKs (CDK2, 
CDK4 and CDK6) and a mitotic CDK (CDK1, also known as cell division control 
protein 2 (CDC2)). CDKs and their respective binding partners at each phase of cell 
cycle: cyclin-D-CDK4/6 complex for G1 progression, cyclin-E-CDK2 for the G1-S 
transition, cyclin-A-CDK2 for S phase progression and cyclin A/B-CDC2 for entry 
into M-phase. 
 
1.10 Cyclin –dependent kinase inhibitors (CKIs) 
Cyclin-dependent kinases (CDKs) associated together with their respective activating 
cyclins present at different phases of the cell cycle positively control cell cycle 
progression (Hunter and Pines 1994; Sherr 1994). The activity of cyclin-CDK 




signals are first integrated with the cell cycle machinery via type-D cyclins and their 
catalytic partners, CDK4 and CDK6. The activity of cyclinD-CDK4/6 complexes are 
kept in check by CDK inhibitors.  
 
There are two main families of CDK inhibitors: ink4 family and cip/kip family. 
p15ink4b, p16ink4a, p18ink4c and p19ink4d from the ink4 family inhibit the function 
of CDK4 and CDK6 by interfering their ability to bind to cyclin D(Roussel 1999). 
However, only p18ink4c and p19ink4d are highly expressed in lymphoid organs/cells 
(Guan, Jenkins et al. 1994; Chan, Zhang et al. 1995; Hirai, Roussel et al. 1995; Guan, 
Jenkins et al. 1996; Zariwala, Liu et al. 1996; Drexler 1998). p21cip1, p27kip1 and 
p57kip2 from cip/kip family are the “universal” CDK inhibitors which are able to 
inhibit a broad spectrum of cyclin-CDK complexes. 
 
p18ink4c 
Little is known about p18ink4c but it has been demonstrated to play a role in 
negatively modulating T cell proliferative response to TCR and CD28 costimulation 
(Kovalev, Franklin et al. 2001). Kovalev et. al. proposed that p18ink4c may set an 
inhibitory threshold in murine resting T cells that is overcome by CD28 costimulation, 
probably through the full induction of cyclin D, which then competes with p18ink4c 
for CDK6 to form active cyclin D-CDK6 complex since the levels of p18ink4c 
remains fairly constant even after T cell activation. The authors also pointed out that 






As with p18ink4c, little is also known about this CDK inhibitor and its effects on T 
cells. T cells with a mutant p19 allele exhibit normal T cell growth (Zindy, van 
Deursen et al. 2000). It has only been demonstrated that IL-10 and type I interferons 
are able to upregulate its level in macrophages (Matsuoka, Tani et al. 1998; O'Farrell, 
Parry et al. 2000). 
 
p21cip1 
p21cip1 has been shown to be expressed highly during S phase and in response to 
DNA damage via the p53-mediated pathway (Dulic, Stein et al. 1998). Two 
independent studies (Zhang, Lawless et al. 2000; Mohapatra, Agrawal et al. 2001) 
using p21-/- mice and another study (Appleman, Berezovskaya et al. 2000) using 
human T cells also demonstrated that p21cip1 is not involved in controlling the initial 
proliferation of T cells, instead its expression is induced during T cell expansion 
(Appleman, Berezovskaya et al. 2000; Balomenos, Martin-Caballero et al. 2000). 
Moreover, p21cip1 also interacts with the proliferating cell nuclear Ag (PCNA), 
preventing DNA replication via polymerase δ (Flores-Rozas, Kelman et al. 1994; 
Nourse, Firpo et al. 1994; Waga, Hannon et al. 1994; Luo, Hurwitz et al. 1995). 
Collectively, these findings suggest that the paradoxical increase in cell cycle 
inhibitor p21cip1 during T cell expansion is to allow a brief arrest in cycling cells to 
allow for DNA repair.  
 
p57kip2 
p57kip2 expression is increased by members of the p53 family that are capable of 




2005). In the case of T cell proliferation, p57kip2 levels are unchanged whether in 
activated or resting T cells (Li, Domenico et al. 2004), suggesting that this CDK 
inhibitor may not play a significant role in restricting cell-cycle entry. 
 
p27kip1 
Of the three members of the cip/kip family, p27kip1 has been the focus of most 
studies because p27kip1 is highly expressed in mature T cells but is down-regulated 
upon mitogen stimulation (Nourse, Firpo et al. 1994; Reynisdottir, Polyak et al. 1995; 
Kwon, Buchholz et al. 1997). Firpo et. al. reported that IL-2 induced T cell 
proliferation was due to inactivation of p27kip1(Firpo, Koff et al. 1994). Two other 
studies went on to demonstrate that IL-2 driven T cell proliferation could be 
suppressed by rapamycin and this was through inhibiting the down-regulation of 
p27kip1(Nourse, Firpo et al. 1994; Luo, Marx et al. 1996). Since then, many others 
have demonstrated that control of lymphocyte proliferation through TCR and CD28 
co-stimulation signalling and even growth-promoting cytokines (such as IL-2) seem 
to converge at down-regulating of p27 expression (Kobayashi, Phuchareon et al. 1997; 
Kwon, Buchholz et al. 1997; Durand, Fero et al. 1998; Kaplan, Daniel et al. 1998; 
Boonen, van Dijk et al. 1999; Banerji, Glassford et al. 2001; Barata, Cardoso et al. 
2001; Tsukiyama, Ishida et al. 2001; Appleman, van Puijenbroek et al. 2002; Slavik, 
Lim et al. 2004).  
 
A study on B cells by Schrantz et. al. also showed that p27kip1 and p18ink4c have 
different roles in G1 arrest in cell cycle. p27kip1 is involved in the control of cell 




necessary for B cell differentiation.(Schrantz, Beney et al. 2000) . Also, it has been 
shown that nuclear export and cytoplasmic degradation of p27kip1 is required for the 
effective progression of the cell cycle to through the G0-G1 transition (i.e to exit out of 
quiescence and into the G1 phase of the cell cycle) (Susaki, Nakayama et al. 2007). 
 
Rowell et. al. reported that p27kip1-/- CD4+ T cells accumulated more cell divisions 
throughout the culture period compared to wild type cells (Rowell, Walsh et al. 2005), 
which suggests that the limited proliferative capacity of CD4+ T cells observed by 
Foulds et. al.(Foulds, Zenewicz et al. 2002) may be due to p27kip1 regulation. In 
addition, they also demonstrated enhanced effector function of p27kip1-/- CD4+ T 
cells after activation by comparing the levels of secreted IL-2 with wild type cells 
(Rowell, Walsh et al. 2005). Thus far, there seems to be sufficient evidence which 
favours p27kip1 as the primary negative regulator in T cell proliferation especially 
during the transition from G0 to G1 and G1 to S phase. 
 
1.11 Kinetics of p27kip1 levels in wild-type CD8+ and CD4+ 
Rowell et. al. reported that when resting CD4+ T cells are activated through TCR and 
CD28 co-stimulation , the high levels of p27kip1 transiently fall but quickly rebound 
and are maintained for the entire first 48hrs of the response. After which, p27kip1 
expression decreases to approximately half the starting level by 72hrs (Rowell, Walsh 
et al. 2005). This is consistent with the findings of Wolfraim et. al. (Wolfraim and 
Letterio 2005). In addition, they also showed that p27kip1 levels in stimulated CD8+ 




Letterio 2005). This may provide an explanation as to why CD8+ T cells are able 
proliferate more rapidly and undergo more cell divisions than CD4+ T cells. 
 
1.12 CD28 and cytokine signalling linked to p27kip1 down-regulation 
Many studies have provided evidence supporting the hypothesis that ligation of the 
CD28 co-stimulatory molecule directly controls T cell progress through the down-
regulation of p27kip1, both through mechanisms independent and dependent on IL-2 
(Boonen, van Dijk et al. 1999; Appleman, Berezovskaya et al. 2000). Appleman et. al. 
showed that CD28 co-stimulation down-regulates p27kip1 through phosotidylinositol 
3-hydroykinase (PI3K) – protein kinase B (PKB) pathway. This leads to ubiquitin-
dependent degradation of p27kip1 (Appleman, van Puijenbroek et al. 2002).  
Cytokines, such as IL-2, have also been shown to be capable of promoting T cell 
proliferation through decreasing p27kip1 levels through PI3K and the mammalian 
target of rapamycin, mTOR (Nourse, Firpo et al. 1994; Brennan, Babbage et al. 1997). 
Some studies suggested that the need for CD28-costimulation in T cells is due to the 
threshold set by p27kip1(Rowell, Walsh et al. 2005; Wolfraim and Letterio 2005). 
This down-regulation of p27kip1 is then maintained through the induction of IL-2 
which “takes over” in maintaining the levels of p27kip1. 
 
Surprisingly, Wolfraim et. al. also demonstrated that in p27kip1-/- & p27kip1-/-CD28-/- 
mice, CD8+ T cells still exhibited enhanced proliferation compared to CD4+ T cells 
(Wolfraim and Letterio 2005), providing further evidence that CD8+ and CD4+ T cell 




& p27-/-CD28-/- CD4+ T cells did not exhibit significant difference from wild-type 
CD4+ T cells. 
 
The findings from Wolfraim et. al. seem to be contradictory to the findings published 
by Rowell et. al. which found enhanced proliferation in p27kip1-/- CD4+ T cells when 
compared to wild-type CD4+ T cells. As mentioned, ligation of CD28 has been 
demonstrated to occur through IL-2 dependent and independent pathways. Thus, it is 
possible that ligation of CD28 may actually lead to the regulation of other cell cycle 
molecules which may be involved in controlling CD4+ T cell proliferation that are 
distinct from p27kip1. Further studies would have to be done to verify this.  
 
From our literature search, the studies on cell cycle regulators were performed in 
different cell types such as mouse embryonic fibroblasts, B cells, splenocytes etc. 
Hence, it would not be right to assume that their findings are universally applicable, in 
this case, to CD8+ and CD4+ T cells as the one molecule can exert its effect differently 
in different cell types.  
 
For example, Bryja et. al. showed that cyclin D2- CDK complexes needed p27kip1 to 
maintain their levels in normal Leydig cells and the absence of p27kip1 resulted in 
abnormal levels of testosterone. In normal non-Leydig cells in the testicles of mice, 
however, p27kip1 was not required to maintain D2 cyclin levels (Bryja, Pachernik et 




phases, it is difficult to cover all the literature available for each of the cell cycle 
regulators in a single review. 
 
1.13 Aims of the study 
From the literature search, the picture of how CD8+ and CD4+ T cell clonal expansion 
is differently regulated intrinsically is incomplete. Through our literature search, we 
find that no one has tried to dissect at which phase of the cell cycle CD8+ and CD4+ T 
cells differ, whether it is at the G0, S, G2 or M phase of the cell cycle. p27kip1, though 
generally involved in the early initiation stages (G0 to S phase) of cell cycle, it is also 
possible that it has a role in the G2/M phase as well since it is a “universal” CDK 
inhibitor. Though briefly mentioned in the introduction, CD8+ T cells have a short 
subsequent cycle of about 6-8 hours while CD4+ T cells have a longer cycle of about 
10hrs, no studies have explained why CD4+ T cells require that additional 2 hours and 
how this additional 2 hours comes about. 
 
It would be appropriate to return to the basics of in vitro cell culture to set up a 
suitable T cells activation model that would allow us to map out the time course and 
kinetics of CD8+ and CD4+ T cells after TCR activation with/without CD28 co-
stimulation with less confounding factors which may be present if performed in vivo. 
The model would also allow for future studies to dissect the molecular mechanisms 
limiting CD4 T cells expansion and to understand the conflicting reports on the 





1.14 Specific Aims 
1) To compare the kinetics of CD8 and CD4 T cell expansion with optimal and 
suboptimal activation 
2) To determine whether CD4 T cells express more p27kip1 than CD8 T cells 
3) To determine how p27-/- will affect CD4 and CD8 T cell expansion kinetics 
and whether differences in proliferative capacity will still be observed. 
4) To determine whether p27-/- also affects the production of effector cytokines 













Chapter 2 - Materials and Methods 
 
2.1 Materials, media and buffers 
2.1.1  PBS buffer 
PBS buffer was commercially obtained from 1st Base as a 10x stock. The 10x stock 
consists of 137 mM NaCl, 2.7 mM KCl and 10 mM phosphate buffer. This stock is 
diluted with 9 parts water to give 1 x PBS. The pH was 7.2 to 7.4. 
 
2.1.2  MACS buffer 
Sterile MACS buffer consisted of 1 x PBS with 2 % FCS and 5 mM EDTA, pH7.2 to 
7.4 at 4ºC. 
1. Sterile filtered 10 x PBS was added to 9 parts of sterile deionised water. 
2. Sterile filtered 0.5 M EDTA was added to 1 x PBS solution to obtain a final        
concentration of 5 mM EDTA. 
3. The pH of this solution was adjusted to 7.2 to 7.4 with HCl. Sterility was ensured 
by taking small samples of the solution for pH adjustment. 
4. The solution was autoclaved with the cap loosely but firmly screwed to the bottle 
to minimize evaporation at this stage. 
5. The solution was allowed to cool to RT before adding FCS to a final     
concentration of 2 % v/v. 
6.  Buffer was chilled to 4ºC and distributed into 50 ml aliquots and used for cell 







2.1.3 FACS buffer 
Sterile MACS buffer consisted of 1 x PBS with 2 % FCS, 0.1% sodium azide and 5 
mM EDTA, pH7.2 to 7.4 at 4ºC. 
Preparation of FACS buffer similar to that of MACS buffer with the exception 
of adding 0.1% w/v sodium azide to the buffer. 
 
2.1.4  Annexin-V binding buffer 
10 mM Hepes/NaOH with 140 mM NaCl, 2.5 mM CaCl2, pH 7.4. 
5 ml of 1M Hepes/NaOH stock was added to 495 ml of sterile deionised water. 4.09g 
of NaCl and 0.184g of CaCl2 were added to this buffer. pH was adjusted to 7.4 and 
stored at 4ºC before use. 
 
2.1.5  Optiprep density centrifugation media for splenic DC isolation 
1. Optiprep (Axis-shield) was provided as a 60% w/v solution with a density of 
1.32g/ml. This was diluted using Optiprep diluent to 10.88% w/v (5.515x dilution 
with Optiprep diluent) with a density of 1.062g/ml, determined empirically to be 
optimal for splenic DC yield. The required density was calculated using the % w/v 
to density (g/ml) linear relationship represented by the formula: 
       y = 0.0052 x + 1.0054         Where y = density, x = % w/v. 
2. Optiprep diluent consisted of 0.8% (w/v) NaCl , 5 mM EDTA, 10 mM Tricine 







2.1.6  Digestion buffer for spleen DC isolation 
1. 25mg Liberase CI (Roche) stock was dissolved in 5ml RPMI-1640 and left for 
5min at 4ºC. 
2. This was then divided into 600µl aliquots (10x stock) and kept at -30ºC. 
3. Aliquots were thawed at 37ºC and diluted with RPMI-1640 and added 1 % v/v 
FCS to a final concentration of 0.5mg/ml. 
 
2.1.7  Complete medium for cell culture 
1. All cells in this study were cultured in complete medium. This was prepared from 
    RPMI-1640 with L-Glutamine (Gibco) with the addition of the following: 
a) 10 % v/v FCS (Hyclone), heat inactivated for 30 mins at 55ºC. 
b) 1 % v/v Non-essential amino acid (Sigma Aldrich) (100x from stock) 
c) 1 mM Sodium pyruvate (Sigma Aldrich) (100x from 100 mM stock) 
d) 5 μM β-Mercaptoethanol (Sigma Aldrich) (2 860 000x from 14.3 M stock) 
e) 100 IU/ml Penicillin and 0.1 mg/ml Streptomycin (Sigma Aldrich)  
      (100x from 10 000IU/ml Penicillin 10 mg/ml Streptomycin stock) 
2. 57.5 ml of FCS, 5.75 ml of 100 mM Non-essential amino acid, 5.75 ml of 100 
mM Sodium pyruvate, 5.75 ml of 10 000 IU/ml Penicillin 10 mg/ml Streptomycin 










2.1.8  DPBS buffer 
1. 0.2g of KCl, 0.2g of KH2PO4, 8.0g of NaCl and 2.16g of Na2HPO4•7H2O is 
added to 1 litre bottle. 
2. Deionised water was added to make up a final volume of 1 litre. 
3. pH was adjusted to pH 7.2-7.4 before storing at 4ºC. 
 
2.1.9 Ethanol fixation solution 
This fixation solution is used in particular for the fixing and permeabilisation of cells 
for DNA content analysis using PI staining. It is important to keep the tubes on ice at 
all times to minimize ethanol evaporation. 
1. 35ml of absolute ethanol was added to 15ml of 1xPBS in a 50ml Falcon tube and 
capped. 
2. The tube was shaken to mix. 
 
2.1.10 PI staining solution 
PI staining solution is used for DNA staining of ethanol-fixed cells to analyse their 
DNA content using flow cytometry. The solution is prepared fresh for each 
experiment. 
1.  1ml of Triton X-100 (Sigma) was added to 9ml of 1xPBS to make 0.1% (v/v) 
Triton-X 100 solution. 
2. Propidium iodide stock (powder form) (Sigma) was dissolved in water to a 
working concentration of 1mg/ml. 
3. 2 mg of DNase-free Rnase A (R6513, Sigma) and 200uL of 1 mg/ml PI (Sigma) 
was added to 10ml of 0.1% (v/v) Triton X-100 solution to make up the PI staining 





2.1.11 4x Upper Tris  
This buffer used in the preparation of the stacking gel for protein separation using 
SDS gel electrophoresis. 
1. 12.1g Tris base (1st Base) was added to 80ml of deionised water. 
2. pH was adjusted to pH6.8 by adding 1M HCl. 
3. The buffer was topped up to 200ml with deionised water and filtered through 
0.45µm membrane before adding 0.8g SDS. 
 
2.1.12 4x Lower Tris  
This buffer used in the preparation of the separating gel for protein separation using 
SDS gel electrophoresis. 
1. 182g Tris base (1st Base) was added to 600ml of deionised water. 
2. pH was adjusted  to pH8.8 by adding 1M HCl 
3. The buffer was topped up to 1L with deionised water and filtered through 0.45µm 
membrane before adding 4g SDS. 
 
2.1.13 10% APS  
10% APS together with TEMED, is used during the casting of gels to catalyze the 
polymerization of acrylamide. 
1. 1g of APS is added to 5ml of deionised water and mixed until it is dissolved. 
2. The solution is topped up to 10ml deionised water to make a 10% APS solution. 








2.1.14 SDS running buffer  
SDS running buffer is used for gel electrophoresis. 
200ml of 5x Tg-SDS buffer stock (1st base) is diluted with 800ml deionised water to 
obtain 1L of SDS running buffer. 
 
2.1.15 Western blot transfer buffer  
Western blot transfer buffer is used during the transfer of proteins onto nitrocellulose 
membrane after gel electrophoresis. 
1. 27.5ml of 1M Tri solution pH8.3 (1st Base) 
2. 211.2ml of 1M glycine (15.84g) 
3. 220ml 100% methanol 
4. 1.1ml of 10% SDS 
5.  Top up to 1.1L with deionised water and store at 4ºC. 
 
2.1.16 PBST buffer & Western blot blocking buffer 
PBST buffer was used during Western blot procedures for washing. Blocking buffer 
is used for blocking steps during Western blot. 
1. 5ml of Tween20 was added to 1L of 1xPBS to make 0.5% PBST. 
2. For blocking buffer, 4% milk powder was added to 1xPBST. (4g of milk powder 






2.1.17 List of antibodies used 
 
Primary antibodies. 
Target Host Clone Conjugation Source 
Anti-BrdU - - APC BD Pharmingen 
CDK2 Mouse D-12 - Santz Cruz 
CD3e Hamster 145-2C11 - BD Pharmingen 
 Hamster 500A2 eFluor450 eBioscience 
CD4 Rat RM4-5 PE-Cy7 Biolegend 
CD8α Rat 53-6.7 PerCp Cy5.5 Biolegend 
CD11c Hamster N418 eFlour450 Biolegend 
 Hamster N418 Alex647 Biolegend 
CD16/32 Rat 2.4G2 - BD Pharmingen 
CD25 Rat PC61 PE Biolegend 
 Rat 3C7 APC  BD Pharmingen 
CD28 Hamster 37.51 - BD Pharmingen 
 Hamster 37.51 PE BD Pharmingen 
CD44 Rat IM7 APC BD Pharmingen 





 Rat APC FITC  Biolegend 
CD69 Hamster H1.2F3 FITC BD Pharmingen 
CD80 Rat 16-10A1 FITC BD Pharmingen 
 Rat 16-10A1 PE BD Pharmingen 
CD86 Rat GL1 FITC BD Pharmingen 
CD122 Rat TM-β1 PE Biolegend 
CD132 Rat 4G3 PE BD Pharmingen 
Foxp3 Rat FJK-16s PE eBioscience 
Gata3 Rat TWAJ APC eBioscience 
Hsp90 Mouse 68/Hsp90 - BD Pharmingen 
IA/IE Rat M5/ 114.15.2 eFlour450 eBioscience 
IFN-γ Rat XMG1.2 Alex647 BD Pharmingen 
IL-2 Rat JES6-5H4 PE BD Pharmingen 
IL-13 Rat eBio13A PE eBioscience 
p27kip1 Mouse G173-524 - BD Pharmingen 








Secondary antibodies/ Detection reagents 
Target Host Conjugation Source 










C57BL/6J mice were obtained from NUS CARE facility. OTI (C57BL/6J background) 
mice were from Charles River Laboratories and transgenic for CD8-TCRs that 
specifically recognise the OVA (257-264) epitope (Rotzschke, Falk et al. 1991). OTII 
mice (C57BL/6J background) were also from Charles River Laboratories and 
transgenic for CD4-TCRs that specifically recognise the OVA (323-339) epitope 
(Robertson, Jensen et al. 2000). p27kip1 (Kiyokawa, Kineman et al. 1996) and Skp2 
knockout mice (from Keiichi Nakayama, Kyushu University in Japan) were kindly 
provided by Dr Philipp Kaldis from Institute of Molecular and Cell Biology (IMCB).  
The mice were euthanized by CO2 asphyxiation and excised for their spleens. Mice 
used were between 8-12 weeks old and kept either in NUS Animal Holding Unit 















2.3.1 Isolation of T lymphocytes 
1. A pair of sterile surgical scissors was used to cut the pooled spleens into tiny 
pieces. 
2. The cut pieces were mashed and passed through a 70µm cell strainer (BD Falcon) 
using the flat end of a 1ml syringe (Braun) to obtain a single cell suspension in a 
50ml Falcon tube. 
3. The cell strainer was washed with RT MACS buffer to collect as many cells as 
possible. 
4. The cells were pelleted by centrifuging at 350G for 5min at RT and the 
supernatant was discarded. 
5. The cells were resuspended with RT MACS buffer (3ml of MACS buffer for 
every  2 spleens) and lymphocyte enriched by layering 3ml of the cell suspension 
onto 4ml of Ficoll-Paque Plus (GE Healthcare) centrifugation gradient. The 
gradient was centrifuged at 550G for 15min at RT without any acceleration or 
brakes. 
6. The buffy coat was collected from the between the layers and resuspended in 
complete RPMI. The cell suspension was centrifuged at 600G for 10min at RT to 
remove the remaining Ficoll-Paque Plus in the suspension. The supernatant was 
discarded and resuspended in complete RPMI. 
7. The cell suspension was transferred into 75cm3 tissue culture flasks (Nunc). 
Adherent cells were removed by 40min incubation at 37ºC, 5% CO2. 
8. The remaining cells were collected, transferred into a 15ml Falcon tube and 





9. 4µl of CD19+ MACS beads and 10μl of CD11c+ (Miltenyi Biotech) per 107 cells 
were added to the cell suspension and incubated for 15min at 4ºC in the dark; the 
tube was raked every 5min. 
10. 3ml of cold MACS buffer was added to the tube. Each washing step consisted of 
centrifugation at 350G for 5min at 4ºC to pellet the cells and discarding the 
supernatant. 
11. The cell pellet was resuspended with 500µl cold MACS buffer per 108 cells and 
loaded onto an LS column (Miltenyi Biotech) pre-wetted with 1ml of cold MACS 
buffer. 
12. The negative flow-through was collected in a 15ml Falcon tube. The LS column 
was washed three times with 3ml of cold MACS buffer each time to collect any 
remaining unbound cells. 











2.3.2 Purification of CD8+ and CD4+ T lymphocytes 
1. Lymphocyte enriched cell population were counted using a hemocytometer. 
2. 4µl CD8+ / 8µl CD4+ MACS beads (Miltenyi Biotech) were added per 107 cells 
into the tube and incubated for 15min at 4ºC in the dark; the tube was raked every 
5min. 
3. 3ml of cold MACS buffer was added to the tube. The washing step consisted of 
centrifugation at 350G for 5min at 4ºC to pellet the cells and discarding the 
supernatant. 
4. The cell pellet was resuspended with 500µl cold MACS buffer per 108 cells and 
loaded onto an LS column (Miltenyi Biotech) pre-wetted with 1ml of cold MACS 
buffer. 
5. The negative flow-through was collected in a 15ml Falcon tube. The LS column 
was washed three times with 3ml of cold MACS buffer each time to collect any 
remaining unbound cells. 
6. The LS column was removed from the magnetic holder and placed onto a new 
15ml Falcon tube. 5ml of complete RPMI was added loaded onto the LS column 
and flushed from the column using the plunger provided. 









2.3.3 Analysis of surface markers using Fluorescence-Activated Cell Sorter (FACS)  
1. Cells were surface labelled with fluorescence-conjugated monoclonal antibodies. 
5x105 cells were first transferred to FACS tubes and centrifuged at 450G for 5min 
at 4°C with chilled MACs buffer to wash.  
2. The supernatant was discarded and the tubes were raked. 1μl of relevant antibody 
was added to each tube.  
3. Cells were incubated in the dark for 20min at 4°C.  After incubation, the cells 
were washed three times with chilled MACS buffer and finally resuspended in 
500µl of MACS buffer.  
4. Cells were then acquired and analysed using Cyan ADP (DakoCytomation).  
 
2.3.4 Isolation of CD11c+ DCs 
1. 1ml liberase (Roche) per spleen was used to flush the cells from the spleen into a 
15ml Falcon tube via a syringe with 27 gauge needle (BD Precision Glide needle).  
2. The spleens transferred into a 6-well plate and were cut into tiny pieces using a 
pair of sterile surgical scissors and incubated at 37ºC water bath for 30min. 
3. The cut pieces were mashed and passed through a 70µm cell strainer (BD Falcon) 
using the flat end of a 1ml syringe (Braun) to obtain a single cell suspension in a 
50ml Falcon tube. 
4. The cell strainer was washed with RT MACS buffer to collect as many cells as 
possible. 
5. The cells were pelleted by centrifuging at 350G for 5min at RT and the 
supernatant was discarded. 
6. The cell pellet was resuspened in 1.5ml of Optiprep (Axis-shield) centrifugation 





7. A 2ml layer of FCS was layered over every 3ml of cell-Optiprep suspension. Cells 
were centrifuged at 1700G for 10min at 4ºC without any acceleration or brakes. 
8. The buffy coat layer was collected into a 15ml Falcon tube and washed with cold 
MACS buffer. The tube was then centrifuged at 600G for 10min at 4ºC. 
9. 1µl of CD16/CD32 antibody (2.4G2, BD Pharmingen) was added per 107 cells and 
incubated for 10min. 
10.  10µl of CD11c+ MACS beads (Miltenyi Biotech) were used per 107 cells and 
were incubated for 10min at 4ºC in the dark; the tube was raked once after 5min. 
11. 3ml of cold MACS buffer was added to the tube. The washing step consisted of 
centrifugation at 350G for 5min at 4ºC to pellet the cells and discarding the 
supernatant. 
12. The cell pellet was resuspended with 500µl cold MACS buffer per 108 cells and 
loaded onto an LS column (Miltenyi Biotech) pre-wetted with 1ml of cold MACS 
buffer. 
13. The negative flow-through was collected in a 15ml Falcon tube. The LS column 
was washed three times with 3ml of cold MACS buffer each time to collect any 
remaining unbound cells. 
14. The LS column was removed from the magnetic holder and placed onto a new 
15ml Falcon tube. 5ml of complete RPMI was added loaded onto the LS column 
and flushed from the column using the plunger provided. 
15. Purity of CD11c DCs was checked using flow cytometry. 
16. This was followed by MACS CD11c+ (Miltenyi Biotech) positive selection to 





2.3.5 In vitro activation and culture of T lymphocytes 
1. U-bottomed 96 well plates (Nunc) were used to culture T lymphocytes. 105 cells 
in 200µl culture medium were seeded into each well.  
2. Wells used for activation were coated with either 1µg/ml anti-CD3ε (145-2C11, 
BD Pharmingen), 1µg/ml anti-CD3ɛ and 0.5µg/ml soluble anti-CD28 (37.51, BD 
Pharmingen) or with 1µg/ml anti-CD3ε co-cultured with CD11c+ DCs. The T cell 
to DC ratio was 3:1. Cells were cultured at 37ºC, 5% CO2. 10ng/ml PMA (P8139, 
Sigma-Aldrich) and 400ng/ml Ionomycin (I0634, Sigma-Aldrich) was used as a 
positive control for activating T lymphocytes. 
3. Activated T lymphocytes were harvested at various time points for subsequent 
experiments. 
 
2.3.6 [3H] thymidine proliferation assay 
1. 1mCi/ml [methyl-3H]-thymidine (Amersham Biosciences) was diluted with 
complete RPMI to obtain a working concentration of 50µCi/ml. 
2. Activated T lymphocytes were pulsed with 20µl of [methyl-3H]-thymidine 
(1µCi/well) 12hrs before harvesting. They were collected onto a harvesting plate 
(Unifilter-96, GF/C from Perkin Elmer) using Filtermate Harvester (Perkin Elmer).  
3.  The plate was then placed in a 50°C oven for 2hrs to dry.  After drying, the 
bottom of the plate was sealed with Backing Tape (Perkin Elmer) and 20μl of 
Microscint 20 (Perkin Elmer) was added to each well containing the harvested 
cells.  
4. The plate was covered with TopSealTM (Perkin Elmer) and transferred to 






2.3.7 Annexin V/ 7-AAD viability assay 
1. Activated cells were harvested from culture plates and centrifuged at 450G for 
5min at 4ºC. 
2. The supernatant was discarded and resuspended with 1ml of PBS and were 
centrifuged at 450G for 5min at 4ºC. 
3. The cells were then resuspended in 100µl of annexin binding buffer and 5µl of 
annexin V FITC (BD Bioscience) and 1µl of 7-AAD (Sigma Aldrich) was added 
into each tube. 
4. The tubes were incubated in the dark at RT for 15min before another 400µl of 
annexin binding buffer was added to the tubes. 
5. The cells were analysed for viable and dead cells using FACS. Dead cells were 
positively stained for Annexin V-FITC and 7-AAD while viable cells were not 
positively stained for both dyes. Dying cells were Annexin V-FITC positive but 7-
AAD negative. 
 
2.3.8 Viability & cell count assay 
1. 16.2mM Hoechst 33342 stock (H3570, Invitrogen) was diluted with dH2O to a 
working concentration of 1mM. 
2. 30 minutes before the stipulated time for harvesting, 2µl of 1mM Hoechst 33342 
was added into each well. This is to allow time for dead cells to pick up the 
Hoechst 33342 (final concentration 10µM). The plates were covered with 
aluminium foil and incubated at 37ºC, 5% CO2. 
3. The cells were then transferred into FACS tubes after 30 minutes incubation and 
topped up to final volume of 300µl with RT FACS buffer. 
4. RT CountBright™ Absolute Counting Beads (Molecular Probes) was vortexed for 





5. The cells were analysed for viability and cell number by flow cytometry. At least 
1000 bead events were collected to ensure a statistically significant determination 
of sample volume. 
6. Calculation of cell concentration: 
      A × C = concentration of sample as cells/μL 
      B     D 
     Where: 
     A = number of cell events 
     B = number of bead events 
     C = assigned bead count of the lot (49,500 beads/50 μL) 








2.3.9 CFSE staining of T lymphocytes 
1. Purified CD8/CD4 T lymphocytes were suspended in 1xPBS with 0.1% BSA at a 
cell concentration of 107cells/ml.  
2. An equal volume of PBS-diluted 7µM CFSE (Invitrogen) was added to the cell 
suspension and pipetted gently several times. The cells were incubated at 37ºC, 5% 
CO2 for 10min with raking once at 5min.  
3. The reaction was quenched by adding complete RPMI to the cell suspension and 
incubated at room temperature in the dark for 10min. The cells were washed twice 
and resuspended in complete RPMI. Final CFSE concentration obtained was 
3.5µM. 
 
2.3.10 Multiplex bead array 
Multiplex bead arrays were performed using Bio-rad multiplex assay kit according to 
the manufacturer’s instruction. However, 2 x less of the stock reagents was used (for 
example, 50x dilution of beads becomes 100 x dilution of beads). This gave the same 
results if we used the dilution factor recommended by the manufacturer and allowed 
us to use the kit for more assays. 
1. The master standard stock was reconstituted with 500 ul of complete RPMI-1640 
with 10 % FCS, and vortexed for 1-3 seconds. This was incubated on ice for 
30mins prior to use. 
2.  4 fold serial dilutions of the standard were made with complete media. 
3. Antibody conjugated beads were vortexed for 30 s before being diluted with 
Bioplex assay buffer according to the recommended dilution factor.  
4. Diluted beads were kept in the dark on ice. 96 well sterile filter plates (Millipore, 
Multiscreen HTS, BV, 1.2 μm hydrophilic low protein binding, durapore 





5.  Buffer was removed using a vacuum manifold (Millipore, MultiscreenTM HTS), 
with pressures not exceeding 2.5 Hg or 85 mBar to prevent breakage of the filter. 
6. Diluted beads were vortexed for 15 to 20 s and 50 μl of beads were added to each 
well. 
7.  Buffer was removed using a vacuum manifold. 
8. 100μl per well of Bioplex wash buffer was added to each well. Buffer was 
removed using vacuum manifold. 
9. 50µl of pre-diluted standards and samples diluted in complete media were added 
into the appropriate wells. The filter plates were sealed with the sealing tape 
provided and placed onto a plate shaker. Plates were shaken at 1100 rpm for the 
first 30 sec and then 300 rpm for 1 hr. Plates were covered with aluminum foil to 
prevent photobleaching. 
10. After incubation, supernatants and standards were removed using vacuum 
manifold. 100 μl of Bioplex wash buffer was added to each well and removed 
using the vacuum manifold. Washing was repeated 2 more times. 
11. Detection antibodies were diluted in detection antibody diluent according to the 
recommended dilution factor given by the manufacturer. 
12. 25µl of diluted detection antibody was added to each well and sealed using sealing 
tape. Plates were shaken at 1100 rpm for the first 30 s and then 300 rpm for 1 hr. 
Plates were covered with aluminum foil to prevent photobleaching. 
13. After incubation, detection antibody solution was removed using vacuum 
manifold. 100μl of Bioplex wash buffer was added and removed using vacuum 





14. 50 µl of streptavidin-PE diluted with assay buffer with the recommended dilution 
factor. Plates were shaken at 1100 rpm for the first 30 s and then 300 rpm for 
20mins. Plates were covered with aluminum foil to prevent photobleaching. 
15. After incubation, streptavidin-PE solution using vacuum manifold, and wells were 
wash thrice with 100 μl Bioplex wash buffer. 
16. Wells were resuspended with 125 ul of Bioplex assay buffer, sealed and shaken at 
1100 rpm for 30 s. Analysis were performed with the Luminex 100 (Qiagen). At 
least 60 events were collected for each cytokine bead. 
 
2.3.11 T cell proliferation with anti-mouse IL-2 neutralizing antibody 
1. 1mg/ml of purified NA/LE rat anti-mouse IL-2 neutralizing antibody (S4B6, BD 
Pharmingen) was diluted with complete RPMI to a working concentration of 
60µg/ml.  
2. Next, 20µl of the neutralizing antibody was added into each well (final 
concentration 6µg/ml) 
 
2.3.12 Depletion of CD4+CD25+T cells from CD4+cells 
1. T lymphocyte single cell suspension was obtained as described in section 2.3.1. 
2. CD4+ CD25+ T cells were removed from the CD4+ population using CD4+CD25+ 
Regulatory T Cell Isolation Kit (Miltenyi Biotech). 
3.  Cells were resuspended in 15ml Falcon tube in cold MACS buffer (40µL per 107 
cells), followed by 10µL of Biotin-antibody cocktail per 107 cells. 
4. The cell suspension was mixed well and incubated at 4ºC for 10min. 
5. Next, 30μL of MACS buffer, 20μL of anti-biotin microbeads and 10μL of CD25-





6. The cell suspension was mixed well and incubated at 4ºC for another 15min. 
7. 1ml of MACS buffer was added per 107 cells and centrifuged at 300g for 10min. 
Supernatant was aspirated. 
8. Cells were resuspended in 500µL of MACS buffer per 1.25x108 cells and passed 
through LD column. 
9. The negative flowthrough containing CD4+ CD25- T cells was collected and 
subsequently used for culture.  
 
2.3.13 OVA peptide proliferation assay 
1. CD11c+ DCs were isolated as described in section 2.3.4. 
2. 2x106 DCs were pulsed with 1µg of peptide in a volume of 1ml complete RPMI 
for 30min at 37°C in 5% CO2.  
3. After 30mins, the DCs were washed twice to remove any excess peptide which 
was not bound onto the DCs. The DCs were then resuspended in complete RPMI. 
4. 1x105 cells in 200μl were seeded into each 96-well round bottomed plates (Nunc) 
well. T cells were stimulated with T cells were stimulated with CD11c+ DCs 
pulsed with OVA peptides: OVA257-264 (Anaspec Inc.) for OT-I CD8 T cells and  
OVA323-339 (Anaspec Inc.) for OT-II CD4 T cells, in the ratio of 10 T cells: 1 DC.   
5. The plate was incubated at 37°C in 5% CO2 over a period of 24-96hrs. Cells were 
then pulsed 12hrs with [methyl-3H]-thymidine) (1μCi/20μl/ well) (Amersham 
Biosciences) before harvesting onto a harvesting plate (Unifilter-96, GF/C from 
Perkin Elmer) using Filtermate Harvester (Perkin Elmer).   
6. The harvested plate was placed in a 50°C oven for 2hrs to dry.  After drying the 
plate, the bottom of the plate was sealed with Backing Tape (Perkin Elmer) and 





harvested cells. The plate was covered with TopSealTM (Perkin Elmer) and 
transferred to TopCount NXT (Perkin Elmer) for counting. Results were 
expressed as counts per minute (CPM). 
 
2.3.14 Purification of naïve and memory CD8 and CD4 T cells 
Enriched T lymphocyte population was obtained as described in method 2.3.1. 
1. Cells were first incubated with 0.5µl CD16/CD32 (2.4G2, BD Pharmingen) per 
107 cells for 10min at 4ºC in the dark. 
2. Next, cells were incubated with CD62LFITC (MEL-14, Biolegend), CD25PE 
(3C7, Biolegend), CD8aPerCP/Cy5.5 (53-6.7, Biolegend), CD4PE/Cy7 (GK1.5, 
Biolegend), CD11cPB (N418, Biolegend) and CD44APC (IM7, BD Pharmingen) 
antibodies for 20 minutes at 4ºC in the dark.  
3. Cells were washed twice. Each washing step consisted of centrifugation at 350G 
for 5min at 4ºC to pellet the cells and discarding the supernatant. 
4. Cells were resuspended in cold MACS buffer to a concentration of 5x107 cells/ml. 
5.  Naïve CD8+ and CD4+ T cells sorted were gated on CD44lo-int CD62L+ CD11c-
CD25-. Memory T cells sorted were gated on CD44hi CD11c- CD25- cells.   
 
2.3.15 In vivo BrdU incorporation  
1. 1mg/10g of body weight of Brdu dissolved in DPBS was injected intraperitoneally 
into each mouse. 
2. After 24hrs, the mice were culled and the spleen excised and processed to detect 






2.3.16 In vitro BrdU incorporation and staining 
1. Dilute 10mg/ml (32.5mM) BrdU stock with DPBS to a working concentration of 
1mM. 
2. 10µl of 1mM BrdU solution was added to each ml of tissue culture media and 
incubated for 1hr before the cells were harvest at their stipulated time points. 
3. Cells were harvested and transferred into FACS tubes. 
4. Cells were centrifuged and pelleted at 450g for 5min at RT. Cells were then 
resuspended in FACS buffer and re-pelleted. 
5. Fluorescent antibodies for cell surface staining were added and incubated for 
15min at 4ºC in the dark. 
6. Cells were washed with FACS buffer, centrifuged at 450g for 5min at 4ºC and 
supernatant discarded. 
7. 100µl of BD Cytofix/Perm buffer was resuspended with the cells to fix and 
permeabilize them. The cells were incubated for 30min at 4ºC. 
8. Cells were washed with 1ml 1x BD Perm/Wash buffer and centrifuged as in step 
6 and supernatant discarded. 
9. Cells were resuspended with 100µl DNAse per tube (30µg DNAse per tube 
diluted in DPBS) and incubated at 37ºC for 1hr. 
10. Cells were washed with 1ml 1x BD Perm/Wash buffer and centrifuged as in step 
6 and supernatant discarded. 
11. Cells were then incubated with Alex Fluor 647 mouse anti-BrdU (3D4,BD 
Pharmingen)  for 20min at RT in the dark. 
12. Cells were washed with 1ml 1x BD Perm/Wash buffer and centrifuged as in step 
6 and supernatant discarded. 
13. Cells were resuspended 500µl FACS buffer and 1µl of 1mg/ml 7AAD solution 





14. Cells were then analyzed using flow cytometry. 
 
2.3.17 DNA content analysis with PI staining 
1.  Kept ethanol-fixation solution on ice to ensure that the solution was ice-cold at all 
time during the experiment. 
2. Harvested the cells into FACS tubes and centrifuged the tubes at 450G for 5min at 
4ºC. 
3. Pipetted to remove supernatant and washed the cells twice with 1xPBS. 
4. Cells were centrifuged for 5min at 350G at 4ºC. 
5. Removed supernatant and resuspended cells by100µl of PBS and vortexed for 
about 30secs. 
6. 1ml of 70% ethanol was added dropwise into each tube while vortexing. 
7. Cells were incubated overnight at 4°C. 
8. Ethanol-suspended cells were centrifuged 10min at 300G at 4ºC.. 
9.  Ethanol was removed completely and resuspended the cell pellet (not very visible 
after ethanol-fixing) in 1ml of 1xPBS and leave for 1min. 
10. Centrifuged the tubes for 5min at 200G at R.T. 
11. The cell pellet was resuspended in the cell pellet in 500μl PI/Triton X-100 staining 
solution with RNase A (approximately at cell concentration of 2x106 cells/ml of 
PI staining solution) and incubated for 30min at 37°C. 
12. Measured for PI fluorescence using FACS. 
 
2.3.18 Bradford assay to determine protein concentration 






2. 1x106 cells were resuspended in 50µl of PBS. 
3. 5µl of the cell suspension was added a single well of a 96 well plate (duplicates). 
4. Standard curve was using dilution of 10mg/ml BSA. 
5. 200µl of the diluted protein assay solution is added into each well before 
analysing protein concentration at 595nm for the amount of protein. 
 
2.3.19 Preparation of 12% SDS-PAGE Gel  
1. The gel setting apparatus was first set up before the stacking and separating gels 
were casted. 
2. Separating gel recipe for 2 plates: 
a) 30%AA/ 0.8% bis-AA (3.3% crosslinker) (Bio Rad)  7.2ml 
b) 4x Lower Tris       4.5ml 
c) Water        6.3ml 
d) 10% APS       100µl 
e) TEMED       40µl 
3. Stacking gel recipe for 2 plates: 
a) 30%AA/ 0.8% bis-AA (3.3% crosslinker) (Bio Rad) 325µl 
b) 4x Upper Tris       625µl 
c) Water        1.75ml 
d) 10% APS       30µl 
e) TEMED       7.5µl 
4. Poured the separating gel solution into the gel cast and layered with 1ml of 1% 





5. The 1% SDS solution was decanted and excess liquid was dried using kimwipes. 
The stacker gel solution was layered on top of the cast separating gel and left 
overnight to cast. 
6. The well comb was removed after the stacker gel had solidified. 
 
2.3.20. SDS gel electrophoresis and transfer onto nitrocellulose membrane  
1. The 12% SDS gel was placed in the gel electrophoresis chamber filled with SDS 
running buffer. 
2. 4µl of pre-stained SDS PAGE standard broad range (Bio Rad) protein ladder was 
loaded as standard marker and equal amounts of sample protein were loaded into 
each well based on the protein concentration obtained from Bradford Assay 
readings. 
3. The loaded samples ran for 10mins at 80V followed by another 100-120mins at 
100V. 
4. After gel electrophoresis, the gel was removed from the chamber and placed onto 
nitrocellulose paper. 
5.  Protein transfer was carried out in transfer chamber filled with transfer buffer and 
ran overnight at 50V on ice. 
 
2.3.21 Western blot 
1. The nitrocellulose membrane was placed in a container and washed with 1xPBS. 
2. PBS was decanted from the container. 
3. Blocking buffer was poured into the container. 





5. Meanwhile, primary antibodies mouse anti-p27 (1:2500 dilution) (BD Pharmingen) 
& mouse anti-Hsp90 (1:1000) (BD Pharmingen) were prepared by diluting 20µl 
and 50µl of antibody respectively in 50ml of blocking buffer. Primary mouse anti-
CDK2 (1:1000) (Santa Cruz) was prepared by diluting 10μl of antibody in 10ml of 
blocking buffer. 
6. Added the primary antibodies to the membrane and incubated on the shaker 
overnight at 4ºC. 
7. Removed the membrane from primary antibody and washed twice with PBST, 
each for 10min at RT. 
8. Reblocked the membrane with blocking buffer twice for 10min at RT on the 
shaker. 
9. Meanwhile, secondary antibody goat anti-mouse IgG-HRP (1:1000) (Santa Cruz) 
was prepared by diluting 50µl of antibody with 50ml of blocking buffer. 
10. Poured away blocking buffer and incubated with secondary antibody for 1-2hr on 
the shaker at RT. 
11. Removed the antibody solution and washed thrice with PBST, each for 10min at 
RT. 
12. The membrane was washed twice with 1xPBS. 
13. Prepared the substrate (1:1 ratio) of HRP + peroxidise solution (Supersignal West 
Pico chemiluminescent substrate from Pierce), approximately 2.5ml of substrate 
solution per membrane. 
14. The membranes were placed in a container and substrate solution was poured onto 
the membranes, ensuring that all parts of the membrane were covered by the 





15. The membranes were incubated for 15min at RT, shaking occasionally to ensure 
no dry areas formed. 
16. The membranes were transferred into the cassette and exposed to the film with 
various timings to obtain different exposures of the membranes. 
17. The film from removed from the cassette and developed through the machine. 
 
2.3.22 Intracellular staining of cells 
1. Monensin (1000x dilution) (BD Biosciences) and Brefeldin A (500x dilution) (BD 
Biosciences) were added to each well of cells 6hrs before harvesting to block 
protein export out of the cells. 
2. Cells were harvested and transferred into FACS tubes. 
3. Cells were centrifuged and pelleted at 450g for 5min at RT. Cells were then 
resuspended in FACS buffer and re-pelleted. 
4. 100µl of BD Cytofix/Perm buffer was resuspended with the cells to fix and 
permeabilize them. The cells were incubated for 30min at 4ºC. 
5. Cells were washed with 1ml of 1x BD Perm/Wash buffer and centrifuged as in 
step 3 and supernatant discarded. 
6. 50µl of BD Perm/Wash buffer was added into each tube and 1µl of the relevant 
antibodies were added to the tubes. 
7. The cells were incubated for 30min at 37ºC in the dark. 
8. Cells were washed with 1ml of 1x BD Perm/Wash buffer and centrifuged as in 
step 3 and supernatant discarded. 







2.3.23 Statistical analysis 
Results were expressed as mean  SEM, where data from more than one experiment 
were pooled.  Unpaired student t-test was used to determine statistical significance. * 





Chapter 3 - Setting up in vitro model to study T cell expansion 
 
3.1 Introduction 
Previously, in vivo studies with listeria monocytogenes and lymphocytic 
choriomeningitis virus (LCMV) have observed a significant increase in the number of 
antigen-specific CD8 T cells as compared to antigen-specific CD4 T cells during the 
course of infection (Whitmire, Murali-Krishna et al. 2000; Foulds, Zenewicz et al. 
2002). The peak of the CD8 response during LCMV infection occurred earlier (day 8) 
than peak of the CD4 response (day 15) in the LCMV infection (Whitmire, Murali-
Krishna et al. 2000). In addition, Foulds et al. also observed that CD8 T cells 
underwent extensive  proliferation and  massive clonal expansion  while proliferation 
of CD4 T cells was limited and clonal expansion restricted (Foulds, Zenewicz et al. 
2002). Though the differences in the ability of CD8 and CD4 T cells to expand has 
been observed (Butz and Bevan 1998; Murali-Krishna, Altman et al. 1998; Whitmire, 
Flavell et al. 1999; Jelley-Gibbs, Lepak et al. 2000; Murali-Krishna and Ahmed 2000; 
Veiga-Fernandes, Walter et al. 2000; Whitmire and Ahmed 2000; Homann, Teyton et 
al. 2001; Kaech and Ahmed 2001; Tan, Dudl et al. 2001; Wong and Pamer 2001; 
Foulds, Zenewicz et al. 2002), the various factors that are involved in limiting CD4 T 
cell expansion as compared to CD8 T cells have not been definitive. 
 
We decided to carry out a study on the proliferation kinetics of T cell expansion in an 
in vitro system as it would allow tighter control of how CD4 and CD8 T cells are 
activated. It would also allow proliferation to be studied in a controlled environment 
in comparison to an in vivo model and allow us to better understand the requirements 





In this chapter, we first set out to design and optimize the conditions to for optimal T 
cell activation and expansion in an in vitro cell culture system that would allow us to 





3.2 Purity of MACS purified CD8 and CD4 T cells from spleen & lymph 
nodes 
To obtain CD4 and CD8 T cells for culture in vitro for activation, we needed to 
isolate T cells pooled from the spleen and lymph nodes. After obtaining a single cell 
suspension from the spleen and lymph nodes, we depleted B cells and DCs using 
CD19+ and CD11c+ MACs beads. The flowthrough was collected and purified for 
CD8+ T cells first and the subsequent flowthrough was purified for CD4+ T cells. 
The forward scatter versus side scatter profile of CD4 and CD8 purified T cells after 
MACS positive selection is shown in Figure 3.2 1 (A). The gate used for determining 
purity included all viable cells (lymphocytes and other cells types).  From the forward 
and side scatter FACS profile, it was observed that the lymphocyte population was 
varied in size, suggesting heterogeneity within the population. However, for the initial 
purpose of setting up the model, we decided to stick with MACS positive selection of 
CD4 and CD8 T cells.  
 
Figure 3.2 1 (B) and (E) show the isotype staining for CD4 and CD8 T cells 
respectively. Figure 3.2 1 (C) and (F) show the purity obtained for CD4 and CD8 T 
cells respectively from the initial experiments based on the procedure detailed in 
material and methods. The typical purity of CD4 and CD8 T cell after MACS positive 











Figure 3.2 1 FACS profile & purity of CD4 and CD8 T cells from C57BL6 mice 
after MACS positive selection.  
Pooled T cells from the spleen and lymph nodes of C57BL6 mice were enriched using 
Ficoll-Hypaque centrifugation gradient and purified using MACS positive selection. 
(A) FSC linear versus SSC linear profile for purified CD4 T cells. (B) Isotype control 
staining and (C) staining with anti-mouse CD3e efluor450 and anti-mouse CD4 PE-
Cy7. (D) FSC linear versus SSC linear profile for purified CD4 T cells. (E) Isotype 
control staining and (F) staining with anti-mouse CD3e efluor450 and anti-mouse 
CD8 PerCP Cy5.5. Typical purity of CD4 and CD8 T cells after MACS positive 
selection ranged between 88-93%. This is representative of a typical profile after 











3.3 Purity of MACS purified splenic CD11c+ DCs 
We wanted to purify CD11c+ DCs to provide a source of co-stimulatory molecules for 
activation for our in vitro activation for T cells. DCs were released from the spleen 
connective tissue by digesting the connective tissue with liberase. The subsequent cell 
suspension was filtered through a 70µM nylon filter before enrichment using Optiprep 
centrifugation gradient. CD11c+ DCs were subsequently purified using MACS 
positive selection.  The forward scatter versus side scatter profile of CD11c+ DC after 
MACS positive selection is shown in  (A). The gate used for determining purity 
included all viable cells.  Comparing the forward and side scatter FACS profiles of T 
cells and DCs, it was observed that DCs are about twice the size of lymphocytes for 
FSC and have slightly higher SSC profile.  (B) was isotype staining for CD11c+ DC 
and the purity of CD11c+ DC for the initial experiment was 93.1% (C). The typical 
purity of CD11c+ DCs after MACS positive selection for subsequent experiments 
















Figure 3.3 1 FACS profile of splenic CD11c+ DCs from C57BL6 mice after 
MACS positive selection.  
Splenic DCs from C57BL6 mice were enriched using Optiprep centrifugation gradient 
and purified using MACS positive selection. (A) FSC linear versus SSC linear profile 
for purified CD11c+ DCs. (B) Isotype control staining and (C) staining with anti-
mouse anti-mouse MHC Class II efluor450 and anti-mouse CD11c Alex fluor647. 
Typical purity of CD11c+ DCs after MACS positive selection ranged between 91-97%. 

















3.4 Expression of co-stimulatory molecules on freshly isolated CD11c+ DCs 
Most studies have activated T cells in vitro using plate-bound anti-CD3e with/without 
soluble anti-CD28 in the culture medium (Appleman, van Puijenbroek et al. 2002; 
Foulds, Zenewicz et al. 2002; Wolfraim and Letterio 2005). We decided to try using 
dendritic cells as a source of our co-stimulatory molecules for T cell activation rather 
than rely solely on anti-CD28 to provide the co-stimulatory signal to T cells in culture. 
 
We stained positively selected MACS splenic CD11c+ DCs with anti-mouse CD80 
FITC and anti-mouse CD86 PE to determine the surface levels of these co-stimulatory 
molecules on the freshly isolated DCs. From Figure 3.4 1 Expression of co-
stimulatory molecules CD80 and CD86 on freshly isolated splenic CD11c+ DCs. 
From Error! Reference source not found., we observed that freshly isolated CD11c+ 
DCs expressed both CD80 and CD86 co-stimulatory molecules, which were needed 
for proper activation of T cells. CD86 expression was, however, much higher than 
that of CD80. This observation has been reported by others (Hathcock, Laszlo et al. 














Figure 3.4 1 Expression of co-stimulatory molecules CD80 and CD86 on freshly 
isolated splenic CD11c+ DCs.  
Freshly isolated CD11c+ DCs were gated on viable cells, followed by gating on the 
double positive expression of CD11c and MHC Class II surface expression. These 
cells were then analysed for (A) expression of CD80 on CD11c+ DCs with a mean 
fluorescence intensity (MFI) of 13.3 and (B) expression of CD86 on CD11c+ DCs 
with a MFI of 28.7. Freshly isolated splenic CD11c+ DCs expressed higher levels of 













3.5 Optimising activation conditions for CD8 and CD4 T cells 
We activated MACS isolated CD8 and CD4 T cells with the commonly used 
activation methods for T cells in vitro as well as our method of co-culturing T cells 
and CD11c+ DCs (as a source of co-simulatory molecules CD80/86) together with 
anti-CD3ɛ. We compared the proliferation of CD8 and CD4 T cells stimulated with 
anti-CD3ɛ with/without varying concentrations of anti-CD28 as well as co-culturing 
with CD11c+ DCs in different T cell to DC ratios using the  incorporation of 3H 
thymidine as a readout for proliferation 48hrs after activation ( 
A).  
 
CD8 and CD4 T cells had low thymidine incorporation when stimulated with anti-
CD3e only ( 
A). When co-stimulation was provided in the form of soluble anti-CD28, increased 
thymidine incorporation was observed for both CD8 and CD4 T cells, although CD8 
T cells exhibited higher thymidine incorporation than CD4 T cells. Increasing the 
concentration of anti-CD28 to 1µg/ml however, reduced thymidine incorporation for 
both T cell subsets. This was due to increased cell death as reflected by the drop in the 
percentage of viable cells ( 
B). Thymidine incorporation was significantly increased for CD8 and CD4 T cells 
when activated with anti-CD3ɛ co-cultured with CD11c+ DCs. This suggests better 
activation of both CD8 and CD4 T cells using anti-CD3ɛ with CD11c+ DCs.  In 
addition, when T cell to DC ratio increased, thymidine incorporation and viability for 
both CD8 and CD4 T cells increased. Therefore, we decided to use 1µg/ml anti-CD3 





























Figure 3.5. 1 [3H] thymidine incorporation of CD8 and CD4 T cells with varying 
concentrations of anti-CD28/ T cell: CD11c+ DC ratio after 48hrs. 
(A) There was no significant difference in T cell proliferation when activating either 
CD8 or CD4 T cells with 1µg/ml anti-CD3e with the varying concentrations of anti-
CD28. Activation of both CD8 and CD4 T cells with 1µg/ml anti-CD3e and CD11c+ 
DCs enhanced their proliferation as compared with anti-CD3e & anti-CD28. Varying 
T cell to DC ratio affected CD8 T cells more than CD4 T cells when CD8 T cells 
were co-cultured in the T cell: DC ratio of 10:1 compared with 5:1 or 3:1. * = p<0.05. 
(B) Viable cells were gated using FSC vs SSC plots and negatively staining for 
annexin V FITC and 7-AAD. There was no statistical significance between 
percentages of CD8 and CD4 viable T cells under the same activating conditions. The 
percentage of viable CD8 and CD4 T cells was significantly increased when activated 
with anti-CD3ε co-cultured with CD11c+ DCs when compared activated with anti-
CD3e and soluble anti-CD28. Viability of CD8 and CD4 T cells was higher at greater 
T cell to DC ratios. *** p<0.001, *p<0.05. Data shown was pooled from three 





3.6 CD8 and CD4 cell concentration & viablity over 72hrs with anti-CD3ε 
and CD11c+ DCs 
We went on to compare the cell concentrations of MACS isolated CD8 and CD4 T 
cells activated with anti-CD3e + CD11c+ DCs.  Cells were first pulsed with Hoechst 
33342 30 minutes before the stipulated harvest times to allow DNA from dead cells to 
bind to the stain. At 24hrs, the cell concentrations did not differ significantly between 
anti-CD3e + CD11c+ DCs activated CD8 and CD4 T cells ( 
Figure 3.6.1 A). This was also observed in positive control CD8 and CD4 T cells. 
This was expected since others have published that CD8 T cells and CD4 T cells 
division commences 24hrs after activation (Jelley-Gibbs, Lepak et al. 2000; Murali-
Krishna and Ahmed 2000; Veiga-Fernandes, Walter et al. 2000; Homann, Teyton et al. 
2001; Kaech and Ahmed 2001; Tan, Dudl et al. 2001; Wong and Pamer 2001; Latner, 
Kaech et al. 2004).  
 
No significant change in cell concentration was observed because the majority of cells 
would not have commenced or have completed their first cell division at 24hrs. At 
48hrs, CD8 T cells exhibited higher cell concentrations than CD4 T cells ( 
Figure 3.6.1 B) for both positive control and activation with anti-CD3ε + CD11c DCs. 
At 72hrs however, there was no significant difference between CD8 and CD4 T cells 
for positive control or for anti-CD3ε + CD11c DCs ( 










Figure 3.6.1 Cell concentrations (cells/µl) of CD8 and CD4 T cells over a 72hr 
activation period.  
 
Both CD8 and CD4 T cells were activated with anti-CD3e + CD11c DCs over a 
period of 72hrs. PMA + ionomycin served as a positive control while unstimulated T 
cells served as a negative control. Calculation of cell concentration is described in 
methods section 2.3.8 Viability & cell count assay. (A) At 24hrs, cell concentrations 
between CD8 and CD4 T cells did not differ significantly between CD8 and CD4 
activated with anti-CD3e + CD11c+ DCs or for the positive control.  (B) At 48hrs, 
there was a significant difference between CD8 and CD4 cell concentration where 
CD8 T cells activated with anti-CD3e + CD11c+ DCs or with PMA + ionomycin had 
a higher cell concentration. (C) At 72hrs, there was no significant difference observed 
between CD8 and CD4 cell concentration for activated with anti-CD3e + CD11c+. 
*p<0.05. Data shown is representative from three independent experiments and 








Viability of CD8 T cells was higher than CD4 T cells at 24hrs for the negative control 
and the various activating conditions (Figure 3.6. 2A). However, at 48hrs, the 
viability of CD4 cells for both activating conditions was significantly higher than that 
of CD8 T cells (Figure 3.6. 2B). This could be due to activation-induced cell death 
(AICD) experienced by CD8 T cells (Kabelitz, Pohl et al. 1993; Tham and Mescher 
2002; Kennedy and Celis 2006). At 72hrs, however, there was no significant 
difference in the viability of CD8 and CD4 T cells. The viability of CD8 and CD4 
negative controls declined over a period of 72hrs (Figure 3.6. 2), indicating that when 
T cells are left unstimulated, whether in the absence of TCR engagement or the 
















Figure 3.6. 2 Percentage of viable CD8 and CD4 cells over a 72hrs activation 
period.  
Both CD8 and CD4 T cells were activated with anti-CD3ε + CD11c DCs over a 
period of 72hrs. PMA + ionomycin served as a positive control while unstimulated T 
cells served as a negative control. .Viable cells stained negative for Hoechst 33342. 
(A) At 24hrs, there was a significant difference in the percentage of viable cells 
between activated anti-CD3ε + CD11c+ DCs CD8 and CD4 T cells. This was also 
observed for the positive control.  (B) At 48hrs, there was a significant difference in 
percentage viability of CD8 and CD4 T cells activated with anti-CD3 + CD11c+ DCs.  
CD8 T cells had higher viability. (C) At 72hrs, there was no significant difference in 
the viability of CD8 and CD4 T cells activated with anti-CD3ε + CD11c+ DCs. *** 
p<0.001, *p<0.05. Data shown is representative from three independent experiments 








3.7 CFSE proliferation of CD8 and CD4 T cells after 48hrs activation 
In order to find out whether CD8 T cells divide faster than CD4 in our in vitro system, 
we used CFSE to stain our MACS isolated CD8 and CD4 T cells to visualise the 
number of cell divisions each T cell subset following activation. Viable CFSE-stained 
T cells were gated on cells negative for Hoechst 33342 stain followed by FSC vs SSC 
plot. 
 
Regardless of the stimulus used or the T cell subset, no new CFSE division peaks 
were observed at 24hrs after activation (Figure 3.7.1A). At 48hrs, CD8 T cells 
activated with either anti-CD3ε + CD11c DCs or PMA + ionomycin had divided at 







Figure 3.7.1 Proliferation of viable CFSE-stained CD8 and CD4 T cells over 
48hrs.  
Both CFSE stained CD8 and CD4 T cells were activated with anti-CD3ε + CD11c 
DCs over a period of 48hrs. PMA + ionomycin served as a positive control while 
unstimulated T cells served as a negative control. Only viable cells were included by 
gating on Hoechst 33342 negative cells followed by gating on FSC vs SSC plot.  The 
upper panels are CD8 T cells and the lower panels are CD4 T cells. The left column is 
cells activated by anti-CD3ε + CD11c DCs while the right column is cells activated 
by PMA + ionomycin. (A) At 24hrs, no cell division was observed regardless of the 
stimulus for both CD8 and CD4 T cells. All the peaks were at peak 0. (B) At 48hrs, 
CD8 T cells activated both by anti-CD3ε + CD11c and PMA + ionomycin had 
divided at least 4 times. CD4 T cells, on the other hand, only divided 3 times.  The 
dotted peak in the plots shows the starting position of the unstimulated T cells. Data 






We set out to establish an in vitro model that would allow us to study the kinetics of T 
cell proliferation so that we would be able to identify the factors that would explain 
why CD8 T cells have the ability for rapid expansion while CD4 T cells did not. 
 
During our optimisation experiments, we observed that increasing the concentrations 
of soluble anti-CD28 in our cultures actually resulted in a drop in 3H thymidine 
incorporation, suggesting that the T cells could be dying or inhibited from 
proliferating. The drop in the percentage of viable cells when activated with 1µg/ml 
anti-CD28 instead of the lower concentrations of anti-CD28 indicates that T cells 
were dying from over co-stimulation. Pardigon, N. et.al. reported that naïve CD8 T 
cells had the ability to bypass the requirement for co-stimulation to become fully 
activated solely through TCR signalling and that co-stimulation merely lowers the 
activation threshold required for T cell expansion (Pardigon, Bercovici et al. 1998). 
CD4 T cells, however, require co-stimulatory signals to lower their activation 
threshold (Viola and Lanzavecchia 1996) or they become anergic (Schwartz 1990). 
Two independent groups using experimental autoimmune encephalomyelitis as a 
model reported that using a high antigen dose  or high avidity myelin basic protein 
actually resulted in a decrease in antigen-specific T cells in the periphery (Critchfield, 
Racke et al. 1994; Anderton, Radu et al. 2001). . Yu, X.Y. et. al. described that using 
antigenic peptides with high TCR avidity, supplementing CD28 co-stimulation 
resulted in reduction of T cell expansion and facilitated apoptosis both in vivo and in 
vitro (Yu, Martin et al. 2003). These findings could also explain why there was a 
decline in the percentage of viable cells when T cells were activated in increasing 
numbers of DCs in our co-culture experiments. As we decreased the T cell to DC ratio, 





However, adding DCs to provide co-stimulation for T cells when activated with anti-
CD3ε in our in vitro system enhanced the viability and 3H thymidine incorporation of 
both T cell subsets, particularly with T cell: DC ratio at 10:1.  
 
Our results also suggest that using 1µg/ml anti-CD3ε to activate both CD8 and CD4 T 
cells provided an adequate TCR signalling strength because the 3H thymidine 
incorporation graphs of CD8 and CD4 T cells were similar in shape at the 48hrs and 
the addition of increasing co-stimulation in the form of soluble anti-CD28 or CD11c+ 
DCs did not increase the 3H thymidine incorporation of CD4 T cells higher than CD8 
T cells. 
 
PMA + ionomycin activation of T cells served as a positive control because it form of 
activation basically bypasses the external TCR signalling pathway by targeting the 
signalling molecules within the cell directly. PMA targets and activates protein kinase 
C (PKC) while ionomycin being a calcium ionophore increases Ca2+ concentration by 
releasing calcium stores within the cell into the cytosol (Chatila, Silverman et al. 1989; 
Dedkova, Sigova et al. 2000). One of the consequential downstream actions of PKC is 
to activate cellular proliferation. 
 
Interestingly, we observed that activating T cells with PMA + ionomycin, CD8 T cells  
seemed to still divide slightly more than CD4 T cells as seen in the significant 
difference in cell concentration between CD8 and CD4 T cells at 48hrs. To further 
verify our observations, we decided to label both T cells subsets with CFSE to track 
the number of cell divisions undergone by them over a period of 48hrs after activation. 





T cells was due to inaccurate seeding of starting cell number would affect the readout 
since starting with a higher number of cells would also result in higher 3H thymidine 
incorporation as well. At periods earlier than 24hrs, no CFSE peaks were observed for 
either CD8 or CD4 T cells. This has also been reported by Latner, D.R. et. al. where 
they did not observe any new CFSE peaks for both naïve and memory CD8 T cells 
24hrs after activating them with the LCMV epitope, GP33-41 peptide (Latner, Kaech 
et al. 2004).  
 
However after 48hrs of activation, we observed CD8 T cells were one cell division 
ahead of CD4 T cells. This observation suggests that the factors limiting CD4 T cell 
expansion after activation may be intrinsic and not externally required by CD4 T cells.  
More experiments will need to be carried out to verify whether this hypothesis is 
correct. 
 
Having optimised the conditions necessary to activate both CD8 and CD4 T cells 
properly, we would be focussing on the factors that could affect T cells expansion and 
would be comparing how these factors affect the expansion of both CD8 and CD4 T 
cells in order to eliminate the factors that may not the crucial in limiting CD4 T cells 




Chapter 4 – Factors affecting T cell proliferation 
 
4.1 Introduction 
In the previous chapter, we optimised the conditions needed to activate both CD8 and 
CD4 T cells in our in vitro system so that it would allow us to study the kinetics of 
CD8 and CD4 T cell proliferation. In the process, we, with others, observed that CD8 
T cells proliferated faster than CD4 T cells. (Whitmire, Flavell et al. 1999; Foulds, 
Zenewicz et al. 2002)  
 
Many factors are involved in the activation and proliferation of T cells and we were 
interested to compare how some of these factors could have enhanced CD8 T cell 
proliferation but not CD4 T cells. Factors such as expression of molecules which 
could affect signalling strength such as CD3ε and co-stimulatory molecule CD28, IL-
2 receptor; a heterotrimeric protein made up of IL-2 receptor α CD25, IL-2 receptor β 
CD122 and the common γ chain CD132 as well as the production of IL-2 itself. We 
also investigated how the presence of certain sub-populations within the CD8 and 
CD4 T cells subsets could have caused CD8 T cells to proliferate more rapidly than 
CD4 T cells. We compared the proliferation of CD8 and CD4 T cells using different 







4.1 CD3ε and CD28 expression on CD8 and CD4 T cells  
The TCR-CD3 complex consists of variable proteins, designated α and β, invariant 
CD3 proteins, γ, δ and ε (Borst, Coligan et al. 1984) as well as ζ chain protein. The αβ 
TCR is responsible for the binding to antigen expressed on MHC molecules, the CD3 
molecules serve as a signalling module in the form of CD3εδ and CD3εγ heterodimers 
and the TCR ζζ serves as a second independent signalling module (Alarcon, Berkhout 
et al. 1988; Wegener, Letourneur et al. 1992; Alarcon, Gil et al. 2003; Malissen 2003). 
Studies have demonstrated the importance of CD3ε in CD3εδ/εγ signalling module 
and the critical role it plays in normal TCR signalling and activation (Gil, Schamel et 
al. 2002; Pitcher, Mathis et al. 2005; Wang, Becker et al. 2009). 
 
CD28 is one of the key co-stimulatory receptors that is involved in T cell activation 
and proliferation and has been considered a potential target for manipulating T cell 
responses as it has been demonstrated that CD28 deficient mice have drastically 
reduced T cells responses (Shahinian, Pfeffer et al. 1993; Wolfraim and Letterio 
2005). 
 
We decided to compare the surface expression of CD3ε and CD28 on CD8 and CD4 
T cells since CD3εδ/εγ signalling module has been shown to be sufficient for normal 
T cell activation even in the absence of functioning ITAM on TCR ζζ (Pitcher, Mathis 
et al. 2005) suggesting that T cell activation with anti-CD3ε was sufficient to activate 
T cells; while CD28 has been shown to be prominent in promoting T cell activation 
and proliferation. One of the pathways CD28 signalling uses is through IL-2 (June, 
Ledbetter et al. 1987; Fraser, Irving et al. 1991; Umlauf, Beverly et al. 1995; Walunas, 




FACS staining of CD3ε on CD8 and CD4 T cells indicated that CD8 had slightly 
lower expression of CD3ε and slightly higher expression of CD28 than CD4 T cells 






Figure 4.1.1 Expression of CD3ε and CD28 on CD8 and CD4 T cells isolated from 
pooled C57BL6 spleen and lymph nodes.  
Lymphocytes were gated, followed by gating on CD4 and CD8α positive cells. These 
cells were then overlayed to compare their expression for CD3ε and CD28. CD4 T 
cells expressed slight higher CD3ε but lower CD28 than CD8 T cells. The differences 
betweenCD8 and CD4 T cell mean fluorescence intensity for both CD3ε and CD28 
were not significantly different. Grey line = isotype control, black line = CD8, Grey = 















4.2 Effects of anti-CD3e alone/ with anti-CD28 on T cell proliferation  
We activated both CD8 and CD4 T cells with either 1μg/ml anti-CD3e alone or 
together with 0.5μg/ml anti-CD28 over a period of 120 hours and measured 3H 
thymidine incorporation (added after 12 hours) (Figure 4.2.1).  
 
3H thymidine incorporation was significantly higher for CD8 than CD4 T cells when 
activated with anti-CD3ε alone for the first 48hrs (Figure 4.2.1A). After which, there 
was a drastic decline in 3H thymidine incorporation for CD8 T cells. The peak of 3H 
thymidine incorporation also occurred earlier for CD8 T cells at 36-48hrs compared to 
60-72hrs for CD4 T cells. 
 
The addition of anti-CD28 together with anti-CD3ε boosted the overall 3H thymidine 
incorporation for both T cell subsets (Figure 4.2.1 B). In addition, provision of co-
stimulatory signalling prolonged the duration of 3H thymidine incorporation for both 
T cells subsets, allowing the peak of 3H thymidine incorporation to peak 
approximately one day later when compared with anti-CD3ε activation alone. The 
peak of 3H thymidine incorporation still occurred earlier for CD8 T cells at 60-72hrs 
compared to 84-96hrs for CD4 T cells. 
 
Our results seem to support the observation by Pardigon N. et. al. that naïve CD8 T 
cells have a low activation threshold where signal 1 alone is able to fully activate 




Figure 4.2.1 3H thymidine incorporation of CD8 and CD4 T cells activated with 
anti-CD3ε alone or with anti-CD28 over a period of 120 hours.  
(A) 3H thymidine incorporation of CD8 and CD4 T cells activated with anti-CD3ε 
alone. CD8 T cells had significantly higher thymidine incorporation for the first 48hrs, 
after which a drastic decline was observed. The peak of CD8 thymidine incorporation 
peaked earlier than CD4 T cells. CD4 T cells. (B) 3H thymidine incorporation of CD8 
and CD4 T cells activated with anti-CD3ε and anti-CD28. CD8 T cells had 
significantly higher thymidine incorporation for the first 72hrs, after which a decline 
was observed. The peak of CD8 thymidine incorporation peaked earlier than CD4 T 
cells. *** p<0.001, **p<0.01, * p<0.05. Data shown was pooled from five 





4.3 IL-2 and T cell proliferation 
Since one of the actions of CD28 signalling to promote T cell activation and 
proliferation is through IL-2 production (June, Ledbetter et al. 1987; Fraser, Irving et 
al. 1991; Umlauf, Beverly et al. 1995; Walunas, Bakker et al. 1996; Appleman, 
Berezovskaya et al. 2000; Thomas, Gao et al. 2005), we decided to look at IL-2 
production in the supernatant of activated CD8 and CD4 T cells after 48hrs. We 
hypothesized that if CD8 T cells were proliferating faster than CD4 T cells, they 
might be producing higher amounts of IL-2 to promote their own growth. In addition, 
we also looked at the two main cytokines for Th1 and Th2 responses, IFN-γ and IL-4 
respectively. We activated both CD8 and CD4 T cells with either anti-CD3ε alone or 
together with anti-CD28 to investigate the effects of suboptimal activation on T cell 
cytokine production. 
 
At 48hrs, we observed that when both CD8 and CD4 T cells were sub-optimally 
activated via anti-CD3ε alone, the levels of IL-2 in the supernatant were too low to be 
detected (Figure 4.3.1A). The same was observed for IFN-γ in the supernatants of 
CD8 and CD4 T cells activated with only anti-CD3e (Figure 4.3.1B). Interestingly for 
IL-4, approximately 60pg/ml of IL-4 was detected in the supernatant of CD4 T cells 
(Figure 4.3.1C) even when activated with anti-CD3ε alone. 
 
When CD8 and CD4 T cells were activated with anti-CD3ε and anti-CD28, there was 
an increase in cytokine concentration of IL-2, IFN-γ for both CD8 and CD4 
supernatants Figure 4.3.1(A) and (B), while IL-4 concentration was only increased in 
CD4 supernatants but undetected in CD8 supernatants (Figure 4.3.1 C). CD4 T cell 




amounts of IL-2 present as compared to CD8 T cells (Figure 4.3.1A). In addition, 
CD8 T cells produced much higher amounts of IFN-γ than CD4 T cells (Figure 
4.3.1B). Interestingly, we observed that for CD4 T cells even though there was an 
increase in IL-4 in the supernatants, IFN-γ was also detected. 
 
As IL-2 was present in higher amounts in CD4 than CD8 supernatants, we were 
unable to conclude that IL-2 is responsible for earlier CD8 growth. However, it is 
possible that CD8 T cells were actively using up the IL-2 in the supernatants to 
enhance their own proliferation resulting in low levels of IL-2 being detected in the 
supernatant. However, the higher amounts of IL-2 observed in our activated CD4 T 
cell supernatant than CD8 T cell supernatant is consistent with what has been reported 
in the literature: IL:-2 is predominantly produced by CD4 T cells and to a lesser 





Figure 4.3.1 IL-2, IFN-γ and IL-4 in supernatant of activated T cells 48hrs after 
activation.  
The graphs represent type of cytokine produced in pg/ml. (A) The levels of IL-2 
detected in the supernatant was the highest in CD4 T cells stimulated with anti-CD3ε 
and anti-CD28 antibodies while CD8 T cells stimulated with the same stimuli had 
significantly lower levels of IL-2 detected in the supernatant. (B) The levels of IFN-γ 
detected in the supernatant was highest in CD8 T cells stimulated with anti-CD3 and 
anti-CD28 antibodies. IFN-γ was also detected in the supernatant of CD4 T cells 
stimulated with anti-CD3 and anti-CD28 albeit at significantly lower levels. (C) IL-4 
was only detected in supernatants of activated CD4 T cells, while undetectable in 
CD8 T cell supernatants. However, the amount of IL-4 detected in the CD4 
supernatants were very low compared to the levels of IFN-y and IL-2 detected. 








4.4 Effects of blocking IL-2 on T cell expansion 
To further investigate the role IL-2 plays in enhancing the proliferation of CD8 cells 
but not CD4 T cells, we activated T cells with anti-CD3ε and anti-CD28 over a period 
of 48hrs (Figure 4.4.1). Activation of T cells with 1µg/ml anti-CD3ε and 0.5µg/m 
anti-CD28 served as the positive control in this experiment. Adding 6µg/ml 
neutralizing antibody against mouse IL-2 at the start of the culture, we observed that 
as early as 12-24hrs, thymidine incorporation was significantly reduced in both T cell 
subsets (Figure 4.4.1A). At 36-48hrs, the effect of the neutralizing antibody continued 
to affect both CD8 and CD4 T cell proliferation although there was a slight increase 
in thymidine incorporation compared to the 12-24hr period, indicating that the T cells 
were still dividing, but at a much slower rate (Figure 4.4.1B). At two time periods 
when we compared thymidine incorporation of IL-2 blocked CD8 T cells and CD4 T 
cells, CD8 T cells still had a significantly higher thymidine incorporation compared to 






Figure 4.4.1 Effect of blocking IL-2 on 3H thymidine incorporation of CD8 and 
CD4 T cells activated with anti-CD3ε and anti-CD28 over a period of 72hrs.  
(A) At 12-24hrs, both CD8 and CD4 T cell thymidine incorporation was significantly 
reduced when neutralizing antibody (6µg/ml) against IL-2 was added. However, there 
was still a significant difference in thymidine incorporation between CD8 and CD4 T 
cells. (B) At 36-48hrs, the difference between CD8 and CD4 thymidine incorporation 
was reduced but there was still a significant difference.* p<0.05, **p<0.01. Data 












4.5 Expression of IL-2 receptor subunits on CD8 and CD4 T cells 
IL-2 receptor is a heterotrimeric protein consisting of three distinct chains non-
convalently associated. They are alpha (α, CD25) (Leonard, Depper et al. 1982), beta 
(β, CD122) (Siegel, Sharon et al. 1987; Teshigawara, Wang et al. 1987; Tsudo, Kozak 
et al. 1987; Takeshita, Ohtani et al. 1992) and gamma (γ, CD132).We examined the 
expression of IL-2 receptor on CD8 and CD4 T cells before and after activation. We 
activated purified CD4 and CD8 T cells with 1µg/ml anti-CD3ε and 0.5µg/ml anti-
CD28 over a period of 48hrs and stained for the surface expression of the IL-2 
receptor subunits on both T cell subsets at 24hrs and 48hrs after activation (Figure 
4.5.1) 
 
Before activation, approximately 10% of CD4 T cell population was CD25+ while 
only 1% of CD8 T cell population was CD25+ (Figure 4.5.1A). The mean 
fluorescence intensity (MFI) for CD4 T cells was about 16.9 while that of CD8 T cells 
was 3.5. After activation, CD25 expression on both CD8 and CD4 T cells increased 
dramatically after 24hrs and increased further after 48hrs (Figure 4.5.1 D & G). The 
majority of the activated CD8 and CD4 T cells expressed CD25 after activation, 
indicating T cell activation. The expression of CD25 on CD8 and CD4 T cells was not 
significantly different at 24hrs (Figure 4.5.1D) but was slightly higher in CD8 T cells 
48hrs after activation (Figure 4.5.1G). 
 
CD122 expression was only slightly higher on unstimulated CD4 T cells (Figure 
4.5.1B) but 24hrs after activation, CD122 expression increased on both CD8 and CD4 




cell subsets also dropped slightly 48hrs later were still similar in their levels of 
expression (Figure 4.5.1H). 
 
CD132 expression was similar in both unstimulated CD8 and CD4 T cells (Figure 
4.5.1C) and increased 24hrs after activation (Figure 4.5.1F) and was maintained at 
48hrs (Figure 4.5.1I). The expression of CD132 was not significantly different 
between both T cell subsets during the period of 48hrs. 
 
Our results indicate that between 0-48hrs after activation, the expression of IL-2 
receptor subunits except CD25 did not differ significantly between CD8 and CD4. 
Both CD122 and CD132 expression increased on both CD8 and CD4 T cells but were 
similar in their expression levels on both T cell subsets. CD25 expression was present 
in about 10% of the CD4 population compared to 1% in CD8 population. These could 
be the naturally occurring T regulatory cells in the population. At 24hrs, the 
expression of CD25 on both T cells was similar while at 48hrs, slightly higher 














Figure 4.5.1 Expression of IL-2 receptor subunits on CD8 and CD4 T cell 
activated with 1µg/ml anti-CD3ε and 0.5μg/ml anti-CD28 over 48hr period. 
(A) At 0hrs, 10% of CD4 T cells were CD25+ while about 1% of CD8 T cells were 
CD25+. (B) At 0hrs, expression of CD122 between unstimulated CD8 and CD4 T 
cells were not significantly different, although CD122 expression was slightly higher 
on CD4 T cells. (C) At 0hrs, expression of CD132 was similar on unstimulated CD8 
and CD4 T cells. (D) 24hrs after activation CD25 expression increased significantly 
from 0hrs for both T cell subsets but there was no significant difference between both 
T cell subsets. (E) CD122 expression only increased slightly after 24hrs and was 
similar in both T cell subsets. (F) CD132 expression increased 24hrs after activation, 
but were similar on both8 and CD4 T cells. (G) CD25 expression increased further 
48hrs after activation and CD8 T cells had a higher MFI (MFI:285.2) than CD4 T 
cells (MFI: 106.2). (H) Expression of CD122 dipped slightly for both T cell subsets 
after 48hrs but no significant difference was observed between the two subsets. (I) 
CD132 expression also did not change significantly and was similar for both T cell 
subsets. Grey line = isotype control, black line = CD8, Grey = CD4. Result is 




4.6 CD4+ CD25+ T cells depletion on CD4 proliferation 
From our previous experiment, we observed that there was about 10% and 1% of the 
CD4 and CD8 population were CD25+, suggesting that they were naturally occurring 
T regulatory cells. This was consistent with was report by Sakaguchi S, et.al. that in 
normal naïve mice, between 5-10% of CD4+ T cells and less than 1% of CD8+ T cells 
were also CD25+ (Sakaguchi, Sakaguchi et al. 1995).  
 
It has been shown that T regulatory cells suppress CD4 and CD8 T cells (Shevach 
2009). One of which is through the production of IL-10 (Belkaid, Piccirillo et al. 2002; 
Maloy, Salaun et al. 2003; Li, Wan et al. 2007). Therefore, we decided to first test for 
the presence of IL-10 in the supernatants of CD8 and CD4 T cells activated with anti-
CD3ε and CD11c+ DCs 48hrs after activation. However, IL-10 was not detected in 
any of the samples (data not shown). 
 
Therefore, we decided to deplete the CD4+ CD25+ T cell population from the CD4+ 
population using CD4+ CD25+ T regulatory cell isolation kit from Miltenyi Biotech 
Company and compared the proliferation of CD25+- undepleted CD4 T cells and 
CD25+-depleted CD4 T cells (Figure 4.6.1). We also stained the CD25 depleted and 
undepleted CD4 population for CD25 to verify if the depletion method worked (Figure 
4.6.1 A). The percentage of CD25+ CD4 T cells dropped from 9% before to 0.5% after 
depletion of CD25+ CD4+ T cells. Next, we stained both sets of CD4 T cells with 
CFSE and activated them over a period of 48hrs with anti-CD3ε and CD11c+ DCs. 
Our results showed that both CD25 depleted and undepleted CD4 T cells had 
undergone three cell divisions (Figure 4.6.1 B) and no significant difference in their 





Figure  4.6.1  Comparison  of  proliferation  of  CFSE‐stained  CD4+  T  cells  and  CD4+ 
CD25‐ T cells 48hrs after activation.  
Only viable cells were included by gating on Hoechst 33342 negative cells followed 
by gating on FSC vs SSC plot. (A) The expression of CD25 was compared before and 
after CD4+ CD25+ T cells were depleted using CD4+ CD25+ regulatory T cell isolation 
kit.  CD4 T cells were gated based on staining positive for CD3ε and CD4. The 
percentage of CD4+ CD25+ cells dropped from 9% to 0.5% after using the kit. Grey 
line = isotype control, black line = before CD4+ CD25+ depletion, Grey = after CD4+ 
CD25+ depletion. (B) CD4 T cells were activated with 1μg/ml anti-CD3ε and CD11c 
DCs for 48hrs. After 48hrs, CD4 T cells with and without depletion of CD4+ CD25+ 
underwent 3 cell divisions. No significant difference in the proliferation of CD4 T 
cells before and after depletion of CD4+ CD25+ T cells was observed. The dotted peak 
in the plots shows the starting position of the unstimulated T cells. Result is 




4.7 CD8 and CD4 T cell proliferation in OVA-specific system  
We also compared the proliferation of CD8 and CD4 T cells using an antigen-specific 
system since the signals experienced by CD8 and CD4 T cells would resemble what 
happens in vivo. For these experiments we used OVA peptide specific CD8 and CD4 
transgenic T cells. 
 
As with previous activation experiments, we compared thymidine incorporation of 
CD8 and CD4 T cells activated with various type of stimuli (Figure 4.7.1). Overall, 
we observed greater thymidine incorporation for both transgenic CD8 and CD4 T 
cells compared to when we were using normal wild-type C57BL6 mice. However,  
CD8 T cells still exhibited greater proliferative response than CD4 T cells, especially 
when the transgenic T cells were co-cultured with DCs pulsed with their respective 
OVA-peptides (OVA257-264 for OT-I CD8 and OVA323-339 for OT-II CD4 T cells) 
(Figure 4.7.1C). 
 
We also stained both OT-I CD8 and OT-II CD4 T cells with CFSE to track the 
number of cell divisions they had undergone 48hrs after activation (Figure 4.7.2). 
When the transgenic T cells were activated with 1µg/ml anti-CD3ε and CD11c+ DCs, 
OT-I CD8 T cells underwent four cycles of cell division while OT-II CD4 T cells 
underwent three cycle of cell division (Figure 4.7.2A) with CD8 T cells leading ahead 
by one cell division. When the transgenic T cells were co-cultured with DCs pulsed 
with their respective OVA-peptides, we observed that both CD8 and CD4 T cells 
divided more rapidly, undergoing five and four cell divisions respectively after 48hrs 
(Figure 4.7.2B). However, we still observed the phenomenon that CD8 T cells were 





Figure 4.7.1 3H thymidine incorporation of OTI CD8 and OTII CD4 T cells over 
a period of 120hrs.  
(A) The transgenic T cells were activated with 1µg/ml anti-CD3ε + 0.5µg/ml anti-
CD28. OT-I CD8 thymidine incorporation peaked at 60-72hrs while OT-II CD4 
response peaked at 84-96hrs. When comparing the peak of both CD8 and CD4 
responses, CD8 had higher thymidine incorporation than CD4 T cells. (B) T cells 
were stimulated with 1µg/ml anti-CD3ε co-cultured with CD11+ DCs in the ratio of 
10:1 (T cell: DC). CD8 thymidine incorporation peaked at 60-72hrs and CD4 
response peaked at 84-96hrs. (C) OT-I CD8 T cells were co-cultured with CD11c+ 
DCs pulsed with OVA (257-264) while OT-II CD4 T cells were co-cultured with 
CD11c+ DCs pulsed with OVA(323-339). Controls were LCMV peptide pulsed DCs, 
Gp(33-41) for OT-I CD8 control and NP(309-328). The peak of thymidine 
incorporation occurred at 60-72hrs  for both CD8 and CD4 T cells. However, the 
amount of 3H thymidine incorporation by OT-I CD8 T cells was significantly higher 
than CD4 T cells.  *p<0.05, **p<0.01, ***p<0.001 are the statistical significances for 
thymidine incorporation between CD8 and CD4 T cells within the same time period. 
Data shown was pooled from three independent experiments and shown as mean ± 
SEM. 
(A) (B) T cells were stimulated with plate-bound anti-CD3 antibody (1ug/ml) with 
soluble anti-CD28 antibody (1ug/ml). (C) Results are consolidated from 3 separate 






Only viable cells were included by gating on Hoechst 33342 negative cells followed 
by gating on FSC vs SSC plot. The left column depicts the proliferation of OT-I CD8 
T cells while the right represents OT-II CD4 T cells. (A) OVA peptide-transgenic T 
cells were activated with 1µg/ml anti-CD3ε co-cultured with CD11+ DCs in the ratio 
of 10:1 (T cell: DC). After 48hrs activation, OT-I CD8 T cells had undergone 4 cell 
divisions while OT-II CD4 T cells had undergone 3 cells divisions. (B) OVA peptide-
transgenic T cells were activated with CD11c+ DCs pulsed with their respective 
OVA-peptides: OVA(257-264) for OT-I CD8 and OVA(323-339) for OT-II CD4 T 
cells. After 48hrs, OT-I CD8 T cells had undergone 5 cell divisions while OT-II CD4 
T cells had undergone 4 cell divisions. The dotted peak in the plots shows the starting 








4.8 CD8 and CD4 T cell proliferation in BALBC mice 
We wanted to investigate whether the ability of CD8 T cells to proliferate faster and 
more extensively than CD4 T cells is only observed in C57BL6 mice due to genetic 
differences or whether CD8 T cells have been programmed this way during their 
development to carry out their function: to rapidly eliminate intracellular pathogens 
that have infected host cells. Rapid expansion is necessary for CD8 T cells to reach a 
critical number in order to carry out their function effectively. 
 
We stained CD8 and CD4 T cells isolated from BALBC mice with CFSE and 
activated them with 1µg/ml anti-CD3ε and CD11c+ DCs over a period of 72hrs. At 
24hrs, both CD8 and CD4 T cells had not completed their first cell division (Figure 
4.8.1A). At 48hrs, CD8 T cells had divided four times while CD4 T cells only divided 
three times, with CD8 leading ahead in one cell division, the same result that was 
observed in our CFSE experiments with C57BL6 mice as well as with OT-I and OT-II 
mice (Figure 4.8.1B). By 72hrs, CD8 T cells had undergone seven cell cycle divisions 
while CD4 T cells had undergone only five, increased the lead by CD8 T cell to two 











Figure 4.8.1 Comparison of proliferation of CFSE-stained BALBC CD8 and 
CD4 T cells activated with 1µg/ml anti-CD3ε and CD11c+ DCs over 72hrs.  
Only viable cells were included by gating on Hoechst 33342 negative cells followed 
by gating on FSC vs SSC plot. (A) At 24hrs, both CD8 and CD4 T cells have not 
undergone any cell divisions. (B) By 48hrs, CD8 T cells have undergone 4 cycles of 
cell division while CD4 T cells have only undergone 3 cell divisions. CD8 T cells 
were one cycle head of CD4 T cells. (C) By 72hrs, CD8 T cells have undergone 7 cell 
divisions while CD4 T cells undergone 5 cell divisions. CD8 T cells lead CD4 T cells 
ahead by 2 cell divisions by 72hrs.The dotted peak in the plots shows the starting 








4.9 Heterogeneity within CD8 and CD4 T cell population 
Memory T cells have been divided into two main subsets, central memory (TCM) and 
effector memory (TEM). A unique characteristic of memory T cells is that they have 
low-activation threshold and are highly responsive to antigenic stimulation (Sallusto, 
Lenig et al. 1999; Veiga-Fernandes, Walter et al. 2000; Geginat, Lanzavecchia et al. 
2003). In addition, the expansion potential of memory T cells has been shown to 
decrease from TCM to TEM (Sallusto, Lenig et al. 1999; Geginat, Lanzavecchia et al. 
2003).  In the mouse, TCM is identified as being CD44hi CD62Lhi and TEM is CD44hi 
CD62Llow (Bjorkdahl, Barber et al. 2003; Roberts, Ely et al. 2005). 
 
We considered the possibility that our CD8 and CD4 population isolated from naïve 
mice were not homogenous and contained memory cells which might have 
contributed to the faster proliferation observed both in our experiments as well as 
reported by others. We stained CD8 and CD4 T cells freshly isolated from the spleen 
and lymph nodes and looked at the CD8 and CD4 T cell subpopulation by staining 
them for CD44 and CD62L (Figure 4.9.1) 
 
Generally, we observed that the percentage of naïve CD8 and CD4 T cells were 
higher in the lymph nodes than in the spleens (Figure 4.9.1). Interestingly, we observed 
that the memory population of CD8 and CD4 T cells are quite distinct. CD8 memory 
T cells in both the spleen and the lymph nodes tend to be of the TCM memory subset 
while CD4 memory T cells were of the TEM memory subset. The memory populations 
make up about 15-20% for both T cell subsets in both the spleen and lymph nodes 
with the exception of CD4 TEM in the lymph nodes which make up of only 5% of the 







(A) The plot shows the CD4 T cell subpopulations from the spleen. Naïve T cells are 
CD44low-int CD62Lhi.  Majority of the CD4 memory T cells are TEM and they make up 
about 15-20% of the CD4 population in the spleen. (B) The plot shows the CD4 
subpopulation within the lymph nodes. Majority of the CD4 memory T cells in the 
lymph nodes are also TEM and they make up about 5% of the total CD4 population in 
the lymph nodes. (C) The plot shows the distribution within CD8 T cell population 
from the spleen. In contrast to CD4 memory cells in the spleen, majority of CD8 
memory T cells are TCM and they also make up about 15-25% of the total CD8 
population in the spleen. (D) The plot shows the distribution within CD8 T cell 
population from the spleen. In contrast to CD4 memory cells in the lymph nodes, 
majority of CD8 memory T cells are TCM and they also make up about 15-25% of the 
total CD8 population in the spleen. Results shown is representative of the three 
independent experiments and consistently observed when these stains were used to 
gate and sort for naïve CD8 and CD4 T cell population for subsequent T cell 




4.10 Proliferation of cell-sorted naïve CD8 and CD4 T cells 
Having observed that CD8 memory T cell population from the spleen and lymph 
nodes consisted of TCM cells which have been demonstrated to have a greater 
proliferative potential than TEM cells (Sallusto, Lenig et al. 1999; Geginat, 
Lanzavecchia et al. 2003) and also the majority memory subset in the CD8 population; 
we decided to sort out the naïve CD8 and CD4 T cell population to determine whether 
this phenomenon of CD8 T cells being able to proliferate faster than CD4 T cells is an 
ability exclusive to naïve CD8 T cells and not naïve CD4 T cells or was it confounded 
by the CD8 TCM within the CD8 population. 
 
Our gating strategy for sorting naïve T cells were as follows: (1) Gating on 
lymphocyte population using FSC vs SSC plot followed by (2) gating on cells that 
were double negative for CD11c and CD25, to exclude any antigen-presenting cells 
and as much of the naturally occurring CD25+ regulatory cells. The cells were then 
gated on either on CD4+ or CD8+ populations followed by cells that stained for 
CD44low-int & CD62Lhi to obtain our naïve T cell population (Figure 4.10.1). 
 
After sorting out the naïve CD8 and CD4 T cell populations, we stained them with 
CFSE to track their proliferation over a period of 48hrs after activation with anti-
CD3ε and CD11c+ DCs and compared the number of cell divisions (Figure 4.10.2). At 
24hrs, no cell division had occurred for either naïve CD8 or CD4 T cells (Figure 
4.10.2A). At 48hrs, CD8 T cells had divided at least four times while CD4 T cells 
only divided three times. Naïve CD8 T cells again led naïve CD4 T cells by one cell 




Figure 4.10.1 Typical gating strategy for 2-way cell sort for naïve CD8 and CD4 
T cells & purity after sorting. 
(A)Lymphocytes were gated using FSC vs SSC plot followed by staining negatively 
for CD11c and CD25 to remove any antigen-presenting cells as well as naturally 
occurring CD25+ T regulatory cells. This was followed by gating either on the CD4+ 
or CD8+ population followed by gating on cells that stained for CD44low-int & 
CD62Lhi. (B) Purity of naïve CD8 T cells obtained after sorting typically ranged 
between 96-99%. (C) Purity of naïve CD4 T cells obtained after sorting typically 






Figure 4.10.2 Proliferation of CFSE-stained naïve CD8 and CD4 T cells activated 
with anti-CD3 and CD11c+ DCs over 48hrs. 
(A) At 24hrs after activation, no cell division was observed for either CD8 or CD4 
naïve T cells. (B) At 48hrs after activation, naïve CD8 T cells had undergone four cell 
divisions while naïve CD4 T cells had only undergone three cell divisions. Data 






In this chapter, we set out to identify some of the factors that contribute to the ability 
of CD8 T cells to proliferate faster than CD4 T cells. We focussed on external factors 
that could have affected the strength of T cell signalling and activation. 
 
We showed that CD8 had slightly lower levels of CD3ε expression on their surface 
than CD4 T cells. This is consistent with the observations reported by others. 
(Thibault and Bardos 1995; Rossi, Reine et al. 2008).  Developments in the study of 
TCR-CD3 complexes have revealed that on TCR-CD3 complexes are not uniformly 
distributed on the surface of the cell but are partially pre-clustered before antigen 
binding (Exley, Wileman et al. 1995; Fernandez-Miguel, Alarcon et al. 1999; 
Schamel, Arechaga et al. 2005) and this pre-clustering of TCR-CD3 complexes 
allows T cells to respond over a range of antigen concentrations (Bray, Levin et al. 
1998). 
 
We also considered that this clustering of TCR-CD3 complexes may also affect that 
ability of antibody binding to CD3ε used for FACS staining as well as for activation 
of T cells in our experiments due to restricted access to CD3ε chain by the antibody 
which may affect the signal strength received by CD8 and CD4 T cells which might 
explain why CD8 T cells divide faster than CD4 T cells in our in vitro model. 
However, Rossi, N.E et. al demonstrated that the TCR-CD3 complexes from both 
CD8 and CD4 T cells are present in monovalent  and multivalent (i.e. pre-clustered 
TCR) complexes and the ratios between the two T cell subsets are similar (Rossi, 




Moreover, our earlier results shown in Figure 3.7.1 from the previous chapter when 
we used PMA and ionomycin, which bypasses surface TCR signalling, to activate 
both CD8 and T cells over a period of 48hrs, we still observed that CD8 T cells 
divided faster than CD4 T cells leading CD4 T cells ahead by one cell division. 
 
On the other hand, CD28 expression was only slightly higher in CD8 T cells 
compared to CD4 T cells. Although, this again may provide better/stronger signalling 
for CD8 T cells which enhances their ability to proliferate. However, from our 3H 
thymidine incorporation experiments using anti-CD3ε alone to stimulate CD8 and 
CD4 T cells, CD8 T cells still exhibited greater proliferation than CD4 T cells. 
 
IL-2 is a pleotropic cytokine which mediates a diverse range of biological functions 
(Esser, Dinglasan et al. 1997; Malek 2008). In T cells, it serves as a growth cytokine, 
enhancing T cells proliferation after activation.  (Morgan, Ruscetti et al. 1976) If CD8 
T cells produced more IL-2 than CD4 T cells or are more sensitive to IL-2 (expressing 
more IL-2 receptors), it could be one of the reasons why CD8 T cells divide faster 
than CD4 T cells. 
 
From our results, we observed that CD4 T cells made more IL-2 than CD8 T cells as 
observed in our multiplex cytokine assays from activated T cell supernatants. The 
ability of CD4 T cells being better producers of IL-2 than CD8 T cells has been 
reported previously (Smith 1988; Setoguchi, Hori et al. 2005; Malek 2008) and is 
consistent with our observations. However, IL-2 is also an autocrine cytokine which 




argue that the low IL-2 in our CD8 supernatants is due to IL-2 consumption by CD8 T 
cells. 
 
IL-2 has been shown to be rapidly and transiently produced upon engagement of the 
TCR and co-stimulatory molecules such as CD28 on T cells. The transient nature of 
IL-2 secretion depends on transcriptional induction and stabilization of IL-2 mRNA 
by co-stimulatory signals (Shaw, Meerovitch et al. 1988; Lindstein, June et al. 1989; 
Fraser, Irving et al. 1991; Serfling, Avots et al. 1995; Umlauf, Beverly et al. 1995).  
 
In order to exclude the role of IL-2 on enhancing CD8 T cell proliferation more than 
CD4 T cells, we blocked the effect of IL-2 using a neutralizing antibody. Our results 
show even though IL-2 substantially affected activated T cell growth when 
neutralized in the supernatant of our cell cultures, the amount of thymidine 
incorporation of CD8 T cells was still statistically significantly higher than CD4 T 
cells. This suggests that CD8 T cells were able to make better use of signalling 
through the TCR-CD3 complex and CD28 costimulation to the initiate cell division 
than CD4 T cells.  
 
We also compared the expression of IL-2 receptors subunits of CD8 and CD4 T cells 
as this could likely affect the sensitivity of CD8 and CD4 T cells to the effects of IL-2. 
Unstimulated CD8 and CD4 T cells expressed CD122 and CD132 at similar levels. 
After T cells activation, both T cell subsets showed an increase expression of the two 
subunits but the levels were similar between CD8 and CD4 T cells. CD25 however, 
was increased slightly more than CD4 T cells 48hrs after activation and this could 




However, it has been shown that high affinity for IL-2 is not dependent on CD25, 
which has low affinity for IL2, but on the expressions of CD122 and CD132 to form 
the high affinity IL-2 receptor complex (Teshigawara, Wang et al. 1987; Wang and 
Smith 1987; Tran, Glass et al. 2009) and therefore unlikely, to have a major role in 
enhancing CD8 T cell proliferation . 
 
Having observed the presence of about 10% of CD4+ T cells population from freshly 
isolated spleen and lymph nodes were also CD25+, we wanted to investigate whether 
these naturally occurring T regulatory cells had an effect on inhibiting CD4 T cell 
proliferation in our in vitro system. T regulatory cells have been shown to suppress 
proliferation of T cell through the production of IL-10 in vivo (Belkaid, Piccirillo et al. 
2002; Maloy, Salaun et al. 2003; Belkaid, Blank et al. 2006; Li, Wan et al. 2007; 
Strauss, Bergmann et al. 2007). We tested for IL-10 in our supernatants of CD8 and 
CD4 T cells but were unable to detect any. It has also been reported that in vitro, T 
regulatory cell mediated suppression is not through the action of IL-10 (Takahashi, 
Kuniyasu et al. 1998; Thornton and Shevach 1998). 
 
We then went on to deplete CD4+ CD25+ T cells using a T regulatory cell isolation kit 
and compared the proliferation of CFSE-stained CD4 populations with and without 
CD4+ CD25+ depletion. Our results showed that proliferation between the two were 
similar and depleting the CD4+ CD25+ T cells from the population did not enhance 






There are numerous reports that C57BL6 mice and BALBC mice due to differences in 
their genetic background (Liu, Matsuguchi et al. 2002) have varying responses in 
different experimental models (Medina 1974; Caspi, Grubbs et al. 1992; Graus, van 
Breda Vriesman et al. 1993; Autenrieth, Beer et al. 1994; Ullrich, Bowles et al. 1996; 
Sun, Rizzo et al. 1997; Avichezer, Liou et al. 2003; Thomas, Gao et al. 2005). For 
example, BALBC mice are susceptible to Brucella abortus infection (Murphy, 
Sathiyaseelan et al. 2001) and  Yersinia enterocolitica (Autenrieth, Beer et al. 1994) 
while C57BL6 mice are resistant with IFN-γ playing an essential role in both models. 
On the other hand, C57BL6 mice are more susceptible to antigen-induced pulmonary 
eosinophilia than BALBC mice (Morokata, Ishikawa et al. 1999). Using the OVA-
specific system as well as using another strain of mouse (BALBC), we also observed 
that CD8 T cells still divided more than CD4 T cells. 
 
Interestingly, we found that the CD8 and CD4 T cell population isolated from naïve 
mice were not homogenous but consisted of subpopulations of naïve and memory T 
cells. A more interesting observation is that the majority of the memory CD8 
population consisted of TCM while the majority of memory CD4 population consisted 
of TEM. This observation was consistent whether the cells were from the spleens or the 
lymph nodes of the mice. Our observations have also been described by others 
(Bjorkdahl, Barber et al. 2003).  We therefore, decided to sort the naïve CD8 and CD4 
populations to see if CD8 T cells were still proliferating faster than CD4 T cells. This 
is because memory T cells have been shown to proliferate faster after antigen 
stimulation compared to naïve T cells and  since TCM cells have been demonstrated to 
have a greater proliferative potential than TEM cells (Sallusto, Lenig et al. 1999; 




memory T cell subpopulations. The proliferation of sorted CD8 naïve T cells was still 
faster than that of naïve CD4 T cells from our results. 
 
We conclude that the ability of CD8 T cells to proliferate more quickly than CD4 T 
cells is an inherent characteristic of CD8 T cells and external factors which enhance T 
cell expansion are not the major contributing factors to this observation suggesting 
that intrinsic factors within CD8 T cells might be regulating its ability to expand 
rapidly compared to CD4 T cells. 
 


















 Chapter 5 – Kinetics of CD8 and CD4 T cells proliferation 
 
5.1 Introduction 
We previously demonstrated that the ability of CD8 T cells to proliferate more than 
CD4 T cells was not related to external factors affecting T cell activation such as 
surface expression of CD3ε, CD28, IL-2 receptor or IL-2 production. We also 
demonstrated that faster CD8 T cell proliferation was observed using OVA-specific 
antigen system as well as in mice of a different genetic background. CD8 and CD4 T 
cell populations from naïve mice were not homogenous, we went on to sort the naïve 
CD8 and CD4 populations, compared their proliferation and observed the same 
phenomenon. Even when we activated CD8 and CD4 with PMA and ionomycin 
which bypasses TCR signaling complex, we observed the differences were still 
evident. We concluded that it was an inherent ability of CD8 T cells to divide faster 
than CD4 T cells and was most likely to be regulated by intrinsic cellular factors. 
 
As described in the previous chapters, PMA is a phorbol ester activates protein kinase 
C (PKC) while ionomycin being a calcium ionophore increases Ca2+ concentration 
within the cytosol of cells to enhance the activity of PKC to activate T cells (Chatila, 
Silverman et al. 1989; Morgan and Jacob 1994; Dedkova, Sigova et al. 2000). PKC is 
activated by diacylglycerols (DAG) (Lee and Bell 1991; Asaoka, Nakamura et al. 
1992; Nishizuka 1992; Nishizuka 1995) as well as Ca2+ (Nishizuka 1986; Bell and 
Burns 1991; Sando, Maurer et al. 1992). It also has a binding site for phorbol esters 
which PMA can bind to and activate PKC (Lee and Bell 1991; Asaoka, Nakamura et 
al. 1992; Nishizuka 1992; Nishizuka 1995). PKC is responsible for the 





enhancer in B-cells inhibitor, alpha (IκBα), an inhibitory protein of nuclear factor 
kappa light chain enhancer of activated B cells (NFκB). This releases IκBα from 
NFκB, allowing NFκB to be translocated into the nucleus (Ghosh and Baltimore 1990; 
Sun, Arendt et al. 2000) to upregulate the genes involved in T-cell development, 
maturation and proliferation (Sun, Arendt et al. 2000; Livolsi, Busuttil et al. 2001). 
Ionomycin increases intracellular concentration of Ca2+ through transporting Ca2+ 
stored in the endoplasmic reticulum (ER) (Parekh and Penner 1997; Lewis 1999) 
which in turn promotes extracelluar Ca2+ transport into the cell (Morgan and Jacob 
1994). Ca2+ is able to bind to PKC to enhance is activity as well as promote the 
translocation of nuclear factor of activated T-cells (NFAT) through the Ca2+ signaling 
pathway consisting of calmodulin (CaM) and calineurin (CN).  NFAT is a key 
transcriptional regulator of IL-2 gene and other cytokine genes and requires sustained 
signaling via the Ca2+ signaling pathway to keep it in the nucleus (Timmerman, 
Clipstone et al. 1996) and to keep it in a transcriptionally active state (Rao, Luo et al. 
1997). 
 
Our results showed even when activated with PMA and ionomycin, CD4 T cells did 
not proliferate as fast as CD8 T cells. This suggests that intrinsic factors regulate this 
difference between CD8 and CD4 T cells lie further downstream of the pathway T 
cell receptor signaling pathway. A simplified schematic of the TCR-CD3 complex 
and CD28 signalling pathways shows how PMA and ionomycin bypasses the initial 
TCR signaling pathway and targets molecules further downstream to initiate T cell 






In this chapter, we will investigate the state cell cycle of resting naïve CD8 and CD4 
T cells in from a naïve mouse. In addition, we will study the kinetics of naïve CD8 
and CD4 T cell proliferation in order to determine whether CD8 T cells proliferate 
more than CD4 T cells because: 1) they initiate cell division earlier than CD4 T cells, 
therefore having a head start to expand more over the same time period, 2) CD8 T 
cells have a shorter cycling time than CD4 T cells (i.e. time taken to complete one cell 
division is shorter in CD8 T cells) or 3) of a combination of (1) and (2). . We will also 
determine the effect that CD8 T cells have on CD4 T cell proliferation and vice versa 
through co-culture experiments because in vivo when priming of naïve T cell occurs 
in the lymph nodes, both T cell subsets are present in the vicinity and may have an 






Figure 5.1.1 Simplified schematic of T cell 
signalling pathway showing the action of 
PMA and ionomycin in initiating T cells 
activation.  
PMA binds to a binding site on PKC which 
activates PKC and in the phosphorylation and 
degradation of IκBα, an inhibitory protein of 
NFκB. This releaseses IκBα from NFκB, 
allowing for the translocation of NFκB into 
the nucleus to upregulate the genes involved 
in T-cell development, maturation and 
proliferation. Ionomycin is an ionophore that 
increases the concentration of Ca2+ inside the 
cell through releasing the Ca2+ stored in the 
endoplasmic reticulum and subsequently 
promoting the extracellular transport of Ca2+ 
into the cell. Ca2+ binds to PKC and enhances 
its activity and promotes the translocation of 









5.2 Resting naïve CD8 and CD4 T cells are in the same stage of the cell 
cycle 
We wanted to investigate whether naïve CD8 T cells divided earlier than CD4 T cells 
because they were in a different phase of the cell cycle. In the peripheral lymphoid 
tissues, the number of naïve T cells is maintained by homeostatic proliferation 
(Freitas and Rocha 1993; Bell and Sparshott 1997; Ernst, Lee et al. 1999; Goldrath 
and Bevan 1999; Surh and Sprent 2000; Holman, Walsh et al. 2005). We 
hypothesized that if more CD8 T cells were undergoing homeostatic proliferation than 
CD4 T cells, they would already have active cell cycle machinery which would 
require less time to initiate cell division. 
 
We isolated and stained naïve CD8 and CD4 T cells with Hoechst 33342 from 
unimmunized mice to determine their DNA content at rest (Figure 5.2.1). We 
observed that 96-99% of both naïve CD4 and CD8 T cells were in the G0/G1 stage 
(quiescent/ resting stage) of the cell cycle with less than 1% of cells in the S phase of 
the cell cycle. No significant differences were observed in the percentage of naïve 
CD8 and CD4 T cells in the quiescent stage of the cell cycle. 
 
In order to verify our observations, we employed another. We injected BrdU into the 
peritoneal cavity of naïve mice and PBS was as a negative control. The mice were left 
for 24hrs before they were culled. If there were more CD8 T cells undergoing 
homeostatic proliferation than CD4 T cells, we expected to observe greater BrdU 






Figure 5.2.1 Stage of the cell cycle of naïve CD8 and CD4 T cells in the naïve 
mouse. 
 Lymphocytes were pooled from the spleen and lymph nodes. Lymphocyte population 
was gated based on FSC vs SSC plots and with CD3e AlexFluor647 staining. (A) The 
CD4 and CD8 T cell population. (B) Naïve CD4 T cells were gated based on 
expression of CD44low-int and CD62Lhi. (C) Naïve CD4 cells were stained with 
Hoechst 33342 to stain for their DNA content. Approximately 97% of the naïve CD4 
T cells were in G0/G1 stage of the cell cycle (i.e resting phase). (D) Naïve CD8 T cells 
were gated based on expression of CD44low-int and CD62Lhi. (E) Naïve CD8 cells 
were stained with Hoechst 33342 to stain for their DNA content. Approximately 98% 
of the naïve CD4 T cells were in G0/G1 stage of the cell cycle (i.e resting phase). 
There was no significant difference in the stages of cell cycle between naïve CD8 and 











We looked at the incorporation of BrdU in T cells pooled from lymph nodes as well 
as T cells from spleen of the mice (Figure 5.2.2 and Figure 5.2.3). The proportion of 
CD4 was slightly higher than CD8 T cells in the lymph nodes, about 48% and 45% 
respectively (Figure 5.2.2A) although the percentages were not vastly different. PBS-
injected control mouse stained with had less than 1% of naïve CD4 T cells with non-
specific staining for BrdU (Figure 5.2.2C) while percentage of naïve CD4 T cells 
from BrdU-inject mouse had similar percentages. The same was observed for naïve 
CD8 T cells (Figure 5.2.2E). 
 
We also compared the BrdU incorporation between naïve CD8 and CD4 T cells from 
the spleen (Figure 5.2.3 C & E) and obtained similar results. Our results confirmed 
that both naïve CD4 and CD8 T cells from naïve mice were in the quiescent stage of 
















Figure 5.2.2 Brdu incorporation in naive CD4 and CD8 T cells from lymph nodes 24hrs after BrdU injection.  
Mice were injected with 1mg/10g body weight of BrdU (10mg/ml stock) intraperitoneally and left for 24hrs before culling. Control mice were 
injected with the same volume of PBS. Lymphocytes were gated based on FSC vs SSC plots followed by positive staining for CD3ε AlexFluor 
405. (A) The percentage of CD3+ CD8 and CD4 T cells in the lymph nodes. (B) Naïve CD4 were gated based on CD44low-int and CD62Lhi. (C) 
The leftmost plot serves as a minus-one fluorescence staining control for anti-BrdU AlexFluor 647 where all stains were used except anti-BrdU 
AlexFlur647. The centre plot is control mouse injected with PBS and stained with anti-BrdU AlexFluor 647. The rightmost plot represents the 
mouse injected with BrdU and stained with anti-BrdU AlexFluor 647. The results indicate that there was no significant difference in BrdU 
incorporation between the control and BrdU-injected mouse. (D) Naïve CD8 were gated based on CD44low-int and CD62Lhi (E) There was no 
significant difference in BrdU incorporation between the control and BrdU-injected mouse. Overall there is no significant difference in the BrdU 
incorporation between naïve CD8 and CD4 T cells. Data shown is representative of three independent experiments consisting of two control 





Figure 5.2.3 Brdu incorporation in naive CD4 and CD8 T cells from spleen 24hrs after BrdU injection.  
Mice were injected with 1mg/10g body weight of BrdU (10mg/ml stock) intraperitoneally and left for 24hrs before culling. Control mice were 
injected with the same volume of PBS. Lymphocytes were gated based on FSC vs SSC plots followed by positive staining for CD3ε AlexFluor 
405. (A) The percentage of CD3+ CD8 and CD4 T cells in the spleen. (B) Naïve CD4 were gated based on CD44low-int and CD62Lhi. (C) The 
leftmost plot serves as a minus-one fluorescence staining control for anti-BrdU AlexFluor 647 where all stains were used except anti-BrdU 
AlexFlur647. The centre plot is control mouse injected with PBS and stained with anti-BrdU AlexFluor 647. The rightmost plot represents the 
mouse injected with BrdU and stained with anti-BrdU AlexFluor 647. The results indicate that there was no significant difference in BrdU 
incorporation between the control and BrdU-injected mouse. (D) Naïve CD8 T cells were gated based on CD44low-int and CD62Lhi (E) There 
was no significant difference in BrdU incorporation between the control and BrdU-injected mouse. Overall there is no significant difference in 
the BrdU incorporation between naïve CD8 and CD4 T cells. Data shown is representative of three independent experiments consisting of two 





5.3 Kinetics of CD8 and CD4 T cell proliferation 
From our previous CFSE results, we observed that the first cell division did not occur 
at 24hrs or earlier. Therefore, for the study of T cell proliferation kinetics, we decided 
to track the T cells from 27hrs to 48hrs to observe the cell division.  
 
CFSE has been commonly used to track cell division, but for our kinetics experiment, 
we used CFSE in a novel way that has not been done by others previously. We 
tracked T cell activation and growth every 3hrs interval from 27hrs to 48hrs. The time 
taken for cell division to complete by each T cell subset is taken as the time needed 
for a new cell division peak to be observed from the previous time point.  
 
We activated T cells with anti-CD3 in the presence or absence of CD11c+ DCs 
(Figure 5.3.1 and 5.3.2) over a 48hr period and compared the time at which observed 
the first appearance of a CFSE peak for CD8 and CD4 T cells as well as the time 
interval taken for a new peak to form. From Figure 5.3.1A, we observe that the first 
CFSE peak appeared at 27hrs for CD8 T cells but the first CFSE peak appeared at 
30hrs for CD4 T cells. The second CFSE peak for CD8 T cells appeared 
approximately 6hrs later while CD4 T cells took approximately 9hrs. The majority of 
CD8 T cells were in their first CFSE peak by 33hrs (Figure 5.3.1A) while it was only 
at 42hrs (Figure 5.3.1 B) that majority of CD4 T cells were in their first CFSE peak. 
Even when we compare the height of the peaks of the second leading peak (i.e. the 
CFSE peak behind the leading CFSE peak), we observe that there more CD8 T cells 







Figure 5.3.1A CFSE proliferation of naïve CD8 and CD4 T cells activated with 
anti-CD3ε and CD11c+ DCs from 27-36hrs. 
The first cell division was observed at 27hrs for CD8 T cells but CD4 remain 
undivided. At 30hrs, the first cell division was observed for CD4 T cells. By 33hrs, a 
second CFSE peak was observed for CD8 T cells but not CD4 T cells. The time taken 
for a new peak to occur for CD8 T cells was approximately 6 hours (27-33hrs). The 
downward pointing arrows in the plots represent the CFSE peak where majority of the 
cells are. At 33hrs, majority of the CD8 T cells had already divided at least once but 
for CD4 T cells majority had not divided. The second CFSE peak for CD4 T cells 
appeared only at 36hrs.  At 36hrs, majority of CD8 T cells were still in the first 
division while for CD4, most were still in the parent peak. Results are representative 





Figure 5.3.1 B CFSE proliferation of naïve CD8 and CD4 T cells activated with 
anti-CD3ε and CD11c+ DCs from 39-48hrs. 
By 39hrs, a third peak was observed for CD8 T cells but not CD4 T cells. Time taken 
from second CFSE to third CFSE peak for CD8 T cells to appear was approximately 
6hrs (33-39hrs). The appearance of the third CFSE peak for CD4 T cells occurred at 
45hrs, 9hrs after the second CFSE peak occurred (36-45hrs).The downward pointing 
arrows in the plots represent the CFSE peak where majority of the cells are. At 42hrs 
after activation, majority of the CD8 T cells had shifted to the second CFSE peak but 
the majority of CD4 T cells were still in the first CFSE peak. From 39-48hrs, CD8 T 






At the end of 48hrs (Figure 5.3.1 B), we observed that CD8 T cells had divided four 
times while CD4 T cells divided three times. 
 
We also compared the proliferation of CD8 and CD4 T cells activated with anti-CD3 
alone (Figure 5.3.2 Aand Figure 5.3.2 B) over the same period. The appearance of the 
first CFSE peak for both CD8 and CD4 T cells was delayed when activated only with 
anti-CD3 compared to anti-CD3 with CD11c+ DCs. The first CFSE peak appeared at 
30hrs for CD8 T cells while CD4 T cells took 33hrs (Figure 5.3.2 A). With anti-CD3 
activation alone, CD8 T cells required approximately 9hrs to complete one cell 
division while CD4 T cells took approximately 12hrs (Figure 5.3.2 B). At the end of 
48hrs, CD8 T cells had divided three times while CD4 T cells had only divided twice 


















Figure 5.3.2 A CFSE proliferation of naïve CD8 and CD4 T cells activated with 
anti-CD3ε alone from 27-36hrs. 
At 27hrs, both CD8 and CD4 T cells had not yet divided. At 30hrs, the first CFSE 
peak appeared for CD8 T cells but not CD4 T cells.  From 33-36hrs, no new peaks 
appeared for CD8 T cells, but the first peak for CD4 appeared at 33hrs. This shows 
that CD8 T cells were able to initiate cell division earlier than CD4 T cells even with 






Figure 5.3.2 B CFSE proliferation of naïve CD8 and CD4 T cells activated with 
anti-CD3ε alone from 39-48hrs.  
At 39hrs, a second CFSE peak appeared for CD8 T cells. Time taken from the first to 
the second CFSE peak was approximately 9hrs (30-39hrs). However, for CD4 T cells 
the second peak only appeared at 45hrs, taking approximately 12hrs from the 
appearance of the first peak (33hrs-45hrs). A third CFSE peak appeared at 45hrs for 
CD8 T cells, approximately 6hrs after the second peak appeared (39-45hrs). At the 
end of 48hrs, CD4 T cells only managed to divide twice with CD8 T cells leading 








To confirm that CD8 T cells initiated cell division earlier than CD4 T cells, we pulsed 
the cells in each well with 100µM of BrdU for 1hr before harvesting them for FACS 
analysis.  shows that BrdU incorporation by CD8 and CD4 T cells. The times 
indicated when BrdU was added into the cultures. At 26hrs, about 9% of CD8 T cells 
had BrdU incorporated while CD4 T cells only had 0.9% (A). BrdU incorporation 
was almost negligible at 11hrs and earlier. We also plotted the percentage of CD8 and 
CD4 T cells with BrdU incorporation as a line graph (Figure 5.3.4). The line graph 
shows that there is a significant difference between the percentage of CD8 and CD4 T 
cells at 26hrs. 
 









Figure 5.3.3 BrdU incorporation of naïve CD8 and CD4 T cells activated with 
anti-CD3ε and CD11c DCs between 0-48hrs. 
Naïve T cells were pulsed with 100µM of BrdU 1hr before the harvesting time. 
Percentages indicate the percentage of cells that were BrdU positive. The numbers 
represent the CFSE peak division. (A)Between 0-12hrs, there was not much BrdU 
incorporation for both CD8 and CD4 T cells. At 26hrs, only 0.9% of CD4 T cells had 
BrdU incorporated while CD8 T cells had about 9%. In addition, CD8 T cells had 
undergone their first cell division. (B) Between 29-32hrs, CD8 T cells exhibited 
significantly higher BrdU incorporation than CD4 T cells but between 35-38hrs, the 
percentage of cells with BrdU incorporation in CD4 T cells was significantly higher 
than CD8 T cells. Between 41-44hrs, the percentage of cells with BrdU incorporation 







Figure 5.3.4 Graphical representation of percentage of cells with BrdU 
incorporation for naïve CD8 and CD4 T cells activated with anti-CD3e and 
CD11c DCs between 0-48hrs. 
At 26hrs, 32hrs, 41hrs and 44hrs, there is significant difference in percentage of cells 
with BrdU incorporation between CD8 and CD4 T cells with more CD8 T cells 
having higher BrdU incorporation. The earlier percentage increase of CD8 T cells 
with BrdU incorporation suggests that they reached their first S phase sooner than 
CD4 T cells, thus initiating cell division earlier. **p<0.01, * p<0.05. Data shown was 















We also compared the proliferation of CD8/ CD4 T cells in the presence of the other 
T cell subset using co-culture experiments (Figure 5.3.5 and Figure 5.3.6). This is 
because in vivo both CD8 and CD4 T cells are found together in the local 
environment where they are activated such as the lymph nodes. We therefore wanted 
to see if they had an effect on the proliferation on each other. CD8 and CD4 T cells 
were cultured in the ratio of 1:1 with the total number of T cells in each well at 105 as 
with previous experiments where each T cell subset was cultured alone. 
 
Though there was a slight drop in the percentage of CD8 cells that entered the first 
cell division (Figure 5.3.5) when co-cultured with CD4 T cells, the time taken for the 
first CFSE peak to appear was the same and they divided the same number of times. 
Similarly for CD4 T cells, the same effect was observed (Figure 5.3.6) in both 






Figure 5.3.5 Comparison of CD8 proliferation with/ without co-culture with CD4 
T cells.  
Naïve T cells were activated with 1µg/ml anti-CD3ε and CD11c+ DCs. Negative 
control was unstimulated cells CD8 T cells were co-cultured with CD4 T cells in the 
ratio of 1:1. Total number of T cells in each well was maintained at 105 T cells per 
well. From the plots, the number of cell divisions undergone by CD8 T cells activated 
in the presence or absence of CD4 T cells was similar between 27-45hrs. However, at 
39hrs, the CFSE peak with the highest percentage of CD8 cells was at the 2nd CFSE 
peak for CD8 co-cultured with CD4 T cells but only 1st CFSE peak for CD8 alone 
(indicated by the arrows). Experiments where CD8 was cultured alone were done 
separately from experiments done with CD8 co-cultured with CD4 T cells. Result 











Figure 5.3.6 Comparison of CD4 proliferation with/ without co-culture with CD8 
T cells. 
Naïve T cells were activated with 1µg/ml anti-CD3ε and CD11c+ DCs. Negative 
control was unstimulated cells CD4 T cells were co-cultured with CD8 T cells in the 
ratio of 1:1. Total number of T cells in each well was maintained at 105 T cells per 
well. From the plots, CD4 T cells co-cultured with CD8 T cells had slightly delayed 
proliferation than CD4 T cells alone (observed at 30-36hrs). The amount of CD4 cells 
in the leading CFSE peak was also lower than that of CD4 T cells alone. Experiments 
where CD4 was cultured alone were done separately from experiments done with 














In this chapter, we first compared the cell cycle stages of naïve CD8 and CD4 T cells 
freshly isolated from naive mice as well as the amount of BrdU incorporation. 
Homeostatic proliferation is how naïve T cells numbers are maintained in the 
periphery (Freitas and Rocha 1993; Bell and Sparshott 1997; Ernst, Lee et al. 1999; 
Goldrath and Bevan 1999; Surh and Sprent 2000; Holman, Walsh et al. 2005).  
 
Our results indicate that for the naïve CD8 and CD4 T cell population, the majority of 
the cells were in the quiescent stages of the cell cycle and were not actively dividing 
in either subset, ruling out the possibility that CD8 T cells have head start in cell 
division because they are already actively cycling. 
 
We then went on to study the kinetics of CD8 and CD4 T cells in-depth because we 
wanted to search for potential intrinsic molecules that might play a role in affecting 
the ability of CD8 T cells to divide faster than CD4 T cells. The in-depth study of the 
kinetics of T cell proliferation would help us to identify and focus our efforts on the 
critical aspects of cell division that may be contributing to the phenomenon. 
 
From the previous chapter, we observed that no cell division is observed at 24hrs or 
earlier via CFSE tracking. Therefore, when using CFSE to track the proliferation of 
CD8 and CD4 T cells, we chose a time between 27-48hrs at every 3 hour intervals to 
study the kinetics of T cell proliferation. We observed that the appearance of the first 
CFSE peak occurred earlier in CD8 than CD4 T cells. In addition, the interval taken 
for the appearance from one CFSE peak to the other was shorter for CD8 T cells than 
CD4 T cells. When activated with anti-CD3 with CD11c+ DCs, CD8 T cells took 





Our results show that CD8 T cells have a shorter cycling time than CD4 T cells. In 
addition, from our BrdU experiments, we saw that DNA synthesis before the 
appearance of the first CFSE peak occurred earlier for CD8 than CD4 T cells. 
 
According to the literature, CD8+ T cell division commences after 24hrs of 
stimulation and takes about 6-8 hours to complete one cycle. CD4+ T cell division, 
however, commences only after 36-48 hours of stimulation and takes about 10 hours 
to complete one cycle (Jelley-Gibbs, Lepak et al. 2000; Murali-Krishna and Ahmed 
2000; Veiga-Fernandes, Walter et al. 2000; Homann, Teyton et al. 2001; Kaech and 
Ahmed 2001; Tan, Dudl et al. 2001; Wong and Pamer 2001). 
 
From our results, it was indeed that case that no cell division was observed at 24hrs or 
earlier for both CD8 and CD4 T cells. CD8 cell division commenced earlier than CD4 
T cells and has a shorter cycling time than CD4 T cells. However, from our results we 
observed that CD4 commenced their first cell division at around 33hrs instead of 
36hrs or later as reported by others. A possible explanation is that because our model 
is an in vitro model and the T cells and DCs are in close proximity together and we 
used a generic form of activation using anti-CD3; less time is required for activation 
unlike in vivo where time is needed for DCs carrying antigen to travel to the lymph 
nodes and present to CD4 T cells that specifically recognize the antigen epitope.  
 
The observation that cell division did not occur earlier than 24hrs for CD8 T cells 
even in our in vitro system also demonstrates that regardless of whether using an in 





needed for an activated T cell to prepare for cell division. This applies to memory 
cells as well (Latner, Kaech et al. 2004). 
 
With using anti-CD3 activation of T cells, we observed that both T cell subsets took 
longer to initiate their first cell division and longer time to complete one cell cycle. 
Without co-stimulation, both T cells subsets divided less than when co-stimulation 
was provided. However, CD8 T cells were still able to proliferate more than CD4 T 
cells after 48hrs, suggesting that CD8 T cells were less restricted by the lack of co-
stimulation. These observations are consistent with our current understanding with the 
role of co-stimulation in T cell activation and proliferation (Wells, Gudmundsdottir et 
al. 1997; Gudmundsdottir, Wells et al. 1999; Gett and Hodgkin 2000; Keir and Sharpe 
2005). 
 
Co-culturing CD8 and CD4 T cells together in the culture plates at a ratio of 1:1 and 
activating them with anti-CD3 and CD11c+ DCs, did not significantly affect the 
proliferation of CD8 and CD4 T cells. CD8 T cells co-cultured with CD4 T cells 
divided as many times as CD8 T cells alone at the end of 48hrs and the same was 
observed for CD4 T cells co-cultured with CD8 T cells. We therefore conclude that 
CD8 T cells proliferate faster than CD4 T cells not because they inhibited the growth 
of CD4 T cells or CD4 T cells significantly enhanced the growth of CD8 T cells. 
 
We therefore conclude that CD8 T cells divide faster than CD4 T cells because (1) 
they are able to initiate the cell cycle earlier than CD4 T cells and (2) they have a 





In the next chapter, we will focus p27kip1 inhibitor which is involved in regulating 
entry into the cell cycle and CDK2 which is involved the S phase of the cell cycle, 
promoting DNA synthesis since we observed that DNA synthesis occurred earlier in 
CD8 T cells and how these molecules may play a role in the difference between the 





 Chapter 6 – The effects of p27kip1 on CD8 and CD4 proliferation 
 
6.1 Introduction 
In the previous chapter, we saw that resting naïve CD8 and CD4 T cells were at the 
same stage of the cell cycle, namely G0/G1 stage or otherwise known as the 
resting/quiescent stage. Kinetic studies of T cell proliferation showed that naïve CD8 
T cells initiated proliferation earlier after activation and required a shorter cell cycling 
time than naïve CD4 T cells. 
 
In this chapter, we will compare the proliferation between naïve CD8 and CD4 T cells 
in the absence of p27kip1, cyclin-dependent kinase inhibitor (CKI) which is involved 
in regulating entry into the cell cycle. We focussed on p27kip1 because of recent 
publications that it had a key role. Coller et al. reported that cellular quiescence is not 
identical in cells when they are induced to quiescence via three independent signals – 
mitogen withdrawal, contact inhibition, and loss of adhesion (Coller, Sang et al. 2006). 
The group demonstrated that different genes are up-regulated and down-regulated 
when quiescence is induced via different signals. Some genes may overlap while 
some are unique to the type of signal used to induce quiescence. In addition, 
Pajalunga et. al. also described the concept of cellular quiescence as an active process 
where cell cycle inhibitors (CKIs) are actively repressing the cell from entering cell 
division (Pajalunga, Mazzola et al. 2007; Pajalunga, Mazzola et al. 2007). They 
demonstrated that with solely withdrawing of CKI, they were able to induce cells to 
enter cell division even in terminally differentiated cells, though terminally 
differentiated cells could not progress past the mid G1 stage (Pajalunga, Mazzola et al. 





expressed at higher levels and already in its active form in memory CD8 T cells but 
not in naive CD8 T cells, which allows for more rapid cell division of memory CD8 T 
cells (Latner, Kaech et al. 2004; Veiga-Fernandes and Rocha 2004). Therefore, we 
hypothesized that p27 may be expressed at higher levels in CD4 than CD8 T cells, 
and plays a role in delaying the initiation of cell division as well as limiting their 
proliferative capacity. 
 
There have been differing reports on the effects of p27kip1 on the proliferation of 
CD8 and CD4 T cells in p27kip1 knockout mice (Rowell, Walsh et al. 2005; 
Wolfraim and Letterio 2005). Rowell et. al. reported that in p27kip1 KO mice CD4 T 
cell proliferation was enhanced in the later stages of cell division compared to wild-
type mice. However, Wolfraim and Letterio showed that proliferation of CD8 T cells 
was enhanced in p27kip1 KO mice but not for CD4 T cells. We therefore, wanted to 
investigate the effects of the absence of p27kip1 on CD8 and CD4 T cells in our in 
vitro system. 
 
We first compared the protein expression of p27 and CDK2 from the cell lysates of 
resting wild-type naïve CD8 and CD4 T cells to determine if CD4 expressed more 
p27 and/or if CD4 has less CDK2 than CD8 T cells, both of which would result in a 
delay in T cell proliferation. Next, we compared the phenotypes of p27KO mice and 
their wild-type littermates, studied proliferation of naïve CD8 and CD4 T cells 
obtained from the p27kip1 gene knockout mice, the geographic distribution and 
whether cytokine production is different in p27KO mice. Cyclin E/CDK2 have been 









6.2 Expression of p27 in resting naïve T cells 
As mentioned in the introduction of this chapter, it has been reported that an active 
form of CDK6 is expressed in CD8 memory cells but not naïve CD8 T cells which 
enables CD8 memory T cells to divide more rapidly than naïve CD8 T cells (Veiga-
Fernandes and Rocha 2004). 
 
We therefore, wanted to investigate whether naïve CD4 T cells expressed higher 
levels of p27 in their quiescent stage than CD8 T cells, setting a higher activation 
threshold for CD4 T cells to enter cell division. We sorted naïve CD8 and CD4 T cells 
from WT mice and obtained the cell lysates. We carried out western blot analysis for 
p27 protein in naïve CD4 and CD8 T cells (Error! Reference source not found.). 
Hsp90 was used as a loading control. A thicker darker p27 band was observed for 
CD4 T cells than CD8 T cells for 100μg of cell lysate protein used. It was more 
obvious when we used 10μg of cell lysate protein as the p27 band for CD8 T cells 
was fainter (Error! Reference source not found.A). The relative density of p27 band 
for CD4 and CD8 T cells was calculated against the undiluted Hsp90 loading control 
and normalizing them against the loading controls for each series of dilutions. From 
the results, we observed that CD4 T cells expressed more p27 than CD8 T cells 





 Figure 6.2. 1 Expression of p27kip1 in resting naïve CD4 and CD8 T cells. 
(A) Western blot gel of naïve CD4 and CD8 T cell lysates detected for Hsp90 
(loading control) and p27kip1. A series of dilution of the cell lysates were in each lane. 
Resting naïve CD4 T cells express slightly more p27 than CD8 T cells from the 
thicker black bands. (B) A graphical representation of the levels of p27kip1 
expression against the loading control, Hsp90. The average adjusted relative density 
of p27kip1 to Hsp90 for CD4 T cells is about 1.7 while that of CD8 T cells is 0.8. The 
resting level of p27 is higher in CD4 than in CD8 T cells. *** p<0.001, **p<0.01, * 
p<0.05. Data shown was averaged from four independent experiments using 100μg 








6.3 Comparison of phenotype between WT and p27KO mice 
We compared the phenotypes of p27KO mice with their WT littermates to see if there 
were observable differences between the types of mice. We observed that p27KO 
mice was larger than their wild-type counterparts in size, had larger spleens and 
lymph nodes compared to WT mice (Figure 6.3.1) and the weights of WT and their 
p27KO littermates and length of their spleen are tabulated (Table 6.3. 1).Table 6.3. 1 
 
 
Figure 6.3. 1Phenotype of WT and p27KO mice.  
Mice of the same litter were used to compare the phenotypes between the WT and 
p27KO. (A) The size of p27KO mice was slightly larger than WT mice. (B) The 
spleen of p27KO mice were almost twice that of WT mice. (C) The axillary lymph 
nodes of p27KO mice were also double the size of WT mice. These observations were 






Table 6.3. 1 Recorded weight & length of spleens of WT and their respective 
p27KO littermates.  
The table shows the recorded weight of 10 mice of each strain. The average weight of 
a WT mouse is 18.81g while that of p27KO is 29.75g while the average length of 
spleen of a WT mouse is 11.7mm while that of p27KO is 20.8mm. The p values of 
both the weight of mouse and length of spleen is p< 0.001. 
 
6.4 Comparison of WT and p27KO T cell proliferation kinetics 
We wanted to determine whether the absence of p27 could affect the proliferation 
kinetics of both CD8 and CD4 T cells and how they might differ from WT T cells. 
p27KO and WT naive CD8 T cells were stained with CFSE, activated with anti-CD3 
and CD11c+ DCs and tracked over a period of 30hr-45hrs at 3hr intervals (Figure 
6.4.1A and Figure 6.4.2A). We observed that p27KO CD8 T cells were already one 
cell division ahead of WT CD8 T cells 30hrs after activation. The approximate 
cycling rate of p27KO CD8 T cells to complete division was about 6hrs. The 
approximate cycling time for WT CD8 T cells was also about 6hrs (Figure 6.4.1A). 
When we compared which CFSE division peak majority of the population of CD8 T 
cells were at, p27KO CD8 T cells were generally ahead of WT CD8 T cells by one 
cell division as well (Figure 6.4.1A and Figure 6.4.2A).At the end of 45hrs, p27KO 
weight (grams) length of spleen (mm) weight (grams) length of spleen (mm)
1 20.2 14 28.3 21
2 17.8 10 29.1 20
3 19.2 12 27.1 19
4 21.4 13 30 24
5 18.8 10 34.1 23
6 19.3 11 29.9 19
7 15.7 11 31.4 20
8 16.4 12 26.6 19
9 18.7 10 32.3 22
10 20.6 14 28.7 21
Average 18.81 11.7 29.75 20.8







CD8 T cells divided at least five times while WT CD8 T cells divided at least four 
times. p27KO CD8 T cells also accumulated a higher 4th CFSE division peak than 
WT CD8 T cells after 45hrs activation. 
 
We also compared the proliferation of p27KO and WT CD4 T cells with the same 
activation conditions (Figure 6.4.1B and Figure 6.4.2B) and observed that p27KO CD4 
T cells were also one cell division ahead of WT CD4 T cells at 30hrs (Figure 6.4.1B). 
In addition, majority of p27KO CD4 T cells were also one cell division ahead of WT 
CD4 T cells at all time intervals. The approximate cycling time to complete one cell 
division for p27KO CD4 T cells was approximately 6hrs while WT CD4 T cells was 








(A) Comparison of WT and p27KO naïve CD8 T cell proliferation. At 30hrs, p27KO 
CD8 T cells had undergone two cells divisions while WT CD8 T cells only divided 
once. The loss of p27 enhanced the proliferation of CD8 T cells. p27KO CD8 T cells 
are ahead by WT CD8 T cells by one cell division. The arrow above the CFSE peak 
indicates the division where majority of the CD8 T cell population is. Majority of 
p27KO CD8 T cells were one cell division ahead of WT CD8 T cells. (B) Comparison 
of WT and p27KO CD4 T cell proliferation. At 30hrs, almost no CD4s divided but 
p27KO had divided once. The arrow above the CFSE peak indicates the division 
where majority of the CD4 T cell population is. Majority of p27KO CD4 T cells were 













Figure 6.4.2 CFSE proliferation of WT and p27KO naive T cells activated with 
anti-CD3ε and CD11c+ DCs from 39-45hrs. 
(A) Comparison of WT and p27KO naïve CD8 T cell proliferation. At 39hrs, p27KO 
CD8 T cells had divided four times while WT CD8 T cell only divided three times. 
Majority of the p2KO CD8 T cells were one cell division ahead of WT CD8 T cells at 
all time intervals. The time taken for p27KO CD8 T cells to complete one cell 
division is approximately 6hrs (33-39hrs) while WT CD8 T cells also took 6hrs (33-
39hrs). (B) Comparison of WT and p27KO CD4 T cell proliferation. At 39hrs, 
p27KO T cells had divided three times while WT CD4 T cells divided twice. Majority 
of p27KO CD4 T cells were one cell division ahead of WT CD4 T cells at all times 
points. The time taken for p27KO CD4 T cells to complete one cell division is 
approximately 6hrs (36-42hrs) while WT CD4 T cells also took 9hrs (36-45hrs). 










 Next, we activated WT CD8 and p27KO T cells sub-optimally with just anti-CD3 
alone. p27KO CD8 T cells were one cell division ahead of WT CD8 T cells between 
30-36hrs. However, from 36-45hrs, the proliferation of p27KO CD8 T cells slowed 
down. At the end of 45hrs, both p27KO and WT CD8 T cells divided 3 times (Figure 
6.4.3A). Whereas, both WT CD8 T cells activated with anti-CD3 alone had a cycling 
rate of approximately 9hrs while p27KO took approximately 12hrs from the second 
CFSE peak to the third CFSE peak (Figure 6.4.3A and Figure 6.4.4A). 
 
For CD4 T cells activated with anti-CD3 alone, p27KO CD4 T cells were one cell 
division ahead of WT CD4 T cells at all time intervals (Figure 6.4.3B and 6.4.4B). 
The cycling time taken by CD4 T cells to complete one cell division when activated 
with anti-CD3 alone was approximately 9hrs for both p27KO and WT. At the end of 
45hrs, p27KO CD4 T cells divided three times while WT CD4 T cells only divided 









Figure 6.4.3 CFSE proliferation of WT and p27KO T cells activated with anti-
CD3ε alone from 30-36hrs. 
(A) Comparison of WT and p27KO CD8 T cell proliferation. At 30hrs, almost all 
p27KO CD8 T cells had entered their first well division while only a small percentage 
of WT CD8 T cells entered their first cell division. The arrow in each plot indicates 
the CFSE peak with majority of the CD4 T cell population. The majority of p27KO 
CD8 T cells were also one cell division ahead of WT CD8 T cells (B) Comparison of 
WT and p27KO CD4 T cell proliferation. p27KO CD4 T cells divided once at 30hrs 
while WT CD4 T cells remained undivided. p27KO CD4 T cells are one cycle ahead 










Figure 6.4.4 CFSE proliferation of WT and p27KO naive T cells activated with 
anti-CD3ε alone from 39-45hrs. 
(A) Comparison of WT and p27KO naive CD8 T cell proliferation. From 39hrs 
onwards, p27KO CD8 T cell division slows down, with WT CD8 T cells dividing the 
same number of times at the end of 45hrs. The arrow in the plots indicates the CFSE 
peak with majority of the CD8 population. The approximate cycling time for p27KO 
CD8 T cells from 2nd to 3rd division was about 12hrs (33-45hrs) while that of WT 
CD8 T cells is about 9hrs (30-39hrs). (B) Comparison of WT and p27KO naive CD4 
T cell proliferation. p27KO CD4 T cells leads WT CD4 T cells by one cell division at 
30hrs.The approximate cycling time for p27KO CD4 T cells is about 9hrs (36-45hrs) 
while that of WT CD4 T cells is about 9hrs as well (33hrs-42hrs) Results are 







6.5 Comparison of proliferation between p27KO CD8 and CD4 T cells 
We compared the proliferation between p27KO CD8 and CD4 T cells activated with 
anti-CD3 alone and anti-CD3 and CD11c+ DCs after 45hrs to investigate whether 
CD8 T cells still had the proliferative advantage over CD4 T cells in the absence of 
p27. Using p27KO mice, CD4 T cells underwent the same number of cell divisions as 
CD8 T cells either with anti-CD3 alone (Figure 6.5.1A) or together with CD11c+ DCs 
(Figure 6.5.1B). However, we observed that CD8 T cells still had a slight proliferative 
advantage over CD4 T cells as CD8 T cells till had a higher CFSE leading peak than 
CD4 T cells with both anti-CD3 activation alone and with CD11c DCs. In addition, 
majority of CD8 T cells activated with anti-CD3 and CD11c DC were in the third 
CFSE division peak while CD4 T cells were only at the second CFSE division peak 
(Figure 6.5.1B). 
 
In addition, we also compared the proliferation of CD8 and CD4 T cells from 
Skp2KO mice activated with anti-CD3 and CD11c DCs (Figure 6.5.1C). Skp2 is part 
of a complex Skp-Cullin-Fbox (SCFskp2) which ubiquitinates p27 and leads to its 
subsequent proteosomal degradation (Sheaff, Groudine et al. 1997; Carrano, Eytan et 
al. 1999; Sutterluty, Chatelain et al. 1999). The use of Skp2KO mice was to verify the 
role of p27 in providing the proliferative advantage of CD8 T cells over CD4 T cells. 
Skp2KO CD8 and CD4 T cell proliferation was greatly hampered even when proper 
activation was provided (Figure 6.5.1C). Both CD8 and CD4 T cells completed 2 cell 








Figure 6.5.1 Comparison of CFSE proliferation p27KO naïve CD8 and CD4 T 
cells activated with anti-CD3e alone, anti-CD3e + CD11c DCs and Skp2KO CD8 
and CD4 T cells with anti-CD3e + CD11 DCs after 45hr activation. 
(A) Comparison of p27KO CD8 and p27KO CD4 T cells activated with anti-CD3 
alone. Both p27KO CD8 and CD4 T cells divided 3 times after 45hrs activation with 
majority of the cells at the first CFSE division peak. (B) Comparison of p27KO CD8 
and p27KO CD4 activated with anti-CD3 and CD11c DCs. With co-stimulation, both 
p27KO CD8 and CD4 T cells divided four times after 45hrs activation. Majority of 
CD8 T cells were at the third CFSE division peak while CD4 T cells were at the 
second CFSE division peak. (C) Comparison of SKp2KO CD8 and Skp2KO CD4 T 
cells activated with anti-CD3 and CD11c DCs. Skp2KO mice express high levels of 
p27, therefore cell proliferation is limited in cells. With Skp2KO, both CD8 and CD4 
T cells underwent two cell divisions after 45hrs activation. Results are representative 
of two independent experiments. For part (C), 3 mice were pooled for each 
experiment. Results (A) and (B) were from earlier experiments and used to compare 





6.6 Effects of p27 on distribution of CD8 and CD4 populations 
We went on to look at the distribution of CD8 and CD4 population in the thymus and 
spleen to see whether the absence of p27 affected the proportion of CD4 to CD8 T 
cells. We stained lymphocytes isolated from the thymus of WT and p27KO mice for 
CD4 and CD8 expression (Figure 6.6.1). The proportion of single positive (SP) CD4 
to SP CD8 T cells in the thymus of WT mice was about 2 to 1. This proportion was 
similar to that of p27KO mice and no significant differences were observed. 
 
We also looked at the proportion of CD4 to CD8 T cells in the spleen between WT 
and p27KO mice (Figure 6.6.2A). Cells were gated based on positive CD3 expression 
and observed that there were no significant differences in the proportion of CD4 to 
CD8 T cells in WT and p27KO spleens. We also observed that the distribution of 
subpopulation within CD8 and CD4 subsets are similar in p27KO mice and WT mice. 
p27KO CD4 T cells still had a greater proportion of effector cells than central 
memory cells (Figure 6.6.2B) while p27KO CD8 T cells still had a greater proportion 
of central memory cells than effector cells (Figure 6.6.2C).  
 
p27KO CD4 T cells had a significantly higher percentage of effector cells than WT 
CD4 T cells. p27KO naïve CD4 T cells was greatly reduced compared to WT while 
the percentage of p27KO central memory CD4 T cells was similar to WT CD4 T cells 
(Figure 6.6.2B). For CD8 T cells, the percentages of the subpopulation of CD8 T cells 








Figure 6.6.1 Comparison of T cell distribution in the thymus between wild type 
and p27 KO mice. 
The plot on the left represents the thymus from WT mice while the plot on the right 
represents thymus from p27 KO mice The distribution of T lymphocytes within the 
thymus of WT and p27 KO mice are similar and no significant differences in the 








Figure 6.6.2 Comparison of T cell distribution in the spleen between wild type 
and p27 KO mice. 
CD3 positive cells were gated first. The left column are plots from WT mice while the 
right column are plots from  p27 KO mice.(A) Percentage of CD8 and CD4 in the 
spleen of WT and p27 KO mice. The percentages of CD8 and CD4 T cells in the 
spleen were similar in both strains of mice. (B) The percentage of naïve CD4 T cells 
between p27KO mice and WT mice is significantly different. p27 KO mice have a 
lower proportion (42.5%) of CD4 cells that are naïve than WTmice (72%). The 
effector population (CD44hiCD62Llow) of p27KO mice is significantly greater than 
WT. (38.5% vs 14.5%). The central memory population of CD4 cells were similar 
between p27KO and WT (2.5% vs 3.5%)  (C) The subpopulation distribution of CD8 
T cells between p27 KO and WT mice are similar. Numbers in each quadrant 
corresponds to the percentages of each subpopulation. Legend: N= naïve, CM = 
central memory, EM = effector memory, R = revertant. Results are representative of 





6.7 Effects of p27 on CD28 expression  
CD28 has been demonstrated to downregulate p27 via IL-2 independent & IL-2 
dependent pathways (Boonen, van Dijk et al. 1999; Appleman, Berezovskaya et al. 
2000; Appleman, van Puijenbroek et al. 2002). We wanted to investigate whether the 
absence of p27 affected the expression of CD28 on T cells since the absence of p27 
has allowed CD4 T cells to become more sensitive to activating signals, allowing 
p27KO CD4 T cells to divide as many times as p27KO CD8 T cells even with 
suboptimal activation by anti-CD3 alone (Figure 6.5.1A). We observed that there was 
no significant difference in the expression of CD28 in CD4 T cells from WT or 
p27KO mice (Figure 6.7.1). The same was observed for CD8 T cells from WT or 
p27KO mice. In addition, p27KO CD4 T cells still had a higher expression of CD28 
than p27KO CD8 T cells (Figure 6.7.1), which was what we previously observed 






Figure 6.7.1 Comparison CD28 between wild type and p27 KO naïve T cells.  
The plots were gated on CD3 positive & CD44low-intCD62Lhi cells. The plot on the 
left represents naïve T cells from WT mice while the plot on the right represents naïve 
T cells from p27 KO mice. The expression of CD28 on CD4 T cells is similar 
between WT (MFI: 25) and p27 KO mice (MFI: 22). The expression of CD28 on CD8 
T cells is similar between WT (MFI: 16) and p27 KO mice (MFI: 14) as well. MFI = 






















Our initial hypothesis was that CD4 T cells expressed higher amounts of p27 protein 
in their quiescent stage than CD8 T cells, thereby requiring a greater threshold to 
overcome before being able to initiate cell division as well as being more susceptible 
to anergy caused by suboptimal activation as compared to CD8 T cells. Quantification 
of amounts of p27 protein in naïve CD4 and CD8 T cells lysates showed that CD4 T 
cells had more p27 protein in the quiescent stage than CD8 T cells.  
 
Interestingly, we were unable to detect CDK2 in WT naïve CD8 and CD4 T cells. 
This has also been reported by Ling et al. on their recent study on how cell cycle and 
apoptotic machineries are coupled in developing T cells. They showed via western 
blot naïve CD8 and CD4 T cells isolated from lymph nodes had no detectable levels 
of CDK2 (Xue, Sun et al. 2010). This suggests that the limitation in inhibiting CD4 
proliferation may lie upstream of the cell cycle such as CDK4 and CDK6 together 
with cyclin D. 
 
We investigated the effect of p27 on T cell proliferation using p27KO mice. We first 
compared the phenotype between WT and p27KO mice and observed p27KO mice 
were larger in body size and had multiple organ hyperplasia, such as the spleen. There 
were also generally more immune cells in these p27KO cells. These observations 
have been reported others (Kiyokawa, Kineman et al. 1996; Nakayama, Ishida et al. 
1996). When we activated p27KO T CD8 and CD4 T cells with anti-CD3 and CD11c, 
we observed that majority of both p27KO CD8 and CD4 T cells entered their first cell 
division earlier than WT T cells, leading WT T cells by one cell division. The cycling 
time taken to complete one cell division was 6 hours for WT and p27KO CD8 T cells. 





entered their first cell division earlier than WT CD4 T cells with majority of the 
parent population entering their first cell division 30hrs after activation. The cycling 
time taken to complete one cell division was 9 hours for WT and 6hrs for p27KO 
CD4 T cells. Thus, p27 does not influence the time of CD4 or CD8 T cells to divide. 
 
Our results suggests that p27 restricts initiation of T cell proliferation by setting a 
threshold that needs to be overcome before T cells can initiate cell division. This is 
supported by the observation that majority of the parent population of p27KO T cells 
entered their first cell division after 30hrs activation compared to WT T cells, which 
took approximately 33hrs. Moreover, we also observed that with proper activation, 
the cycling times of p27KO T cells did not differ greatly from WT T cells, which 
supports the role of p27 in controlling entry and exit of cell division of T cells (Singh, 
Jatzek et al. 2010). 
 
 Our results indicate that the absence of p27 enhances T cell proliferation through 
shortening the time take to complete one cell division for CD4 T cells but not in the 
case of CD8 T cells. In addition, proliferation is enhanced in p27KO T cells because 
p27, which limits the number of times each cell can divide is now removed, allowing 
T cells to divide more in the same environment. 
 
In chapter 5, we demonstrated that CD8 T cells were better able to be activated with a 
sub-optimal stimulus than CD4 T cells as they were able to divide more than CD4 T 
cells when activated with anti-CD3 alone. In this chapter, when we activated p27KO 
CD8 and CD4 T cells with anti-CD3 alone, p27KO CD4 T cells divided as many 





activated with anti-CD3 alone. Though, p27KO enhanced CD4 T cell proliferation to 
that seen with p27KO CD8 T cells, we observed that CD8 T cells still maintained the 
slight proliferative advantage over CD4 T cells because the leading CFSE peak of 
p27KO CD8 T cells was still higher than that of p27KO CD4 T cells and the cycling 
time for CD8 T cells (6hrs) was still shorter than p27KO CD4 T cells (9hrs) with anti-
CD3 and CD11c DC activation. This suggests that other cell cycle machinery also 
contribute to the cycling efficiency of CD8 T cells compared to CD4 T cells. 
 
We verified our observations using Skp2KO mice. As mentioned earlier, Skp2 is part 
of a complex Skp-Cullin-Fbox (SCFskp2) which ubiquitinates p27 and leads to its 
subsequent proteosomal degradation (Sheaff, Groudine et al. 1997; Carrano, Eytan et 
al. 1999; Sutterluty, Chatelain et al. 1999). Mice with Skp2KO exhibit proliferative 
defects because p27 degradation is compromised. For SkpKO CD8 and CD4 T cells, 
proliferation was significantly inhibited and the majority of the parent population 
remained undivided after 45hrs activation. Although both Skp2KO CD8 and CD4 T 
cells divided twice, the percentage of cells in the leading CFSE peak were very low in 
both T cell subsets. Our results support the role of p27 in regulating entry into cell 
division in T cells. 
 
We went on to look at the distribution of the CD8 and CD4 T cells in the thymus and 
spleen of p27KO mice to investigate whether the absence of p27 would affect the 
proportion of CD4 to CD8 T cells in these lymphoid organs. Our results show that in 
the absence of p27, the proportion of CD4 to CD8 T cells is thymus is similar to that 
of the wild-type thymus. Our results are consistent with the observations of others 





observed that the proportion of CD4 to CD8 T cells in the spleen was also similar in 
WT and p27KO mice. 
 
The effector/memory subpopulation distribution of CD8 T cells in the spleens of 
p27KO mice was similar to that of WT mice. CD44hi cells in the CD8 subpopulation 
of p27KO mice were mainly central memory cells (CD44hiCD62Lhi), similar to our 
observations in the WT spleens. CD4 T cells in the spleens of p27KO mice however, 
had a significant increase in the percentage of effector cells (CD44hiCD62Llow) 
compared to WT CD4 T cells. 
 
CD28 co-stimulation has been shown to down-regulate p27 and promotes cell 
division (Boonen, van Dijk et al. 1999; Appleman, Berezovskaya et al. 2000; 
Appleman, van Puijenbroek et al. 2002), therefore we were speculated whether in 
p27KO mice, expression of CD28 would be down-regulated in the T cells as a means 
to regulate their sensitivity to co-stimulatory signals due to p27 gene knockout. 
However, our results showed that CD28 expression on CD8 and CD4 T cells in 
p27KO mice was similar to that of WT mice. The expression of CD28 on p27KO 
CD4 T cells was also higher than that of p27KO CD8 T cells; similar to our 
observations in WT CD4 and CD8 T cells. From our results, the expression of CD28 
is not affected by p27. 
 
 
In summary, we have shown that the initiation of cell division is later in CD4 T cells 
than CD8 T cells due to CD4 T cells expressing higher levels of p27 in their resting 





of p27KO T cells enter their first cell division after activation while only a small 
proportion enter their first cell division in WT T cells. We also observed that the 
effect of removing p27 was greater in CD4 T cells because CD4 T cells underwent the 
same number of proliferation as p27KO CD8 T cells. Interestingly, removal of p27 
did not affect the distribution of CD8 and CD4 T cells in the thymus and spleen. 
However, it increased the effector subpopulation (CD44hiCD62Llow) in CD4 T cells 
but did not affect the subpopulation distribution of CD8 T cells. 
 
The cycling time of p27KO CD8 was still shorter than p27KO CD4 T cells, 
suggesting that there may be other aspects of the CD8 cell cycle machinery that are 
more efficiently controlled than CD4 T cells. However, we’ve shown that the longer 
lag in the initiation of first cell division in CD4 T cells is due to p27 acting as the 












 Chapter 7 – Final discussion 
 
7.1 Discussion 
In this study, we demonstrated with our in vitro model that we were able to observe 
the same phenomenon reported in vivo that CD8 T cells divided faster than CD4 T 
cells (Jelley-Gibbs, Lepak et al. 2000; Murali-Krishna and Ahmed 2000; Schluns, 
Kieper et al. 2000; Veiga-Fernandes, Walter et al. 2000; Whitmire, Murali-Krishna et 
al. 2000; Homann, Teyton et al. 2001; Kaech and Ahmed 2001; Tan, Dudl et al. 2001; 
Wong and Pamer 2001; Foulds, Zenewicz et al. 2002) regardless of the type of 
activation stimuli or mouse strain used ( 
, Figure 4.2.1, Figure 4.7.2 and Figure 4.8.1). 
 
The ability of CD8 T cells to rapidly expand compared to CD4 T cells seems to be 
inherent to the T cell subset as described by others (Mercado, Vijh et al. 2000; Bevan 
and Fink 2001; Kaech and Ahmed 2001; van Stipdonk, Lemmens et al. 2001; Foulds, 
Zenewicz et al. 2002). A possible explanation is that CD8 T cell expansion is on 
“autopilot” mode as described by Bevan M.J. and Fink P.M (Bevan and Fink 2001), 
namely that CD8 T cells are pre-programmed to expand rapidly after activation.  
 
It had been reported that naïve CD8 T cells are programmed to go through multiple 
rounds of proliferation just with a brief encounter with antigen (as short as 2hrs), 
which results in the acquisition of effector function and the eventual generation of 
CD8 T cell memory (Mercado, Vijh et al. 2000; Kaech and Ahmed 2001; van 
Stipdonk, Lemmens et al. 2001). CD4 T cells, on the other hand, require the 




Rabenstein and Obst suggested that an inducible mechanism is triggered in CD4 T 
cells which may explain the need for antigen persistence for continual expansion of 
CD4 T cells but not in CD8 T cells (Rabenstein and Obst 2009). Although Foulds. et 
al through their observations on Listeria infections in vivo (Foulds, Zenewicz et al. 
2002) demonstrated that CD8 T cells were able to undergo rapid expansion and 
underwent extensive proliferation compared to CD4 T cells, the model used did not 
address whether the persistence of antigen presentation to CD8 and CD4 T cells was 
comparable throughout their experiment. These studies suggest the CD8+ and CD4+ T 
cells inherently differ in their ability to expand. 
 
The support that there are intrinsic differences controlling CD8+ and CD4+ T cell 
proliferation from our literature search is strong but the importance of p27kip1 in 
CD8+ and CD4+ T cells may not be the same as initially thought. More studies need to 
be done to verify the importance of p27kip1 as the crucial regulator of cell cycle 
progression in CD4+ T cells especially in determining the proportion of CD4 T cell 
population which are effector cells. 
 
Using antibodies (Figure 4.2.1), anti-CD3 co-cultured with CD11c+ DCs (Figure 
3.7.1and Figure 5.3.1A), PMA and ionomycin (Figure 3.7.1) as well as ovalbumin 
peptides (Figure 4.7.1C), our in vitro data has also demonstrated that CD8 T cells 
underwent more cell divisions than CD4 T cells at the same time points. The 
advantage of using an in vitro system is that as a closed system, “antigen” persistence 
is mimicked throughout the expansion phase of the activated T cells for the duration 




to control the type of stimuli used to activate the two T cell subsets to see whether 
CD8 T cells continue to divide more than CD4 under different stimulating conditions.  
 
Another advantage of using an in vitro model for studying T cell kinetics allowed for 
better control on the role of growth/ survival cytokines on T cell expansion, 
particularly IL-2. As mentioned, IL-2 serves as a growth cytokine, enhancing T cell 
proliferation after activation (Morgan, Ruscetti et al. 1976). From our results, we 
observed that CD4 T cells made more IL-2 than CD8 T cells as observed in our 
multiplex cytokine assays from activated T cell supernatants (Figure 4.3.1). This 
ability of CD4 T cells to be better producers of IL-2 than CD8 T cells has been 
reported previously (Smith 1988; Setoguchi, Hori et al. 2005; Malek 2008). 
 
Using an in vitro system, we were able to purify CD8 and CD4 T cells and separately 
compare the kinetics of CD8 and CD4 T cell proliferation. This allowed us to exclude 
the possibility of CD8 T cells making use of growth cytokines such as IL-2 produced 
by CD4 T cells to enhance their proliferation. This would have been a confounding 
factor to our results that the ability of CD8 T cells to proliferate more rapidly than 
CD4 T cells was intrinsic to CD8 T cells if our experiments were done in vivo as it 
would have been difficult to block/ isolate the interaction of the cytokines produced 
by CD4 T cells on CD8 T cells as well as their physical interaction in their native 
environment such as the lymph nodes and spleen when they are found in close 





One unique feature of our in vitro model was the use of anti-CD3 CD11c+ DC co-
culture method for activating T cells instead of the conventionally used non-specific 
activation methods of using high concentrations of anti-CD3 antibody alone or 
together with anti-CD28 (Rowell, Walsh et al. 2005; Wolfraim and Letterio 2005). 
We used CD11c+ DCs to provide co-stimulatory signals in our cell cultures instead of 
anti-CD28 for subsequent proliferation kinetic experiments for CD8 and CD4 T cells 
because it allowed us to continue using a non-specific method of activation that more 
closely resembled in vivo situation where co-stimulatory signals are provided by the 
APCs. In addition, other co-stimulatory molecules expressed on DCs such as 4-1BB 
ligand/ CD137 ligand, OX40 ligand and CD40 (Wegener, Letourneur et al. 1992; 
Whitmire, Flavell et al. 1999; Whitmire and Ahmed 2000; Bertram, Lau et al. 2002; 
Lee, Myers et al. 2004; Pitcher, Mathis et al. 2005) would provide the additional co-
stimulatory signals for better activation of T cells as compared to a single co-
stimulatory signal through anti-CD28. We observed in our experiments that our non-
antigen specific method of activating T cells resulted in better proliferation and 
improved viability of both T cell subsets compared to anti-CD3 and anti-CD28 alone ( 
). 
 
Although we did compare the proliferation of CD8 and CD4 T cells using antigen-
specific system by using OT-I and OT-II cells and still observed that OT-I CD8 T 
cells divided faster than OT-II CD4 T cells. There have been criticisms that the 
OVA257-264 peptide that the CD8 OT-I T cells recognise has an artificially high 
affinity for the TCR, which activates CD8 OT-I T cells more strongly as compared to 
the OVA329-337 peptide which OT-II CD4 T cells recognises, therefore we did not use 




addition, in later experiments where we investigated the effects of p27 on T cells 
expansion, we only had access to p27-/- mice but did not have access to OT-I p27-/- 
or OT-II p27-/- mice. It would have been impossible to make a fair comparison on the 
effects of removing p27 if we had used the OVA-antigen specific system. 
 
During the course of our experiments, we also observed that when we stained T cells 
obtained from naïve C57BL6 mice with CD44 and CD62L antibodies, CD8 and CD4 
T cells had distinctly different subpopulation distributions (Figure 4.9.1). In the mouse, 
TCM is identified as being CD44hi CD62Lhi and TEM is CD44hi CD62Llow (Bjorkdahl, 
Barber et al. 2003; Roberts, Ely et al. 2005). CD8 memory T cell subpopulation 
mainly consisted of TCM while CD4 memory T cell subpopulation mainly consisted of 
TEM. This observation has also been reported by Seki et. al (Seki, Suzuki et al. 2010). 
 
We specifically sorted out the naïve T cell subpopulation (CD44low-intCD62L+) to 
study the kinetics of CD8 and CD4 T cell proliferation because a unique characteristic 
of memory T cells is that they have a low-activation threshold and are highly 
responsive to antigenic stimulation (Sallusto, Lenig et al. 1999; Veiga-Fernandes, 
Walter et al. 2000; Geginat, Lanzavecchia et al. 2003). In addition, the expansion 
potential of memory T cells has been shown to be lower in TEM than TCM (Sallusto, 
Lenig et al. 1999; Geginat, Lanzavecchia et al. 2003). Since CD8 T cells have more 
TCM while CD4 T cells have more TEM in the population, the presence of these cell 
types would confound the results of our kinetic experiments. After sorting out the 
naïve T cell population, we activated these cells and showed that even comparing 
between naïve CD8 and CD4 T cells, we still observe that CD8 T cells proliferate 





Having set up our in vitro model, we went on to study the kinetics of the early time 
points of T cell expansion. We chose to track T cell expansion kinetics for the first 
48hrs of cell division because we observed in our system that CD8 T cell proliferation 
response peaked earlier than CD4 T cells at around 48hrs (Figure 4.2.1). Moreover, 
we wanted to determine whether CD8 T cells went through more cell divisions within 
a certain time because they: (1) started cell division earlier than CD4 T cells (2) had a 
shorter cell cycling time than CD4 T cells or (3) a combination of starting cell 
division earlier as well as having a shorter cell cycling time than CD4 T cells. 
Therefore, it was important to track the cell division in the earlier time points 
following T cell activation.  
 
CFSE has commonly been used to track the number of cell divisions a population of 
cells has been through over a period of time. In our study, we made use of the 
appearance of one CFSE peak to another to determine the time needed for CD8 and 
CD4 T cells to complete one cell division by harvesting activated CFSE-stained T 
cells at 3hr intervals to observe the appearance of new CFSE peaks. So far, we have 
not come across any papers that have made use of CFSE in this manner to determine 
the cycling rates of cells. Together with BrdU incorporation and 7-AAD staining to 
stain for DNA content, this method is useful for determining the time taken for CD8 
and CD4 T cells for each individual stage of the cell cycle (i.e. G1 phase to S phase, S 
phase to G2/M phase). 
 
We observed that no cell division occurred before 24hrs from our CFSE tracking for 




(Bradley, Duncan et al. 1991; Gramaglia, Cooper et al. 2000; Latner, Kaech et al. 
2004). This suggests that 24hrs is the minimum time T cells need to prepare for cell 
division after receiving activation signals due to an inefficiently coupled signalling 
machinery (Fraser, Irving et al. 1991; Cai, Kishimoto et al. 1997; Gil, Schamel et al. 
2002; Alarcon, Gil et al. 2003; Malissen 2003; Wang, Becker et al. 2009). Although 
we did not observe the appearance of first cell division before 24hrs for either CD8 or 
CD4 T cells, our BrdU incorporation experiments indicated that DNA synthesis 
occurred earlier in CD8 than CD4 T cells before the first cell division occurred 
(Figure 5.3.3). 
 
From our CFSE tracking experiments, we observed that CD8 T cells entered their first 
division earlier than CD4 T cells as well as taking a shorter time to complete one cell 
cycle division (Figure 5.3.1A and Figure 5.3.2 A). Our in vitro cycling times are 
within the range with reported in vivo data; approximately 4-8hrs for CD8 and 8-
12hrs for CD4 (Butz and Bevan 1998; Callan, Tan et al. 1998; Doherty 1998; Murali-
Krishna, Altman et al. 1998; Jelley-Gibbs, Lepak et al. 2000; Veiga-Fernandes, 
Walter et al. 2000; Homann, Teyton et al. 2001; Kaech and Ahmed 2001; Tan, Dudl 
et al. 2001; Wong and Pamer 2001) as well as from in vivo CD8 proliferation of 
influenza infected mice from our lab. 
 
Using PMA & ionomycin to activate T cells bypasses the external TCR signalling 
pathway by targeting the signalling molecules within the cell directly, eliminating the 
need of TCR engagement. Interestingly, our CFSE data using PMA & ionomycin to 
activate CD8 and CD4 T cells showed that even after bypassing the TCR, CD8 T cells 




the view that CD8 T cells have the intrinsic capability to expand rapidly than CD4 T 
cells. 
 
The concept of intrinsic capability to expand may explain why there is a higher 
frequency of CD8 epitope-specific T cells than CD4 T cells in vivo during an 
infection (i.e. the number of epitope-specific CD8 T cells are greater than CD4 T cells) 
(Whitmire, Murali-Krishna et al. 2000). This concept has also been proposed by 
Turner et al through their study on B cells. They suggested that B cell proliferation 
capacity is intrinsically limited even in maximal stimulation conditions (Turner, 
Hawkins et al. 2008). In addition, they demonstrated that Bcl-2 over-expressing B 
cells compared to wild-type B cells underwent the same maximal number of divisions 
even when survival was enforced in the transgenic B cells, suggesting cell division 
progression and cell death are regulated independently, and cell death has no effect on 
the rate of division of cells. They also demonstrated B cells that divided earlier did not 
necessarily have a higher total cell number compared to cells that divided later 
because cell death is an age-dependent stochastic event (Turner, Hawkins et al. 2008). 
As such, it is likely that internal cellular mechanisms are responsible for controlling 
immune responses (Alarcon, Berkhout et al. 1988). 
 
p27kip1 is a “universal” CDK inhibitor which is able to inhibit a number of cyclin-
CDK complexes as various stages of the cell cycle in a variety of cell types (Sherr 
1994). It is an important regulator of G1 phase of cell cycle entry (Sherr 1994) and is 
highly expressed in quiescent mature T cells but is down-regulated upon mitogen 
stimulation (Nourse, Firpo et al. 1994; Kwon, Buchholz et al. 1997). The control of 




growth-promoting cytokines (such as IL-2) seem to converge to down-regulate 
p27kip1 (Kobayashi, Phuchareon et al. 1997; Kwon, Buchholz et al. 1997; Durand, 
Fero et al. 1998; Kaplan, Daniel et al. 1998; Boonen, van Dijk et al. 1999; Banerji, 
Glassford et al. 2001; Barata, Cardoso et al. 2001; Tsukiyama, Ishida et al. 2001; 
Appleman, van Puijenbroek et al. 2002; Slavik, Lim et al. 2004). Our results on T cell 
kinetics indicate that CD8 T cells initiated proliferation earlier than in CD4 T cells, 
suggesting that the levels of p27kip1 may be lower than CD4 T cells, allowing earlier 
initiation of cell division, making p27kip1 likely candidate to study as one of the key 
intrinsic factors that controls the ability of T cells to proliferate. 
 
CD28 co-stimulation has been shown to down-regulate p27 to promote cell division 
(Boonen, van Dijk et al. 1999; Appleman, Berezovskaya et al. 2000; Appleman, van 
Puijenbroek et al. 2002). From our results, we also demonstrated that CD8 T cells 
have a lower requirement for co-stimulatory signals than CD4 T cells because CD8 T 
cells divided more than CD4 T cells when activated with anti-CD3 alone (Figure 5.3.2 
A). This less stringent requirement for co-stimulation by CD8 T cells has also been 
reported by others (Jelley-Gibbs, Lepak et al. 2000; Murali-Krishna and Ahmed 2000; 
Veiga-Fernandes, Walter et al. 2000; Whitmire and Ahmed 2000; Homann, Teyton et 
al. 2001; Kaech and Ahmed 2001; Tan, Dudl et al. 2001; Wong and Pamer 2001). 
Since CD28 co-stimulation downregulates p27, we hypothesized that naïve CD8 T 
cells have less of p27 in their resting state than CD4 T cells, therefore, requiring less 
co-stimulation to initiate cell division. From our western blot analysis, we saw that 
quiescent naive CD8 T cells expressed lower levels of p27 than naive CD4 T cells 




There have been differing reports on the effects of p27kip1 on the proliferation of 
CD8 and CD4 T cells in p27kip1 knockout mice (Rowell, Walsh et al. 2005; 
Wolfraim and Letterio 2005). Rowell et. al. reported that they in p27kip1 KO mice 
that CD4 T cell proliferation was enhanced in the later stages of cell division 
compared to wild-type mice. However, Wolfraim and Letterio reported that 
proliferation of CD8 was enhanced in p27kip1 KO mice but not for CD4 T cells.  
 
From our results, we saw that removing p27 enhanced the proliferation of both CD8 
and CD4 T cells and allow T cells to enter cell division earlier than WT T cells. 
Particularly for CD4 T cells, removing p27 had a greater effect on their proliferation 
as compared to CD8 T cell because not only was cell division initiated earlier, the 
cycling time was shortened comparable to that of WT CD8 T cells (Figure 6.4.1 and 
Figure 6.4.2). To demonstrate the importance of p27 regulating in T cell expansion, 
we activated Skp2KO CD8 and CD4 T cells and looked at the number of cell 
divisions at the end of 45hrs (Figure 6.5.1). Skp2 is a protein that is part of a large 
protein machinery complex responsible for the degradation of p27. Deletion of Skp2 
results in high levels of p27. Majority of the Skp2KO cells remain undivided even 
with proper activation. 
 
Our results seem more consistent with was had been reported by Rowell et al. One 
possibility for this discrepancy is that for Wolfraim and Letterio is that even though 
the T cells were isolated from naïve mice, the naïve population was not sorted. Since 
p27KO mice had more CD4 TEM in the CD4 population in these mice (Figure 6.6.2B) 
and TEM are reported to have less proliferative capacity, it is possible that the 





Comparing p27KO CD8 and CD4 T cell proliferation, deletion of p27 enhanced CD4 
T cell proliferation more than in CD8 T cells. It is likely that p27 plays a bigger role 
in regulating CD4 T cell responses than in CD8 T cells, restricting initiation of CD4 T 
cell proliferation after activation by setting a higher threshold that needs to be 
overcome before CD4 T cells can initiate cell division as well as the duration of cell 
division. This is supported by the observation that in p27KO CD4 T cells, majority of 
the parent population entered their first cell division after 30hrs activation compared 
to WT T cells. Since p27kip1 controls both cell cycle entry as well as cell cycle exit 
(Yu, Martin et al. 2003; Singh, Jatzek et al. 2010), we expected that the cell cycling 
time for T cells to be shortened. Interestingly, only the cycling time of p27KO CD4 T 
cells was shortened to 6hrs, comparable to CD8 T cells, but in p27KO CD8 T cells the 
cycling time remained unchanged. The fact the cycling time remained unchanged for 
p27KO CD8 T cells suggests that other cell cycle molecules are the limiting factor in 
affecting CD8 T cell expansion. 
 
We observed that the distribution of the subpopulations within CD8 T cells in p27KO 
spleen was similar to that of WT mice. CD44hi cells in the CD8 subpopulation of 
p27KO mice were mainly TCM (CD44hiCD62Lhi). For CD4 T cells in the spleens of 
p27KO mice however, they had a significant increase in the percentage of TEM 
(CD44hiCD62Llow) compared to WT CD4 T cells. A recent publication highlighted 
the role of p27 in the generation of CD8 memory T cells after vaccination with 
recombinant Listeria monocytogenes. These authors demonstrated that p27kip1 




memory population subset (Singh, Jatzek et al. 2010). This may also explain Homann 
et al’s observation that CD8 memory T cells numbers are stably maintained for the 
whole of life while CD4 memory T cells gradually declines over time. They proposed 
that CD8 and CD4 T cell immunity is differentially regulated (Homann, Teyton et al. 
2001).  
 
We think that it possible that the differential regulation of CD8 and CD4 T cell 
immunity suggested by Homann et al is through the regulation of p27kip1. Il-7 is an 
important cytokine in the homeostatic proliferation of T cells. It does this through the 
destabilization of p27kip1 (Barata, Cardoso et al. 2001; Li, Jiang et al. 2006) and is 
also one of the cytokines required for the maintenance of CD4 memory (Seddon, 
Tomlinson et al. 2003) and CD8 memory (Schluns, Kieper et al. 2000).  
 
In our study, we have shown that p27kip1 plays a role in limiting CD4 T cell 
expansion more than CD8 T cells by setting a higher threshold that needs to be 
overcome to initiate cell division as well as limiting the TEM subset of CD4 memory 
cells. Since p27kip1 affects both the expansion as well as the maintenance phase of 
the immune response (Figure 1. 2 ), this makes p27kip1 a good candidate to 
manipulate to enhance CD4 T cell proliferation and maintaining CD4 memory 
population, especially the TEM subset. 
 
7.2 Limitations of the study 
One main limitations of our study is that the model used was an in vitro model. 




proliferation, in vivo there are multiple factors which can control CD8 and CD4 T cell 
proliferation. In vivo studies report that CD8+ T cell division commences after 24hrs 
of stimulation and takes about 6-8 hours to complete one cycle. CD4+ T cell division, 
however, commences only after 36-48 hours of stimulation and takes about 10 hours 
to complete one cycle (Jelley-Gibbs, Lepak et al. 2000; Murali-Krishna and Ahmed 
2000; Veiga-Fernandes, Walter et al. 2000; Homann, Teyton et al. 2001; Kaech and 
Ahmed 2001; Tan, Dudl et al. 2001; Wong and Pamer 2001). These observations of 
faster rate of CD8+ T cell divisions may partially explain why CD8+ T cell responses 
tend to peak 1-2 days before CD4+ T cell responses (Whitmire, Flavell et al. 1999; 
Homann, Teyton et al. 2001). Nevertheless, the data of our in vitro T cell proliferation 
kinetic studies also showed that CD8 T cells took approximately 6 hours to complete 
one cycle and they reached their peak earlier than CD4 T cells, is similar to in vivo 
observations reported.  
 
Another limitation is the tracking of T cell proliferation was limited to only the first 
two days following T cell activation. It would have been more comprehensive if 
proliferation was tracked for longer periods (4-5 days). However, to keep the T cells 
alive for longer duration in culture wells would require adding growth cytokines such 
as IL-2 which would have complicated the experiments. One possible approach to this 
would be to track T cell proliferation in vivo. This can be done by sorting out the 
naïve CD8 and CD4 T cells and stain them with CFSE. The CFSE- stained T cells (~ 
4x106 cells) can be adoptively transferred intravenously together with 1μg anti-CD3 
per gram of mouse weight as activation stimulus and allowed to proliferate in vivo for 
a few days before the mice are culled and T cells isolated from the spleen and lymph 




made more precise if transgenic antigen-specific naïve CD8 and CD4 T cells are 
transferred with antigen-pulsed DCs. This approach can also be used to study p27KO 
T cells proliferation more closely in vivo. 
 
Using a generic way to activate T cells in our in vitro system may not have been as 
ideal as using an antigen-specific system to study T cell proliferation kinetics. This 
was mainly due to time constraint in generating transgenic antigen-specific p27KO 
mice in time for use. However, the results again, are comparable to observations 
reported in vivo. 
 
7.3 Future Work  
Several studies have showed that T-helper cell-dependent events during the initial 
priming period are required for the generation of CD8+ T cell-mediated protective 
immunity (Janssen, Lemmens et al. 2003; Shedlock, Whitmire et al. 2003; Sun and 
Bevan 2003). Deletion of p27 improved CD4 T cell proliferation more than CD8 T 
cells and skewed CD4 subpopulation towards the TEM (Figure 6.6.2B). It would be of 
interest using p27KO CD4 T cells to investigate how enhanced CD4 might affect 
generation of CD8 memory in diseases model such as LCMV or Listeria 
monocytogenes where generation and maintenance of functional CD8 T cell memory 
(Shedlock and Shen 2003; Sun and Bevan 2003; Sun, Williams et al. 2004) is 
dependent on CD4 T cell help.  
 
CD4 T cells prime CD8 through CD40L –CD40 signalling (Bennett, Carbone et al. 
1998; Schoenberger, Toes et al. 1998). For effective priming, this help must be 




lymphocyte recognize antigen on the same antigen-presenting cell (von Herrath, 
Yokoyama et al. 1996; Bennett, Carbone et al. 1997). Although direct interaction 
between CD4 and CD8 T cells via CD40L-CD40 interaction is important for robust 
memory generation for noninflammatory antigens (Bourgeois, Rocha et al. 2002), 
direct CD40L-CD40 interaction between CD4 and CD8 T cells is not involved during 
viral or bacterial infections (Lee, Hartson et al. 2003; Sun and Bevan 2004). 
 
CD40L expression on p27KO CD4 T cells can be studied and whether these p27KO 
CD4 T cells may be more efficient in converting APCs into more efficient APCs. One 
area that can be studied is the efficiency as well as the quantity of antigen-MHC 
complexes expressed on DC surface. 
 
Another long-term plan may be to crossbreed the p27KO mice with antigen-specific 
transgenic mice, for example OT-I or OT-II, which would provide another new tool 
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